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Abstract.............................................................. 
The majority of tryptophan metabolism passes through the kynurenine pathway. Kynurenine 
pathway metabolites are involved in a range of physiological effects, and the most significant 
metabolites in the pathway include 3-hydroxykynurenine, 3-hydroxyanthranilic acid, and 
quinolinic acid, which are considered to be neurotoxic, and kynurenic acid (KYNA), which is 
considered to be neuroprotective. Imbalances of these metabolites are implicated in a range of 
neurological, psychiatric and peripheral diseases. KYNA, formed through a transamination 
process mediated by the kynurenine aminotransferase (KAT) enzymes, is observed elevated 
in patients with schizophrenia. Schizophrenia is a neuropsychiatric disease with limited 
treatment options and highly debilitating symptoms, leading to poor personal, social and 
occupational outcomes for an afflicted individual. The complexity of schizophrenia has 
denied a clear understanding of the disease, but it is thought that the dopaminergic and 
glutamatergic systems have a significant role in the pathogenesis of the disease. KYNA, itself 
an endogenous glutamate antagonist, may at least be partially involved in the development of 
the disease. 
Four homologues of KAT are reported, all of which are pyridoxal 5‟-phosphate-dependent 
enzymes. All four KAT isoforms have been analysed structurally and biochemically, 
however the most extensive research is on KAT-I and KAT-II. These two enzymes have been 
targeted by rational drug design to develop inhibitors which can normalise raised KYNA 
levels. KAT-II in particular has received attention as it is thought to be primarily responsible 
for KYNA production in the human brain. KAT-II inhibitors are not only effective in 
reducing KYNA production, but they also increase neurotransmitter release and elicit 
pro-cognitive effects in animal studies, indicating that they have great potential for 
therapeutic application  as a novel way of treating schizophrenia. 
Previously, several approaches have been taken to develop KAT-II inhibitors. In this work, 
fragment-based drug design (FBDD) approaches have been exploited for the first time in this 
context to provide lead compounds which can be designed further towards novel inhibitors. 
Surface plasmon resonance (SPR) was used to screen a fragment library containing 1000 
compounds, of which 41 hits were identified. These hits were further evaluated with SPR, 
and 18 were selected for inhibition studies. From these hits, two fragments, F6037-0164 and 
F0037-7280, were pursued and determined to have an IC50 of 524.5 μM and 115.2 μM, 
respectively. This strategy shows the viability of using FBDD in gleaning knowledge about 
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KAT-II inhibition and generating novel lead scaffolds for the production of KAT-II 
inhibitors.  
Another strategy employed was to consider estrogen and steroid compounds closely, to 
exploit their inhibition profiles. Schizophrenia is a sexually dimorphic condition, and women 
who have schizophrenia have reduced estrogen levels in their serum. Exploring the 
interactions of estrogens in the kynurenine pathway could hope to yield a better 
understanding of the condition, for the purpose of improving approaches to ameliorating its 
effects. Enzyme inhibitory assays and binding studies showed that estradiol disulfate is a 
strong inhibitor of KAT-I and KAT-II (IC50: 291.5 μM and 26.3 μM, respectively), with 
estradiol, estradiol 3-sulfate and estrone sulfate inhibiting more weakly (IC50 > 2mM). These 
results indicate the possibility of estrogen levels influencing the balance of kynurenic acid in 
the brain. Inhibition assay results and molecular modelling suggest that the 17-sulfate moiety 
in estradiol disulfate is very important in improving its potency as an inhibitor, increasing the 
inhibition by approximately 10-100 fold compared to estradiol. 
The work in this study also demonstrates that the effect of this 17-sulfate moiety can be 
simulated in existing KAT-II inhibitors, from the development of two novel inhibitors, JN-01 
and JN-02. Both inhibitors were based on NS-1502 (IC50: 315 μM), but the deliberate 
placement of a sulfonamide group significantly improved the potency of JN-01 
(IC50: 73.8 μM) and JN-02 (IC50: 112.8 μM) in comparison to the parent compound. This 
3-4 fold increase in potency provides the evidence for these moieties to be accommodated in 
the KAT-II active site and the effect they can have on improving inhibitors, and the 
environments in which the inhibitors in the KAT-II active site have been suitably modelled 
using docking calculations. Attempts to co-crystallise JN-01 and JN-02 in KAT-II also 
resulted in the determination of a human KAT-II crystal structure (PDB ID: 6D0A) with 
1.47 Å resolution, the highest resolution structure yet provided for KAT-II. In addition, 
validation statistics show that this crystal structure provides a model with fewer structural 
problems and inconsistencies in comparison to the other deposited structures.  
To follow-up the possibility that estrogens inhibit kynurenine pathway enzymes rather 
indiscriminately, molecular docking was performed on the enzymes tryptophan 
2,3-dioxygenase (TDO), indoleamine 2,3-dioxygenase (IDO), KAT-I, KAT-II, and 
kynureninase. The estrogens could only dock into TDO, IDO, and KAT-II when their 
respective cofactors were not present as the estrogens tended to feature in the cavities 
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formerly occupied by the cofactor. Conversely, the docking of estrogens into KAT-I and 
kynureninase resulted in poses that were largely similar, regardless of whether their cofactor 
was present in the active site or not. These docking results were suggestive of different 
inhibitory mechanisms for the estrogens of the enzymes in the kynurenine pathway. 
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Synopsis and aim................................. 
The work in this thesis pertains to the implications of abnormal activity of the kynurenine 
pathway enzymes and metabolites in neurological conditions, with specific attention towards 
the kynurenine aminotransferase (KAT) enzymes. The background information 
encompassing the thesis will be discussed in Chapter 1 and Chapter 2. The overarching aim 
of this study is to develop novel, reversible KAT-II inhibitors, to aid in the treatment of 
schizophrenia, by: 
 Fragment-based drug design approaches to identify fragment compounds that can be 
used as novel scaffolds for KAT-II inhibition (Chapter 3). 
 Structure-based drug design approaches to identify and evaluate estrogen inhibitors of 
KAT-II (Chapter 4), and apply the information learnt to improve and develop KAT-II 
inhibitors (Chapter 5). 
The techniques contributing to these approaches include: 
 Inhibition assays to determine the KAT-II inhibition capability of the fragment leads, 
estrogens and novel inhibitors (Chapters 3-5, Appendix A), and kinetics of KAT-II 
(Appendix A). 
 Surface plasmon resonance to identify fragment hits (Chapter 3), and evaluate the 
binding of estradiol disulfate (Chapter 4) and NS-1502 (Appendix B) to KAT-II. 
 Molecular docking to analyse and rationalise the binding mechanism of the fragment 
leads, estrogens and novel inhibitors to KAT-II (Chapters 3-5), the potential of 
estrogens to impact the kynurenine pathway enzymes (Appendix C), and the 
promiscuity of fragment molecules in binding to KAT-II (Appendix C) . 
 Attempts of co-crystallising KAT-II with inhibitors (Appendix D). 
Supplementary information for the articles in Chapters 3, 4 and 5, are also available in 
Appendix E.  
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Chapter 1 General introduction 
1.1 Kynurenine pathway and disease 
1.1.1 A brief history 
The kynurenine metabolites first became evident in 1853 when Justus von Liebig isolated 
kynurenic acid (KYNA) from canine urine [1], aptly deriving the name from the classical 
Greek words kynos (dog) and ouron (urine). The exact constitution of KYNA would be 
investigated throughout the next half century, concluding in its identification as 
4-hydroxyquinoline-2-carboxylic acid in 1914 [2].  The early 20th century also brought the
discovery of tryptophan in casein [3] and subsequent finding that tryptophan administration 
induced KYNA excretion [4]. Other metabolites, such as kynurenine (KYN) [5] and 
xanthurenic acid (XA) [6] were discovered in the decades that followed, culminating in the 
description of the kynurenine pathway of tryptophan metabolism becoming well established 
by the 1960s. The full biological scope of kynurenine metabolites, beyond their peripheral 
activities and role in nicotinamide adenine dinucleotide (NAD) synthesis, was not realised 
until 1981, when quinolinic acid (QUIN) was found to be an agonist of the 
N-methyl-D-aspartate (NMDA) receptor in the central nervous system (CNS) [7]. Nowadays,
kynurenine metabolites have been implicated in many disease states in both the peripheral 
system and CNS. 
1.1.2 The kynurenine pathway 
Tryptophan is an essential amino acid that must be acquired from dietary sources. Up to 99% 
of excess dietary tryptophan not involved in protein production is metabolised through the 
kynurenine pathway (Fig. 1-1) [8]. The first, rate-limiting step of the kynurenine pathway is 
the oxidative cleavage of tryptophan by tryptophan 2,3-dioxygenase (TDO) or indoleamine 
2,3-dioxygenase (IDO1/IDO2) to form N-formylkynurenine. TDO, expressed predominantly 
in the liver but also in astrocytes in the CNS [9], can be induced by glucocorticoids [10] and 
tryptophan [11], and can have its expression further regulated by the activity of its haem 
cofactor [12]. IDO is distributed widely in tissues, including the CNS, and is strongly induced 
by the pro-inflammatory cytokine, interferon- (IFN-) [13]. Other pro-inflammatory 
cytokines can also induce IDO to a lesser degree or potentiate the induction by IFN-, while 
anti-inflammatory cytokines can inhibit the induction by IFN- [14]. As part of the immune 
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response, IFN- activates macrophages, microglia and dendritic cells, all of which express the 
suite of kynurenine pathway enzymes [15]. When these effects are compounded, immune 
activation through pathogenic infections and disease can dramatically elevate IDO activity 
and tryptophan utilisation [14]. 
In the next step of the pathway, kynurenine formamidase, expressed in the liver, kidney and 
brain, converts N-formylkynurenine into KYN, and this can then be taken through multiple 
branches. KYN can be transaminated into KYNA by the KAT enzymes. There are four KAT 
isoforms, distributed in the liver, kidney, and brain. The KAT enzymes have relatively low 
expression in macrophages, microglia and dendritic cells [15], and are therefore principally 
active in astrocytes in the CNS [16]. KAT-II is the main isoform responsible for KYNA 
synthesis in the mammalian brain [16, 17]. The KAT isoforms and the enzyme, kynureninase, 
all incorporate pyridoxal 5‟-phosphate (PLP) as a cofactor in their activity. 
KYN can also be hydrolysed into anthranilic acid (AA) by kynureninase, or hydroxylated 
into 3-hydroxykynurenine (3-HK) by kynurenine 3-monooxygenase (KMO) and then further 
transaminated into XA by KAT. 3-HK can additionally be metabolised into 
3-hydroxyanthranilic acid (3-HAA) by kynureninase. 3-HAA is converted into an unstable
intermediate by 3-hydroxyanthranilate 3,4-dioxygenase (3-HAAO), which can undergo 
non-enzymatic cyclization to form QUIN and leads into the NAD production pathway. 
The QUIN producing branches of the kynurenine pathway are broadly expressed in the 
peripheral tissues, including the liver and kidney. Unlike the KAT enzymes, in the CNS, 
KMO is predominantly localised in microglial cells rather than the astrocytes [16]. 
Effectively, QUIN production in the brain primarily takes place in the microglia. 
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Figure 1-1. The initial steps of tryptophan metabolism through the kynurenine pathway in humans. 
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1.1.3 Physiological effects of kynurenine metabolites 
Broadly speaking, the kynurenine pathway is integral for the regulation and bioavailability of 
plasma tryptophan and the synthesis of NAD [18]. The physiological relevance of the 
metabolites QUIN, 3-HK, 3-HAA, and KYNA is discussed below based on their clinical 
significance in rodent and human studies. 
QUIN was identified as a possible neurotoxin when intracerebral injections caused strong 
convulsions in mice [19], and neuronal lesions in rats [20]. The toxicity of QUIN is 
multifaceted as it can selectively activate NDMA receptors [7], stimulate glutamate release 
and inhibit astroglial reuptake of glutamate [21], cause mitochondrial dysfunction [22], and 
generate free radicals and cause oxidative stress [23, 24].  
3-HK and 3-HAA are neuroactive compounds that can readily autooxidise into hydrogen
peroxide and other highly reactive oxygen species [25-27]. As generators of oxidative stress, 
they can initiate apoptosis in striatal neurons [28] and monocyte/macrophage cell cultures 
[29]. QUIN induced neuronal damage is also potentiated with the co-injection of 3-HK, but 
can be prevented by NMDA receptor antagonists or free radical scavengers [30]. 
Contrastingly, KYNA can be considered neuroprotective as it inhibits excitatory receptors. It 
acts as an antagonist to the glutamate and glycine binding sites of NMDA receptors [31, 32], 
kainate receptors [33], and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) 
receptors [34]. KYNA can antagonise the excitotoxic QUIN [32], and exhibits anticonvulsant 
effects [35, 36]. In rats, KYNA reduction has been associated with an increased vulnerability 
to excitoxicity [37]. KYNA also has antioxidant capabilities as it scavenges free radicals [38]. 
KYNA can also noncompetitively inhibit α7-nicotonic acetylcholine receptors [39], which 
can mediate dopamine and glutamate release in the brain [40]. In peripheral systems, KYNA 
also acts as a ligand for the G-protein coupled receptor 35, [41] and the aryl hydrocarbon 
receptor [42], which are involved in immune responses [43]. 
KYNA modulation of neurotransmitter release has been observed in animal studies. KAT-II 
inhibitors, which inhibit KYNA production, increased levels of glutamate [44], dopamine 
[45], acetylcholine [46] and GABA [47] in the rat brain. These studies also showed that 
application of KYNA, or its precursor KYN, neutralised this increase if co-injected with the 
KAT inhibitor, S-4-(ethylsulfonyl)benzoylalanine (S-ESBA), or decreased the levels of the 
neurotransmitters released when injected alone [44-47]. Additionally, improvements in 
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cognitive performance were observed in rats [44, 48] and non-human primates [49] 
administered with KAT-II inhibitors, and in KAT-II knock-out mice [50].  
The kynurenine pathway is also intrinsically linked to the immune system as IFN- can 
induce IDO and bolster production of downstream metabolites, and the metabolites in turn 
are involved in immunomodulation. QUIN, 3-HK, and 3-HAA are able to suppress T-helper 
cells [51, 52], while KYNA decreases pro-inflammatory cytokine response [53]. 3-HAA also 
inhibits activation of the inflammatory NF-ΚB, and nitric oxide synthase activity and 
expression in macrophages [54]. 
Underpinned by the effects exhibited by these metabolites, kynurenine pathway dysfunction 
is implicated in many diseases and therefore it is considered that targeting the actions of the 
enzymes in this pathway may provide therapeutic strategies. 
1.1.4 Role in neurological and psychiatric disease 
Physiological variations in kynurenine metabolites have been measured in the plasma, 
cerebrospinal fluid (CSF) and brain of patients in an extensive number of conditions, 
including neurological disorders (e.g. Huntington‟s disease (HD), Alzheimer‟s disease (AD), 
Parkinson‟s disease (PD), amyotrophic lateral sclerosis, epilepsy), psychiatric disorders (e.g. 
schizophrenia, depression), autoimmune diseases (e.g. multiple sclerosis), cardiovascular 
diseases,  cancers, and infectious diseases (e.g. HIV infection) [55, 56].  
1.1.4.1 Huntington’s disease 
HD is an inherited disorder caused by abnormally long CAG triplet repeats in the huntingtin 
(HTT) gene. The expressed mutant HTT protein is prone to misfolding and aggregation, 
particularly in the striatum and cortex, leading to progressive neurodegeneration [57]. Levels 
of 3-HK and QUIN in the striatum and cortex were measured substantially elevated in HD 
mice models [58], and during the early phases of HD in post mortem brain tissue [59, 60], 
relative to controls. Post-mortem examination of HD patients revealed elevated 3-HAAO 
activity (responsible for QUIN production) in comparison to controls [61]. QUIN induced 
lesions in rats with a profile of neurotransmitter depletion that resembles HD [62-64], and 
there is evidence that QUIN can induce expression of the HTT gene [65]. Post-mortem brain 
tissues show that KYNA levels are decreased in the CSF [66], cortex [67], and striatum [68] 
of HD patients, with the latter associated with a loss in KAT activity [68].  
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HD is also marked with a clear immune response. Pro-inflammatory cytokines have been 
observed elevated in the blood plasma [69] and post-mortem brain [70] of HD patients, and 
microglia, responsible for mediating immune response, are extensively activated in 
preclinical HD [71]. Both these factors can up-regulate IDO activity, which can increase 
production of downstream kynurenine metabolites such as 3-HK and QUIN.  
A genomic screen of yeast also revealed that the deletion of the gene encoding KMO 
(responsible for 3-HK production) and 3-HAAO suppressed the toxicity of a mutant HTT 
fragment, while the deletion of KAT enhanced toxicity [72]. Suppression of mutant HTT by 
deletion of genes unrelated in function to the kynurenine pathway also decreased 3-HK and 
QUIN levels in yeast, and treatment with neuroprotective agents blocked up-regulation of 
kynurenine metabolites in HD mice models [73].  
The biological and genomic studies of HD show that kynurenine metabolites may be innately 
involved. High flux towards the 3-HK and QUIN producing branches of the kynurenine 
pathway, or low flux towards the KYNA producing branch, which is protective against 
QUIN, creates an imbalance towards neurotoxicity in the pathogenesis of this disorder. 
1.1.4.2 Alzheimer’s disease 
Hallmarks of AD include the formation of β-amyloid plaques, neurofibrillary tangles 
composed of tau protein, and major neuronal loss [74]. There is no clear cause of AD, with 
many genetic and environmental factors involved, but disruptions in the kynurenine pathway 
have been implicated. In the hippocampus of AD patients, immunoreactivity to IDO and 
QUIN was observed elevated in the microglia, astrocytes and neurons, with the highest signal 
in close proximity of senile plaques [75]. β-amyloid protein can induce IDO expression and 
significantly elevate QUIN production in macrophages and microglia [76]. Increased IDO 
expression can also be linked to the immune activation that occurs in Alzheimer‟s disease 
[74]. Another reflection of IDO activity was an increased KYN/tryptophan ratio observed in 
the plasma of AD patients [77, 78], which, along with elevations of plasma QUIN [78], is 
inversely correlated with cognitive performance [77, 78]. QUIN also induces genes involved 
with tau phosphorylation in human neurons [79], which links it to the production of 
neurofibrillary tangles, and QUIN can also have a role in AD progression by promoting 
chemokine production and receptor expression [80, 81].  
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Coinciding with the increase in flux directed towards QUIN production, 3-HK is found to be 
elevated in the serum of AD patients [82]. Measurements of KYNA levels in AD patients are 
varied and are found to be reduced in plasma [78], erythrocytes [83], and CSF [66], elevated 
in post-mortem brain tissue [84], or found to be unaltered in the CSF [85]. By way of NMDA 
receptor activation promoting β-amyloid production [86], an increase in QUIN or reduction 
in KYNA can be further implicated as they are NMDA agonists and antagonists, respectively. 
Although the exact nature of how the different kynurenine metabolites are involved in AD 
needs further clarification, there is a clear up-regulation of IDO and metabolism through the 
kynurenine pathway in microglia and astrocytes. Overproduction of 3-HK and QUIN can 
induce excitotoxicity and generate damaging reactive oxygen species, and it is interesting to 
note that QUIN toxicities share a number of similarities to β-amyloid mediated toxicities 
[87].  
1.1.4.3 Parkinson’s disease 
PD is a neurodegenerative disease, classically associated with deteriorating motor symptoms 
and a loss of dopaminergic neurons in the substantia nigra. It is however a multifaceted 
disease, in which both oxidative stress and neuroinflammation play a role [88]. Typical of an 
inflammatory response, increased cytokine production, including IFN-, is observed in PD 
animal models [89]. The ability of IFN- to induce the kynurenine pathway was reflected in 
an elevated KYN/tryptophan ratio measured in the serum and CSF of patients, relative to 
controls, which is suggestive of increased IDO activity [90]. The KYN/tryptophan ratio was 
also higher in advanced disease stages relative to earlier disease stages [90].  
This increase in kynurenine pathway metabolism seems to be shunted away from KYNA 
production, with reductions of KYNA levels measured in the frontal cortex, putamen and 
substantia nigra [91], and plasma [92] of PD patients [91], increasing susceptibility to 
excitotoxicity from glutamate and QUIN. Coinciding with this, reduced KAT-I expression in 
the substantia nigra of mice PD models [93], and reduced KAT-I and KAT-II activity in 
plasma of PD patients [92] have been reported. Instead, kynurenine metabolism moves 
towards the 3-HK production branch, with elevated levels measured in the brain [91], which 
could increase the oxidative stress on neurons. Further, in the PD models, QUIN was 
observed to be accumulated in the substantia nigra by activated microglial cells, the latter of 
which also co-localised with dopaminergic neurons [94]. Therefore the release of QUIN by 
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microglia can, along with glutamate, exert an excitotoxic action on NMDA receptors in the 
dopaminergic neurons and facilitate progressive loss of the neurons [94]. 
As with the previous neurodegenerative diseases discussed, up-regulation of the kynurenine 
pathway, particularly 3-HK and QUIN production, appears to be a feature of the development 
of PD. The resulting increased excitotoxicity at NMDA receptors and oxidative stress may 
contribute to the deterioration of dopaminergic neurons, which is an essential aspect of PD, 
and a reduction of KYNA production may additionally enable this.   
1.1.4.4 Schizophrenia 
Schizophrenia is a psychiatric illness characterised by a range of negative symptoms (e.g. 
flattened affect, poverty of speech), positive symptoms (e.g. delusions, hallucinations), and 
cognitive deficits in patients. The kynurenine pathway is up-regulated in schizophrenia, with 
an elevation in TDO expression in the brain of patients [9, 95]. Reduced KMO and 3-HAAO 
activity has also been observed [96, 97] and, altogether, these changes in enzyme activities 
could account for increased KYN and KYNA levels that are observed in the prefrontal cortex 
[98] and CSF [99, 100], and increased AA levels in the serum of patients [101]. No 
significant differences were found in the levels of 3-HK and QUIN in the brain [98] and CSF 
[102], respectively, of patients and controls, and decreased 3-HK levels were observed in the 
serum of patients [101], which is again indicative that only the products upstream of KMO 
are elevated in patients with schizophrenia. 
The antagonism of the NMDA receptors and α7-nicotinic acetylcholine receptors by KYNA 
is the mechanism by which it may affect symptoms seen in schizophrenia, particularly the 
cognitive dysfunction aspects [103]. In animal studies, inhibiting KAT-II or deleting the 
KAT-II gene to reduce KYNA production increases the release of key neurotransmitters 
implicated in schizophrenia, such as glutamate [44, 48, 50], dopamine [45, 48], acetylcholine 
[46], and GABA [47], and improves cognitive function [44, 48-50]. Conversely, increasing 
KYNA levels has the opposite effect and impairs neurotransmitter release and cognitive 
performance [44-47]. 
The evidence for whether there is astrocyte or microglial activation in schizophrenia is 
contradictory, likely due to differing factors such as the brain region studied, illness stage, 
and treatment exposure of patients [104], however neuroinflammation is strongly associated 
with schizophrenia [105]. By mimicking an immune response to infection in developing 
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animals, it was shown that schizophrenia-related changes to neurotransmitter release [106], 
and behavioural and cognitive deficits [107, 108] would occur in adulthood. In humans, 
pre-natal exposure to viruses such as influenza [109], rubella [110] or herpes simplex virus 
type 2 [111], and the pro-inflammatory cytokine, interleukin-8 [112], has been associated 
with an increased risk factor for developing schizophrenia and other psychoses. 
Although environmental factors are anticipated to have a role in the aetiology of 
schizophrenia, there is a strong genetic component involved [113]. A meta-analysis of 
genome-wide association studies revealed 108 independent genomic loci associated with 
schizophrenia [114]. Noteworthy associations include the DRD2 gene (encoding the 
dopamine receptor D2, which antipsychotics target), and genes involved in glutamatergic 
transmission, and synaptic function and plasticity [114]. A non-synonymous single nucleotide 
polymorphism (SNP) of the KMO gene, likely decreasing the activity of KMO, was 
associated with an increase in KYNA concentrations in the CSF of patients with 
schizophrenia, compared to controls [115].  Although this study was of a small sample size, it 
shows the possibility of genetic variance in the kynurenine pathway being involved in 
schizophrenia. 
There are many factors in the aetiology of a complex disease such as schizophrenia, and 
dysfunction of kynurenine metabolites is among those that are involved. In particular, KYNA 
levels are observed elevated in patients.  Although KYNA is inherently considered to be 
neuroprotective, this is a clear indication that maintaining homeostasis is of paramount 
importance to avert disease. Therefore developing KAT inhibitors, for the purpose of 
lowering KYNA levels, is an avenue of therapy that must be considered. However this needs 
to be done with careful deliberation as the kynurenine pathway is involved in many other 
conditions and physiological effects, and in particular the neurotoxic metabolites, 3-HK and 
QUIN, need to be considered.  
1.2 Estrogen and the kynurenine pathway 
Estrogen levels are generally higher in females than in males, but can vary as a result of 
biological and drug- or food-induced changes. Differences in estrogen levels can influence 
the activity of kynurenine pathway enzymes and the production of the kynurenine 
metabolites. Estrogen has been raised as an important factor in disease as sexual dimorphism, 
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typically in the age of onset and prognosis, has been observed in many diseases such as AD, 
PD, and schizophrenia. 
1.2.1 Estrogen influence on kynurenine pathway enzymes 
1.2.1.1 Tryptophan 2,3-dioxygenase induction 
TDO activity increases significantly following the injection of its natural substrate, 
tryptophan [11, 116]. TDO activity is also moderately induced by a variety of other 
compounds, including histidine and adrenaline, by a separate manner thought to be an effect 
of the pituitary-adrenal gland, as this activity was lost following an adrenalectomy [116]. 
Increase in TDO activity following an injection of adrenocorticotrophic hormone [117], and 
the glucocorticoid, cortisone, following adrenalectomy [10], further supports the role of the 
adrenal gland in inducing TDO by the secretion of corticosteroids. 
Women taking oral contraceptives excrete increased KYN, XA, 3-HK, and 3-HAA [118], 
QUIN [119], and nicotinic acid metabolites [120], after being given a tryptophan load. 
Elevated levels of KYN, XA and 3-HK are reflective of similar metabolite profiles seen 
during vitamin B6 (PLP) deficiency, suggestive of the PLP-dependent enzymes in the 
kynurenine pathway being depleted of PLP or inhibited by estrogen. Supporting this, the 
increased metabolite excretion was restored by pyridoxine supplementation [118]. However 
enzyme inhibition or depletion may not fully account for products such as 3-HAA, QUIN and 
nicotinic acid metabolites, as they are formed downstream to the PLP-dependent enzymes.  
Hence it was hypothesised that estrogen may also be involved in the pathway by inducing 
TDO. In female rats, TDO activity increased following estrogen treatment and decreased 
following an ovariectomy, compared to controls [121-123]. These changes peaked with 
13-week old, mature rats, as opposed to younger or older ones, and increased activity was 
also observed in rats with estrogen treatment following an ovariectomy [121].  
Rats treated with estradiol benzoate, both intact and those with an adrenalectomy, displayed 
increased TDO activity, relative to controls [122]. The activity in adrenalectomised rats 
treated with estradiol benzoate was however less than in controls without an adrenalectomy, 
suggestive that the increase in TDO activity by estrogen is via a separate mechanism than the 
increase derived from corticosteroid secretion by the adrenal gland.  
10
  
An oral load of L-kynurenine, instead of tryptophan, in women also demonstrated the typical 
increased excretion of metabolites in those taking contraceptives, relative to controls [124]. 
As kynurenine is an entry point in the metabolic pathway downstream of TDO activity, this 
indicates that the results are not only due to effects on TDO. Similarly, increased excretion of 
XA, 3-HK, and 3-HAA following a tryptophan loading dose in women taking oral 
contraceptives, in comparison to controls, was confirmed [125], but little change in 
tryptophan clearance was observed which suggested no induction of TDO activity. 
Comparable results were found when female rats treated with estrogen compounds also 
displayed no changed TDO activity [126].  Different methodologies in measuring TDO 
activity could possibly account for the discrepancies seen between these and previous 
experiments. However,  in the same rat experiments, decreased TDO activity was observed in 
those that had an ovariectomy in comparison to controls, suggesting that estrogen may have 
some indirect effect in promoting TDO expression [126]. 
1.2.1.2 Kynureninase inhibition 
Measurement of rat liver enzyme activity indicated that male controls displayed higher 
kynureninase activity than females [127]. Estrogen treated male rats had kynureninase 
activity which was significantly lower and towards the values of female controls, however 
estrogen treated female rats did not differ significantly from female controls [127, 128]. An 
estrogen and progestogen combination however was able to significantly elevate 
kynureninase activity in female rats, compared to controls [127].  
A separate experiment showed that kynureninase activity in female rats was able to be 
reduced slightly, relative to controls, through estrogen administration [129], while 
progesterone alone could not reduce this activity [129]. Orchiectomised male rats also had 
reduced kynureninase activity [123], suggesting the importance of androgen status as well as 
that of estrogen. 
Evidence of kynureninase inhibition also came from administration of synthetic and natural 
estrogen in humans, which increased urinary excretion of kynurenine metabolites prior to the 
kynureninase step in the pathway [118, 130]. Kynureninase inhibition was also directly 
demonstrated using estrone sulfate on rat liver homogenates [131]. Interestingly, the 
inhibition was in a competitive manner with respect to kynurenine but uncompetitive with 
respect to PLP [131], which contradicts the previously reported idea that PLP 
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supplementation rescues the estrogen inhibited PLP-dependent enzymes in the kynurenine 
pathway. 
Taking into consideration that the estrogens may also be affecting the other PLP-enzymes in 
the kynurenine pathway along with kynureninase, it is possible that KYN levels can 
accumulate until they eventually offset the inhibition caused by these estrogen compounds. 
This could allow the metabolic pathway to continue producing the downstream metabolites 
observed elevated in women taking estrogen compounds [119, 120]. 
1.2.1.3 Kynurenine 3-monooxygenase inhibition 
The KMO activity in the liver and kidney of rats was tested after administration of 
progesterone and estrogen [132]. Progesterone had only a slight effect on the activity of liver 
KMO after one week of treatment, but was able to reduce its activity more considerably after 
two weeks. In that time, it only had a slight effect on kidney KMO. In comparison, estrogen 
reduced hepatic KMO activity relatively more after two weeks, while also reducing kidney 
KMO activity significantly after one week [132]. Estrogen treatment in ovariectomised 
rhesus monkeys also caused a reduction in KMO expression [133]. 
1.2.1.4 Kynurenine aminotransferase inhibition 
Rat kidney KAT apoenzyme was incubated with a variety of steroid related compounds, of 
which estradiol disulfate and diethylstilbestrol disulfate reversibly inhibited it at low 
concentrations, while estrone sulfate did so only at higher concentrations [134]. Incubating 
KAT with lower amounts of PLP demonstrated increased inhibition from the conjugates, 
suggesting that it competed with PLP for the enzyme. Pregnanediol glucuronide and bile 
acids also inhibited the KAT enzyme at relatively high concentrations (IC50: > 10
-3
 M), but 
did so irreversibly. Unconjugated steroid compounds, such as estrone, estradiol, 
diethylstilbestrol, progesterone, were not found to be very inhibitory. The estrogen sulfates 
also appeared to have a protective effect on the irreversible inactivation of the protein caused 
by chymotrypsin or higher temperatures [134].  
Because only low levels of steroid sulfates were required for KAT inhibition in vitro, it was 
concluded that it was possible this inhibition also occurred in tissues. However it should be 
noted that disulfate compounds, which were the most potent inhibitors, are not known to 
naturally occur. A number of other studies have found that these steroid conjugates also 
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inhibit a range of other PLP-dependent enzymes, including rabbit muscle phosphorylase a 
[135]  and phosphorylase b [136],  rat liver tyrosine transaminase [137], rabbit liver serine 
transhydroxymethalase [137],  and many others [138]. Estradiol diphosphate was also 
observed to be more inhibitory towards rat kidney KAT than estradiol disulfate [139].  
Experiments on rat renal KAT homogenates demonstrated that KAT activity in male rats 
increased as the rats grew, but the activity in females plateaued as they reached a body weight 
of 100 g and was lower than that of the males [138]. Ovariectomised female rats between 
175 – 200 g were found to have higher levels of renal KAT activity than non-ovariectomised 
females, indicating a large influence of the ovaries on KAT activity. No such difference was 
seen in liver KAT activity after ovariectomy [138]. Orchiectomised male rats displayed some 
reduced renal KAT activity, while females treated with testosterone propionate had increased 
renal KAT activity, compared to controls, indicating that perhaps both androgens and 
estrogens are important factors in the enzyme activity. 
Vitamin B6 deficiency was observed to cause little change to kidney mitochondrial KAT, 
whereas the supernatant KAT activity was reduced [140]. As the renal KAT is mostly found 
in the soluble fraction and the hepatic KAT is predominantly in the mitochondrial fraction, 
this could account for the lack of influence of estrogen on liver KAT compared to kidney 
KAT [138, 140]. It was hypothesised that the depletion of both supernatant KAT and 
kynureninase could cause a build-up of kynurenine passing through to the mitochondria, 
where it is more readily converted to 3-HK by KMO as it has a lower KM for the substrate 
(KM: 0.014 mM) [141] than KAT (KM: 4.7 mM) [142]. 3-HK is then converted into XA by 
the preserved mitochondrial KAT, explaining the increased XA observed in vitamin B6 
deficiency [140]. Similar effects were demonstrated when estrogen treated male rats had 
lower renal KAT activity, towards the level of control females, while maintaining relatively 
unaffected liver KAT activity [123, 138]. The administration of estrogen, progesterone, and a 
combination of an estrogen and progestogen did not seem to significantly influence the 
activity of hepatic KAT activity in male and female rats [127]. 
1.2.2 Physiological effects of estrogen concentration variation 
1.2.2.1 Oral contraceptives 
The increased excretion of tryptophan metabolites, including KYN, XA, 3-HK, 3-HAA and 
QUIN, following a tryptophan loading dose, was observed both in women taking combined 
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oral contraceptives (estrogen and progesterone preparations) [118, 119, 125, 143, 144], and in 
males and females taking estrogen preparations alone [118, 145]. In contrast, subjects given 
progestogen contraceptives or progestogen preparations did not display any significant 
changes in tryptophan metabolism [145, 146]. Therefore it is apparent that estrogen 
components of the oral contraceptives are associated with these metabolic changes. 
The profile of the metabolite excretion changes is similar to that which is observed in 
pyridoxine deficiency. Supplementation of pyridoxine alleviates this and enables a more 
regular excretory pattern [118, 119, 143, 145, 146]. It was observed that XA can increase 
within the first month of taking oral contraceptives, and by three months the levels of KYN, 
XA, 3-HK and 3-HAA may all be elevated [146]. After approximately five months of 
estrogen treatment, these metabolites can reach the higher levels of excretion that are 
measured in severe pyridoxine deficiency [145, 146].   
The tryptophan load tests also revealed that the ratio of excretion of 3-HK:3-HAA is 
increased in subjects that take oral contraceptives or estrogen preparations [119, 147]. This 
data is consistent with what is observed in vitamin deficiency [148], and is reflective of 
impaired activity of the PLP-dependent enzyme kynureninase, as it is responsible for the 
conversion of 3-HK to 3-HAA. However other markers of a deficient vitamin B6 state, such 
as pyridoxic acid and cystathionine excretion, plasma phosphate concentrations, and 
erythrocyte alanine and aspartate aminotransferases, were not different between controls and 
women taking oral contraceptives [124, 144, 149].  
1.2.2.2 Biological observations  
Following a tryptophan load, pregnant women have been observed to excrete elevated levels 
of XA [150, 151], and other metabolites such as KYN, 3-HK, and 
N-methyl-2-pyridone-5-carboxamide (a nicotinic acid metabolite) were also increased in 
comparison to the same women in post-partum and controls [152, 153]. The levels of these 
metabolites lowered towards the normal values when given pyridoxine supplementation [151, 
153], while the administration of other vitamins produced no effect on the excretory patterns 
[153]. Post-partum women also excreted higher levels of KYN, KYNA, XA, and 
acetylkynurenine than controls, indicating that a return to normal tryptophan metabolism 
takes some time [153].  
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It is suggested that pregnancy is associated with a possible vitamin B6 deficient-like state due 
to increased demands of the vitamin or as a result of hormonal changes, such as an increase in 
estrogen levels. Supporting the former notion, in pregnant women the concentrations of PLP 
decreased and XA levels increased, following a tryptophan load, throughout the duration of 
the pregnancy [154]. However for a given PLP concentration, the levels of XA produced 
were greater in pregnant women than non-pregnant women, suggesting that a vitamin B6 
deficiency is not the sole reason for this metabolic change [154]. In rats, a pregnant state 
alone contributed to a greater reduction in the kynureninase activity than vitamin B6 
restriction induced by dietary changes [155]. 
The stage of the menstrual cycle also appears to affect metabolite levels, with XA, 3-HK and 
3-HAA all increasing at the time of ovulation [156].  Metabolite excretion in different age 
groups of Japanese and British women displayed that the levels of XA, 3-HK and 3-HAA 
were higher in pre-menopausal women than post-menopausal women [156, 157], and also 
men [156], following a tryptophan load test. As was indicative of estrogen studies, 
pre-menstrual British women had total metabolite excretion levels correlating with increasing 
plasma estrogen levels [157]. However, the metabolite levels of post-menopausal women 
were not different to men [156]. 
1.2.3 Sexual dimorphism in disease states 
1.2.3.1 Alzheimer’s disease 
In AD, which typically affects people from the age of 65 and older, women have a higher 
incidence rate than males in corresponding age groups [158]. Reduced estrogen may increase 
the risk factor for AD, as both AD mice models and post-mortem brain examinations of 
women with AD revealed depleted levels of estrogen in the brain, relative to controls [159]. 
However evidence for estrogen treatment in AD is contentious, with studies showing that it 
may both decrease the risk of AD [160, 161] and improve cognitive performance[162], or 
conversely increase the risk of probable dementia [163]. The latter study enrolled women 
aged 65 years and older, and consequently it has since been hypothesised that a window of 
opportunity may exist shortly after menopause in which hormone replacement therapy may 
be effective [164, 165]. 
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1.2.3.2 Parkinson’s disease 
Men have a higher incidence rate of PD than women, with a 1.5 – 2 times greater relative risk 
[166, 167], and the risk to women increases following oophorectomies [168]. Most women 
were found to develop PD after menopause [169], and a greater exposure to endogenous 
estrogen correlated with later onset and reduced severity of PD [169, 170]. Whether age of 
onset differs between males and females is not clear however, with studies suggesting that it 
is later in females than males [171] or that no difference exists [172].  Estrogen therapy in 
postmenopausal women has been associated with a lowered risk of developing PD [173], and 
in patients that had PD, it improved motor disability scores [174]. However a meta-analysis 
of fourteen observational studies concluded that hormonal replacement therapy ultimately 
may not be effective in PD [175]. 
1.2.3.3 Schizophrenia 
An association with estrogen is also seen in schizophrenia, where males have an earlier peak 
age of onset, between 15 – 25 years, than females, whose peak is between 20 – 29 years 
[176]. This later peak for females may be linked to a protective effect of relatively higher 
estrogen levels during adolescence [177]. Reinforcing this, females display a secondary peak 
of late onset schizophrenia during the ages of 45 – 49 [176], which coincides with lower 
estrogen levels during menopausal transition [178, 179].  Further, women that have 
schizophrenia have reduced levels of estrogen in all phases of their menstrual cycle, and the 
severity of schizophrenia is also associated with low circulating estrogen levels [180, 181].  
1.2.4 Concluding remarks 
Evidence of the ability of estrogen to induce TDO is not conclusive, however kynureninase, 
KMO and KAT inhibition is well supported. Impaired adrenal status was also shown to 
reduce kynureninase and KAT activity, while ovariectomies increased KAT activity. Whether 
by administration of synthetic estrogen preparations, through oral contraceptives or 
otherwise, or as a result of natural fluctuations of estrogens in different stages of life, higher 
estrogen levels result in a larger accumulation of kynurenine metabolites. This effect of 
estrogens on the kynurenine pathway enzymes and metabolites is similar to that seen in 
vitamin B6-deficient states, and in many situations the enzyme activity and metabolite levels 
were reversed by PLP supplementation. 
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The effect that some of these raised metabolite levels have on different diseases has been 
discussed in section 1.1.4. However, with an effect on the kynurenine pathway, estrogens 
may further introduce sexual dimorphic considerations into these conditions. In PD and 
schizophrenia, males typically have a lower age of onset and higher rate of incidence than 
females, which may correlate with an exposure to estrogens. AD is different in this regard, 
but tends to afflict people over the age of 65 which is after the onset of menopause. The 
evidence for benefits of estrogen therapy is conflicting with some studies suggesting good 
promise in reducing risk and improving symptoms, while others find no benefits. The 
potential inclusion of estrogen as a therapy also needs to be weighed against possible 
negatives of estrogen therapy. In looking at the treatment of dementia by the Women‟s 
Health Initiative, a combination of estrogen and progestin was found to increase the risk of 
breast cancer, coronary heart disease and stroke [182] while estrogen therapy alone has been 
found to increase the risk of stroke [183]. Other studies have shown that estrogen only 
preparations may also increase the risk of breast cancer [184]. 
1.3 Drug discovery and rational drug design 
Drug discovery is the process by which chemical entities that have a biological activity 
indicative of beneficial pharmaceutical interventions are sought to satisfy a need in treating 
medical conditions, where no therapy existed before or where improvements are desired 
[185]. Although serendipity and trial-and-error approaches have historically played a 
significant role in the development of some important drugs, with penicillin being a 
well-known example [186], rational drug design is employed as a deliberate and concerted 
approach to identify and optimise a lead molecule that generally activates or inhibits a 
specific target or pathway. There are two overarching categories of rational drug design: 
structure-based drug design (SBDD) and ligand-based drug design (LBDD). The broad 
distinction between the two is whether a three-dimensional structure of the target is used 
during the design process. 
1.3.1 Structure-based drug design 
The first step of SBDD involves identifying and validating an effective drug target that is 
linked to disease, and is druggable and safe to target [185, 187]. Ideally, or in the simplest of 
situations, the target, such as a protein, would bind a small molecule in a distinct and well 
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delineated binding site to enact its function, and compounds can be designed to compete for 
this site and modulate the effect of the target without affecting other systems. 
If a specified target in question is available, its structure is determined by experimental 
techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) [187, 188]. 
If the target is unable to be procured, homology modelling is typically used to generate a 
model based on a structure of a related protein that has been determined experimentally.  
These models can then be used to evaluate the potential ligand binding sites for a range of 
characteristics including the presence of hydrophobic regions, hydrogen bond donors and 
acceptors, water molecules, ions and cofactors. There are a number of techniques that can be 
used, not necessarily in isolation, to generate lead candidates, including virtual screening, 
visual inspection, and de novo synthesis.  
Virtual screening usually involves the computational docking of large databases of molecules 
into the active site to determine their mode of binding. Predicted interactions that the 
molecules have within the binding site are used to score and rank them, and the top hits can 
be experimentally tested for their activity. Virtual screening can be used standalone or 
complementarily to practical screening methods such as high-throughput screening (HTS), 
and is also far more cost effective than HTS [189]. More on docking calculations is discussed 
in section 1.5.3. 
Drug design aided by direct inspection requires the co-crystallisation of a target with its 
recognised ligands, such as its cofactor or substrate, or an inhibitor, in the active site [187, 
188]. These ligands can then be adapted and modified to optimise interactions within the site, 
and inhibit the activity it previously induced. The modified molecules can be further 
evaluated experimentally or by docking. 
In de novo synthesis, a ligand is built up from scratch based on constraints in the binding 
sites. Small molecules are positioned in separate regions of the site and docked in silico. 
Depending on their performance in assays, these molecules can be linked together or grown 
incrementally to form a larger ligand that encompasses the different regions of the available 
site in the protein, and can be tested experimentally. 
Potential compounds determined by these approaches, and analogous compounds that may 
also be pursued, ideally need to be stable, simple to synthesise or acquire, and orally active 
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after optimisation, the latter of which can be guided by Lipinski‟s Rule of 5 [190]. The 
compounds are tested in biochemical assays to determine their activity, potency, selectivity, 
bioavailability, and other pharmacokinetic parameters in vitro, and are optimised to improve 
these considerations [191]. Promising leads can be co-crystallised with the target to 
determine the manner in which they bind, and this can allow further optimisation. If the lead 
candidate is suitably bioavailable, safe, and potent, it can enter pre-clinical and subsequently 
clinical trials to determine pharmacokinetics, pharmacodynamics, and toxicity profiles in vivo 
[185, 191]. The entire process of drug design is an iterative one, with structural determination 
and optimisation potentially occurring repeatedly to generate the final drug candidate. 
Although ultimately drug candidates need to be evaluated in practical settings to determine 
the success of the drug design process, in silico approaches can also be used throughout the 
development process to model and optimise selectivity, pharmacokinetic parameters, and 
toxicity [192]. 
1.3.2 Ligand-based drug design 
When the structure of a target is unknown, LBDD can be employed based on what is known 
of the ligands that bind to the target [189]. Commonly used LBDD approaches include 
generating pharmacophore and quantitative structure-activity relationship (QSAR) models 
in silico, which can also then find application in virtual screening. 
A pharmacophore refers to the structural features essential for a ligand to exert biological 
activity [193]. In pharmacophore modelling, an ensemble of active compounds that exert 
their effects using the same mechanism, and inactive compounds, are required to make a 
training set. These ligands are superimposed and the features responsible for bioactivity are 
identified and represented in different pharmacophore models. 3D pharmacophores can also 
be built if sets of ligand conformations are generated prior to the modelling. The 
pharmacophore models are intended to reflect information about the ligand-target interaction 
as they characterise features such as aromatic rings, hydrogen bond donors and acceptors, 
hydrophobic regions, and regions likely to be positively or negatively ionised [189].  
Successful pharmacophores must be validated using ligands outside of the training group 
[193]. Small molecule, chemical databases can then be searched using the validated 
pharmacophore to find new potential leads that fit the constraints of the model.  
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While pharmacophore models describe features necessary for an active ligand, QSAR can be 
used to determine how chemical characteristics positively or negatively affect the activity. 
QSAR requires both structural and activity information for this evaluation. As with 
pharmacophore modelling, the initial stages of QSAR require collecting a set of compounds 
which includes known active ligands. The activity of these ligands is often expressed as a 
function of their IC50 [194], Ki [195], or EC50 [196], but may include other quantifiable 
functions if it is pertinent to the lead generation. Structural information is encoded into 
quantifiable information in the form of weights given to molecular descriptors [197]. The 
correlation between the biological activity and the descriptor values are evaluated by QSAR 
algorithms to develop a robust model, which is validated and used to predict the activity of 
new compounds [189]. 
1.4 Fragment-based drug design 
Fragment-based drug design (FBDD) is one of the more recent and important approaches 
taken in drug discovery, and as with HTS, it involves a screen performed in the initial stages 
of lead development. The main feature of FBDD which differentiates it from other techniques 
is the utilisation of low molecular weight fragment molecules, typically envisioned to be less 
than 300 Da [198].  
Fragment libraries are generally much more manageable and smaller than libraries in HTS, 
using fewer than 5 x 10
3
 compounds compared to often 1 x 10
6
 compounds [199]. However 
estimates of the size of the chemical space for molecules less than 160 Da is around 1.4 x 10
6
 
compounds [200] while the total chemical space is in the region of 1 x 10
60
 compounds [201], 
and therefore the smaller fragment libraries may be considered to sample the chemical space 
much more efficiently than in HTS. Smaller molecular dimensions and reduced complexity 
means that fragments are inherently more promiscuous, with up to 10 – 1000 times higher hit 
rates than in HTS [202].  
However, the lower functionality also means that fragments bind with weaker affinity, and 
therefore a sensitive biophysical detection technique must be used such as fluorescence-based 
thermal shift, X-ray crystallography, NMR, or surface plasmon resonance (SPR) [203]. 
Higher concentrations are also used in fragment detection to off-set the weak binding, and so 
this can increase the risk of false-positives through aggregation and non-specific binding. 
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1.4.1 Detection techniques 
Fluorescence-based thermal shift measurement is a relatively fast method of detection [204]. 
Fragment binding is expected to stabilise the folded target, and therefore an increase in 
temperature is required for unfolding if binding occurs. This change is measured and a 
fragment is considered a hit if the temperature increase exceeds the standard deviation of the 
melting point. However, the reproducibility of results in this method is poorer than in others. 
In X-ray crystallography, large cocktail solutions, sometimes containing up to 100 fragments, 
are soaked into crystals of the target [199]. Because of the low affinity of fragments, high 
concentrations of 25 – 100 mM are not unusual. A resolution for  the structure  of 2.5 Å or 
better is preferable [204], and software such as AutoSolve can be used to automatically and 
rapidly fit ligands into the electron density maps with minimum intervention [205]. The 
ligands that bind can then be re-screened as a single fragment if necessary to confirm the hits. 
Apart from determining the location of the ligand binding site, specific details of the 
interaction can become available through crystallography. 
NMR can be used to detect fragment binding by many different techniques, including 
1
H, 
13
C 
or
 15
N NMR to measure chemical shift, 
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F NMR to measure chemical shift anisotropy, 
saturation transfer difference NMR, and water ligand observed via gradient spectroscopy 
[199]. The many approaches allow NMR to be used in a wide range of ligand and target 
structures. Broadly there are two categories of detection methods used: protein-detected 
NMR and ligand-detected NMR [203]. In protein-detected methods, the spectra of the target 
protein with and without the presence of fragments are compared, and changes to the 
chemical shifts can indicate binding. If individual residues in the protein are able to be 
assigned to the chemical shifts, the fragment binding site can be determined based on these 
changes. Drawbacks of the protein-detected method are that it is restricted to smaller proteins 
and consumes larger amounts of protein. In contrast, ligand-detected methods, which rely on 
changes to NMR parameters of the fragments instead of the protein, can be used with proteins 
of any size, and consume less sample.    
In SPR, the target protein is bound onto a channel in a gold sensor chip and the fragments are 
subsequently allowed to flow through over the protein [206]. Molecules that interact with the 
target can be detected in real-time by properties relating to the mass changes that occur on the 
surface of the chip upon binding. Binding can be further analysed to measure affinity, and 
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kinetic parameters such as the association and dissociation rate constants, although in the case 
of fragments the interactions may often be too rapid to determine these rate constants. SPR 
allows large libraries to be screened quickly with relatively little protein consumption, and 
multiple proteins may be screened simultaneously in multi-channel chips. SPR is discussed in 
further detail in section 1.5.4. 
The detection techniques described above can be used in conjunction with one another as part 
of a fragment screening cascade. High-throughput methods such as fluorescence-based 
thermal shift and SPR can be used as a primary screen for hits. The hits can be validated 
using an orthogonal method such as NMR, and fragment binding is typically evaluated using 
X-ray crystallography for optimisation by SBDD approaches. However, it is also possible to 
directly detect fragment hits in a screen and evaluate binding of specific fragments in parallel 
by X-ray crystallography, through crystal soaking. 
1.4.2 Hit evaluation 
Once a screen for fragments is completed, the hits must be evaluated. Similar to Lipinski‟s 
Rule of 5 governing drug-like compounds, a “Rule of 3” was proposed for fragments with the 
criteria [198]: 
 Molecular mass ≤ 300 Da 
 No. of hydrogen bond donors ≤ 3 
 No. of hydrogen bond acceptors ≤  3 
 cLogP (the partition coefficient) ≤ 3.  
However this exists only as a guideline and success has still been possible when neglecting 
one or more parameters [203].  
Because fragments have low molecular weight and are innately weak binders, steps can be 
taken to evaluate hits relative to their size to get a corrected reflection of their affinity [203, 
207]. One metric used is measuring the ligand efficiency of molecules, which is calculated as 
follows: 
   
      
            
 
Equation 1-1.    is the ligand efficiency,    is the free energy of binding, and              is the number of 
non-hydrogen atoms in the ligand. 
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Because    can be expressed as              , Eq. 1 can be re-written as:  
   
             
            
 
Equation 1-2.   is the ideal gas constant,   is the temperature, and    is the dissociation constant. 
For a drug-like compound that has a desirable KD of 10 nM, and fits within the upper limit of 
Lipinski‟s Rule of 5 for the maximum molecular mass (i.e. 500 Da, which is approximately 
38 non-hydrogen atoms), the ligand efficiency can be calculated to be 0.29 kcal mol
-1
 per 
heavy atom at standard conditions (R = 1.987 x 10
-3
 kcal K
-1
 mol
-1
, T = 300 ºK). Using this 
value as a benchmark, one can better assess fragment hits. For example, while a fragment 
molecule of mass 200 Da with a KD of 1 mM can be described as having low absolute 
affinity, the ligand efficiency calculated for it is the same at 0.29 kcal mol
-1
 per heavy atom.  
Other metrics to evaluate fragments have been proposed considering parameters such as 
molecular mass, lipophilicity, binding efficiency index and polar surface area. By whichever 
criteria, when the hits are selected they proceed to the next stage of the development cycle, 
where they are elaborated to improve the potency from the millimolar range of a hit towards 
the nanomolar range of a drug candidate. Because fragments are smaller molecules, they have 
a greater capacity for optimisation while remaining within the constraints of being suitable as 
a drug-like compound.  
1.4.3 Elaboration of fragment hits 
As with a standard SBDD approach, optimisation involves an iterative process of structural 
determination, through X-ray crystallography or NMR, and binding affinity measurements. 
There are three main categories of elaborating fragment hits: fragment growing, fragment 
merging, and fragment linking.  
The process of fragment growing begins with identifying a single region in which a fragment 
or set of fragments bind within the active site [199, 204]. By analysing the interactions 
formed by the hits, related fragments or novel fragments can be formulated to optimise the 
interactions at this specific part of the site. Alternatively, the ideal fragment scaffold to 
pursue could be an unaltered hit from the initial screen. For the initial, selected fragments, 
functional groups are incrementally placed onto the structure in an iterative process to form 
further contributing interactions with other parts of the active site. It is ideal to evaluate 
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structural information and binding affinity of the fragments at each stage of growth of the 
prospective molecules to conclude if the modifications were optimal. Metrics such as ligand 
efficiency can assist with these determinations. An example of fragment growth is seen in 
Fig. 1-2, showing the development of PIN1 inhibitors [208]. The initial fragment was 
extended (IC50: 180 μM) by a benzyl amide moiety which improved inhibition six-fold 
(IC50: 31 μM), and the subsequent placement of a chlorine to fill a small pocket in the active 
site near the phenyl ring of the fragment improved it further (IC50: 2 μM).  
   
Figure 1-2. Fragment growth used to develop PIN1inhibitors [208]. In each of the panels, the region of the 
PIN1 binding site (PDB ID: 2XP4) is represented in cartoon form and in light green, in the same 
orientation. The progress of the incremental inhibitor design is from left to right. The initial fragment is 
displayed with yellow carbons, and the improved inhibitor, after growth using a benzyl amide moiety and 
then chlorine (green), is shown by the structures containing red and orange carbons, respectively. The 
structural figures in this chapter have been created with PyMOL [209], unless otherwise stated. 
Fragment merging is employed when multiple fragment hits are bound to a similar region 
with both overlapping and unique contacts [204]. By combining the fragments at the location 
of the overlap, a new, single, more potent fragment can be sought that interacts with a 
broader region. Fig. 1-3 displays the fragment merging process employed to produce a lead 
molecule, with a KD of 28 μM, from two haem protein-binding fragments, with a KD of 
1.6 mM and 400 μM, that were hits in an original screen against the Mycobacterium 
tuberculosis CYP121 enzyme [210]. 
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Figure 1-3. Fragment merging used to develop a Mycobacterium tuberculosis CYP121 inhibitor [210]. 
The active site of the enzyme (PDB ID: 4G44) is displayed in cartoon form and in green, in the same 
orientation, and contains the bound fragments and the haem cofactor (purple). The two fragments, displayed 
in the left and middle panels with yellow and red carbons, respectively, were merged together to create a 
more potent lead inhibitor, shown with orange carbons, on the right panel. 
Fragment linking involves joining multiple fragment molecules that bind to distinct, 
non-overlapping regions of the active site [199, 204]. The ideal linker will allow the fragment 
hits to maintain their optimum configurations at their respective binding sites, and may 
feature additional contacts with the protein. A compound formed by fragment linking is also 
expected to have binding free energy greater than the sum of the individual fragments 
because of reduced translational and rotational entropic penalties. In Fig. 1-4, fragment 
linking is shown in the development of a replication protein A inhibitor [211]. Two 
fragments, binding in two separate sites, had a KD of 580 μM and 1400 μM, respectively. The 
resulting linked compound was vastly more potent with a KD of 26 μM. 
   
Figure 1-4. Fragment linking used to develop a replication protein A inhibitor [211]. The binding site 
(PDB ID: 4LUV) is represented cartoon form and in green, in the same orientation. The two fragments that 
bound initially, displayed with yellow and red carbons in the left panel, were linked together to produce a 
more potent inhibitor, shown with orange carbons, in the right panel. 
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Beyond the initial consideration of improving potency through fragment growth, merging and 
linking, further optimisation steps are similar to SBDD to also improve the selectivity, 
physicochemical properties, and other desirable drug-like traits.  
1.4.4 Successes in fragment-based drug design 
Arguably the first demonstration of FBDD was a little over two decades ago, when NMR was 
used for the detection of fragment hits and identification of the residues they bound to [212]. 
Fragments binding to two different sites of the target, FK506 binding protein, were sought 
and discovered. The two fragments were optimised for binding at their respective sites by 
observing structure-activity relationships, yielding molecules with a KD of 2 μM and 
100 μM. A linker between these two fragments was demonstrated to yield a tightly binding 
compound with a KD of 19 nM. 
In the relatively short time that has followed, over thirty drugs derived from FBDD 
approaches have entered clinical trials [213].  Vemurafenib, indicated for late-stage 
melanoma, was the first of these fragment-derived drugs to gain approval from the United 
States Food and Drug Association and entered the market a mere six years after its 
development began, in 2011. More recently, in 2016, venetoclax was also approved for the 
treatment of chronic lymphocytic leukaemia. The speed in which FBDD approaches can 
develop a drug is a significant bonus to the prospect of finding effective, novel compounds. 
1.5 Techniques used in the study and related theory 
Novel, reversible KAT-II inhibitors were designed and developed for the purpose of reducing 
brain KYNA levels, to aid in the treatment of schizophrenia. Wet-lab techniques employed in 
this endeavour included detecting protein binding interactions using SPR, and characterising 
KAT-II structure, activity and inhibition using assays and X-ray crystallography, all of which 
required suitable amounts of KAT-II to be expressed. Molecular modelling was also used to 
supplement these techniques with an in silico approach.  
1.5.1 Protein production and enzymology 
1.5.1.1 Heterologous protein expression and purification 
There are many variables in protein production protocols, and therefore the following is 
intended as a general outline that describes heterologous expression in prokaryotic organisms.  
26
  
Initially, complementary DNA is obtained by amplification of genomic DNA of eukaryotic 
cells or by gene synthesis, and this is sub-cloned into an expression vector [214]. The DNA 
sequence can be fused to incorporate other features including affinity tags, such as an 
N-terminal hexahistidine tag, which are designed to aid in protein purification without 
affecting the structure or characteristics of the protein. 
A commonly used expression vector is the pET vector, which regulates recombinant gene 
expression by the T7 RNA polymerase promoter (responsible for stimulating expression) 
[215] and lac operator (responsible for preventing expression) [216]. Expression vectors are 
transformed into bacterial cells of a chosen strain by inducing increased permeability of the 
outer membrane of the cells through processes such as heat shock, chemical treatment, or 
electroporation. 
The BL21(DE3) strain of E. coli is widely used as it is compatible with the T7 promoter and 
lac operator system [215]. In addition to the recombinant gene, antibiotic resistance (for 
example, resistance to ampicillin or carbenicillin) is also embedded into the expression vector 
that is transformed into the bacteria. By growing the bacterial cells on a media containing the 
selected antibiotic, the survival of the bacterial cells will be limited to those that have 
successfully incorporated the expression vector containing the antibiotic resistance and the 
recombinant gene. These surviving colonies are then amplified to larger quantities and, in T7 
systems, chemical inducers such as isopropyl-β-D-thiogalactoside or auto-induction through 
manipulation of the carbon source [217] are used for promoting protein expression. 
The bacterial cells are then lysed chemically or mechanically to extract the recombinant 
protein [214]. The conditions used in this step ideally maximise lysis, and protein solubility 
and stability by using a high ionic strength buffer, while minimising protein oxidation and 
proteolysis by using reducing agents and protease inhibitors, respectively, in the buffer.  
A histidine tagged protein in the bacterial lysate can be purified relatively simply using 
immobilised metal affinity chromatography (IMAC), as the metal ions in the column have 
affinity towards the tagged protein thereby retaining it in the column [218]. Imidazole can be 
used to out-compete the retained molecules for the metal ions, by raising its concentration in 
a step-wise gradient in order to elute contaminants, and then the recombinant protein itself. 
EDTA and DTT can be added to the eluted protein at this step to reduce aggregation by metal 
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ion contaminants [219] and to prevent the formation of unwanted disulfide bonds [220], 
respectively.  
If desirable and designed in such a way, the affinity tags fused onto the protein may be 
cleaved for the purpose of promoting native structure or activity [214]. Additional generic 
purification steps, such as gel filtration, can also be taken if the protein purity is insufficient. 
The purity and quality of the protein can be evaluated using methods such as SDS-PAGE, 
UV spectroscopy, mass spectroscopy, and activity assays. Most proteins can be stored safely 
at -80 ºC with their activity retained after thawing. 
1.5.1.2 Enzyme kinetics – single substrates 
The kinetic profile of many enzymes can be modelled by Michaelis-Menten kinetics [221, 
222]. This model describes reactions in which the enzyme (E) binds to a substrate (S), 
forming an enzyme-substrate complex (ES), and catalyses the formation of the product (P). 
This can be represented schematically as: 
    
  
 
   
   
  
 
 
     
Scheme 1-1. The enzyme and substrate react to form the product. k1, k-1, and k2 describe the rate constants of 
the ES formation, ES dissociation to E and S, and P formation, respectively. 
It is assumed in Scheme 1-1 that the product does not revert back to the initial substrate. In 
this scenario, the formation and breakdown of the [ES] complex at steady-state is expressed 
by the Michaelis-Menten constant, KM. KM is independent of enzyme concentrations, and is 
given by Eq. 1-3:  
   
        
  
 
Equation 1-3. The rate constants k-1 and k2 represent the breakdown of the ES complex, while k1 represents the 
formation of the ES complex. 
At a fixed enzyme concentration, the rate of enzyme catalysis (V0) varies with the substrate 
concentration, as reflected in the Fig. 1-5 plot. When the substrate concentration is small, V0 
rises almost linearly. As the substrate concentration increases, the reaction velocity increases 
asymptotically until it approaches maximum velocity (Vmax). The substrate concentration 
required to achieve half of Vmax is given by KM. The relationship between enzyme velocity, 
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substrate concentration and KM can be mathematically derived into the Michaelis-Menten 
equation (Eq. 1-4). 
 
 
Figure 1-5. Plot of reaction velocity measured against substrate concentration for an enzyme reaction. At 
high substrate concentrations the velocity approaches the Vmax. 
 
    
       
        
 
Equation 1-4. The Michaelis-Menten equation. 
Eq. 1-4 has embedded within it the features observed by the plot in Fig. 1-5. At low substrate 
concentrations where [S] is negligible compared to KM, the enzyme velocity is directly 
proportional to the substrate concentration (i.e. V0 = [S][Vmax/KM]). At substrate 
concentrations much greater than KM, the enzyme velocity will be at maximal capacity 
(i.e. V0 = Vmax). When substrate concentration is equal to the KM, the definition of the 
Michaelis-Menten constant is derived (i.e. V0 = Vmax/2). 
KM can approximate [ES] affinity when the value of k2 is small, where a low KM reflects 
strong binding and a high KM reflects weak binding [222]. Unlike KM, the Vmax of an enzyme 
is dependent on enzyme concentration (Eq. 1-5). 
               
Equation 1-5. kcat is the catalytic rate constant, [E]T is the total active site concentration. 
In the scenario described by Scheme 1-1, kcat is equal to k2. kcat, also known as the turnover 
number, is another important descriptor of the kinetics. The turnover number is the maximum 
number of conversions of substrate to product by one molecule of enzyme active site per unit 
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time when the enzyme is fully saturated. Also the ratio of kcat/KM is a measure of catalytic 
efficiency, and can be used to compare the preference of an enzyme for different substrates. 
1.5.1.3 Enzyme kinetics – multiple substrates 
Many systems are capable of involving two substrates and the release of two products, as 
either sequential displacement reactions or double displacement reactions (also known as 
ping-pong reactions) [223]. Sequential displacement reactions require the binding of all the 
substrates to the enzyme to form a ternary complex before the products are released. These 
substrates bind to the enzyme in an ordered (Fig. 1-6A) or random (Fig. 1-6B) manner. In 
double displacement reactions, products are released before other substrates interact with the 
enzyme (Fig. 1-6C). The KAT enzymes are examples where double displacement reactions 
take place. Briefly, KYN enters the active site and reacts with the enzyme-PLP complex, 
transferring an α-amino group onto PLP and converting the latter into PMP. Subsequently, 
KYN itself spontaneously closes its ring structure to form the product, KYNA, and then is 
released. PMP then transfers the α-amino group onto a second substrate, an α-ketoacid, and 
regenerates back into its PLP form. 
 
Figure 1-6. Diagrams showing reaction schemes in the abbreviated Cleland notation. (A) Ordered 
sequential reaction. (B) Random sequential reaction. (C) Double displacement/ping-pong reaction. A and B 
are substrates, P and Q are products, E is the enzyme. E‟ is the altered state of the enzyme after reacting 
with the substrate in double displacement reactions. Adjoining letters represent complexes that are formed. 
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1.5.1.4 Enzyme inhibition 
Enzyme inhibition can be broadly classified as irreversible or reversible inhibition, and the 
latter can be further subdivided into competitive inhibition, uncompetitive inhibition, mixed 
inhibition, and noncompetitive inhibition [224, 225]. 
Competitive inhibition refers to the mutually exclusive binding of a substrate or inhibitor to 
an active site of an enzyme. In this manner, the substrate and inhibitor inherently compete 
with one another for this site. The dissociation constant of the enzyme-inhibitor complex, Ki, 
is a parameter that is used to evaluate the potency of an inhibitor at an enzyme. A high Ki 
signifies that the enzyme-inhibitor complex dissociates quickly and therefore has weak 
affinity, whereas a low Ki indicates tight binding between the enzyme and inhibitor. Due to 
the presence of the inhibitor, the substrate concentration needs to be higher to achieve a given 
reaction rate and therefore the apparent KM increases in competitive inhibition.  However the 
Vmax for an enzyme remains unchanged as saturation concentrations of the substrate can 
completely overcome the inhibition.  
Uncompetitive inhibitors bind only to an enzyme-substrate complex, without affecting the 
free enzyme. Depletion of the enzyme-substrate complex not only results in the Vmax 
lowering but also shifts the equilibrium of free enzyme and substrate to produce more 
enzyme-substrate complexes, increasing substrate consumption (i.e. the enzyme has higher 
substrate affinity) and decreasing the apparent KM. 
In mixed inhibition, the inhibitor can bind to the enzyme alone or the enzyme-substrate 
complex with different affinities. In either case, mixed inhibition results in the Vmax being 
lowered and can alter the KM. If the affinity of the inhibitor for the free enzyme is greater 
than the enzyme-substrate complex, then the KM will increase by affecting substrate binding. 
Conversely, if the affinity of the inhibitor for the enzyme-substrate complex is greater, then it 
will resemble uncompetitive inhibition in that a decrease in apparent KM will be observed. 
Noncompetitive inhibition is a special case of mixed inhibition, where the affinity towards 
the inhibitor binding to the free enzyme alone or the enzyme-substrate complex is equal. 
Resulting from this is that there is a lower pool of active enzymes available, which decreases 
the Vmax, but substrate binding is unaffected and the apparent KM remains the same.  
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The potency of reversible inhibitors can be expressed by the IC50, which is the inhibitor 
concentration required to achieve 50% inhibition [226]. IC50 values are dependent on the 
assay conditions such as substrate concentration, protein concentration, and incubation times, 
and therefore it is difficult to compare IC50 across different experiments unless the protocols 
are standardised. Another invaluable constant is the Ki, as it is in theory independent of assay 
conditions. 
Irreversible inhibitors permanently inactivate an enzyme or effectively do so by very tightly 
binding and not dissociating within a biologically relevant time period [227]. Permanent 
inactivation of the enzyme typically occurs by the formation of a covalent bond with key 
features in the active site of the enzyme, rendering the enzyme incapable of functioning, 
however some irreversible inhibitors can act on allosteric sites [228]. As irreversible 
inhibition steadily decreases the amount of free enzyme available over time without 
dissociation, an IC50 is an inappropriate measure of potency and will instead reflect a value 
biased by the total enzyme concentration in the assay. Therefore, irreversible inhibitor 
potencies are often expressed by the ratio of the rate of enzyme inactivation (Kinact) and the 
inhibition constant (Ki). 
1.5.2 X-ray crystallography 
1.5.2.1 Protein crystallisation 
As the function of proteins is dependent on their 3D conformations, and as describing ligand 
binding is an imperative aspect of drug design, considerable effort is often spent to observe 
both by the structural determination of proteins. X-ray crystallography is at the forefront of 
techniques employed for this task, especially when handling large proteins [229]. There are 
two significant bottlenecks in X-ray crystallography, namely the production of pure, 
concentrated protein solutions (5 – 15 mg/mL), and the establishment of the particular 
conditions for high-quality crystal production [230]. The premise of crystal production is to 
vary protein solution conditions so that a non-equilibrium, supersaturated state is created, so 
as to promote crystallisation as the equilibrium is re-established [231].  
Supersaturation drives the two important steps in crystallisation: nucleation and growth of 
crystals [232]. Nucleation involves a phase transition from a disordered solution to an ordered 
crystalline lattice for a small cluster of proteins, called the nucleus. Crystal growth occurs 
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when molecules are incorporated onto the nucleus surface, causing the body of associated 
molecules to increase in size.  
A phase diagram can be used to consider the relationship between saturation and 
crystallisation [233]. The phase diagram illustrated in Fig. 1-7 describes the solubility of the 
protein as a function of the precipitant concentration. This diagram considers just one 
parameter for simplicity, as many variables aside from precipitant concentration can affect 
the system, such as buffer conditions, additives, and the pH, ionic strength and temperature of 
the solution. The phase diagram is separated into undersaturated and supersaturated regions 
by the solubility line, and the supersaturated region is further divided (although by no 
definitive boundaries) into the metastable zone, labile zone, and precipitation zone.  
 
Figure 1-7. Phase diagram displaying solubility as a function of precipitant concentration. The solid black 
curve is the solubility curve. The dotted boundaries between the metastable, labile and precipitation zones 
are reflective of these zones being less definable than the solubility curve. This figure is also a schematic 
representation of the processes that occur in the following crystallisation methods: (A) microbatch in 
paraffin oil, (B) vapour diffusion, (C) dialysis, (D) free interface diffusion. The solid black circles represent 
the starting conditions in the respective methods. Figure adapted from Chayen et al., 2008 [230]. 
Supersaturation has to exceed the solubility by at least a factor of three for spontaneous 
nucleation to occur, and the area corresponding to this in the phase diagram is the labile zone. 
In the metastable zone, supersaturation is too low for nucleation to occur quickly enough to 
be considered practical. Ideally, once nuclei are formed, the protein concentration will 
reduce, taking the system from the labile zone into the metastable zone, which will promote 
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crystal growth without concomitant nucleation. If supersaturation is too pronounced, 
corresponding to the precipitation zone, aggregates and precipitates form faster than crystals, 
which is also undesirable. Unrestrained nucleation by high supersaturation can also result in 
too many competing crystals, which is not conducive to productive growth. 
As previously mentioned, there are many variables that can be altered to try to increase the 
likelihood of crystallisation. However there are no clear correlations between the optimal 
crystallisation conditions and the type of protein dealt with [230]. Screening must therefore 
generally be performed by trialling the protein with a wide range of agents and conditions. 
Although larger laboratories may screen as many as 1000 crystallisation conditions per 
protein, it is estimated that approximately 300 trials ought to be sufficient for finding the right 
conditions [234].  
There are different methods that can be employed for crystallisation, including microbatch 
experiments, vapour diffusion, dialysis and free interface diffusion, typically using equal 
volumes (approximately 0.5 – 1 μL) of protein solution and precipitant solution for screening 
[230].  
In microbatch experiments, the protein and precipitant solutions are mixed into a well and 
covered with paraffin or silicone oils or a combination of the two. Often the solutions are 
mixed into their final concentrations (Fig. 1-7A), as the aqueous samples within paraffin oils 
are protected from evaporation (as an aside, they are also protected from airborne 
contamination). The inclusion of silicone oils to the oil phase, either alone or as a mixture, 
allows the diffusion of water, which can cause a faster increase in protein and precipitant 
concentration and may be conducive to an increased success rate for crystal growing [235].  
Vapour diffusion is the most commonly used method for crystallisation [230]. A droplet of 
protein mixed with reagents, including buffers and precipitant, is set to equilibrate against a 
much large reservoir (500 – 1000 μL) that typically contains a higher concentration of these 
reagents. The protein and precipitant concentration in the droplet rises gradually as water 
vapour slowly leaves the droplet for the reservoir solution, allowing supersaturation and 
crystal growth (Fig. 1-7B). Vapour diffusion can be accomplished by sitting drops into a shelf 
within the well or by hanging drops on siliconised or plastic coverslips, with the wells sealed 
by clear sealing tape or coverslips (Fig 1-8) [236]. 
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Figure 1-8. Vapour diffusion by hanging drop (left) and sitting drop (right). The water diffuses from the 
droplet through the vapour phase, concentrating the protein solution. 
The dialysis method uses a semipermeable membrane that separates the protein solution and 
the precipitant solution [237]. By establishing a concentration gradient, the small precipitant 
molecules are allowed to diffuse and mix with the protein solution, and approach 
concentrations that allow crystallisation to occur (Fig. 1-7C). An advantage of dialysis during 
trialling of crystallisation conditions is that the sample can be recycled by changing the 
reservoir containing the precipitant solution, allowing different conditions to be tested. 
In the free interface diffusion technique, concentrated protein and precipitant solutions are 
layered over each other in a capillary. Upon opening of the valves at the interface, the 
solutions begin to slowly diffuse into one another and forms supersaturated conditions 
optimal for nucleation (Fig. 1-7D). As further diffusion occurs over time, the two solutions 
dilute one another, reducing protein concentrations until nucleation is no longer induced 
spontaneously but growth of the existing crystals can occur. In this manner, the system 
almost selects its own optimal conditions for nucleation and crystal growth, assuming 
suitable precipitants, buffers, additives, and other variables are already selected [230]. 
However it can also be tailored to screening trials by feeding protein solution into multiple 
capillaries that come into contact with different precipitant solutions. 
In addition to growing crystals of the native protein, often it is also desirable to form and 
observe protein-ligand complexes within the crystal structure. This can be achieved by using 
the ligand during protein expression or protein purification steps, co-crystallising the ligand 
by adding it to the protein during the crystallisation method, or soaking existing protein 
crystals with the ligands prior to X-ray diffraction [238].  
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1.5.2.2 X-ray diffraction 
There are a range of physical characteristics that make crystals less appropriate for diffraction 
experiments including having a needle-like structure, growing as a cluster, containing defects, 
and being of an inadequate size [239]. If suitable protein crystals have been procured, their 
structures can be determined at an in-house X-ray generator or at a synchrotron.  
The initial step in X-ray diffraction involves positioning a single crystal on a small loop and 
flash-freezing it by placing it in a stream of cold gas or submerging it in a liquid cryogen 
[240]. The cryocooling of crystals reduces both the damage induced by X-ray radiation, and 
the noise caused by thermal displacement of atoms [241]. However, crystals may need to be 
soaked with cryoprotectant to minimise damage from the cooling itself. There are also 
questions about the biological relevance of proteins at low temperatures, as side-chains, 
should they ordinarily be very flexible, may be sensitive to changes in temperature and may 
go from being mobile at room temperature to well-ordered at low temperatures [240]. 
Nevertheless, cryocooling can significantly improve the quality of the data. 
The cryocooled crystal is mounted onto a spindle, where it is kept at low temperatures by a 
stream of cold nitrogen during the experiment, and exposed to X-rays to obtain diffraction 
patterns as it is rotated [242]. A crystal diffracting close to 3 Å will be sufficient to display 
the basic contours of the protein chain in the electron density maps, while high resolution 
images at 1 – 1.5 Å can clearly display individual atoms in the map. Important information on 
the crystal and the diffraction dataset is obtained from the data processing steps, which 
include calculating the unit cell dimensions (which is the smallest repeating unit in the 
crystal, expressed as lengths a, b, and c, and angles α, β, and ), integrating the intensities of 
the diffraction images, determining the space group which describes the symmetry of the 
crystal, and scaling and merging of multiple images and symmetry equivalent reflections into 
a single set of internally consistent measurements [243].  Statistics generated from data 
processing, such as the resolution, merging R values, multiplicity or redundancy 
of individual reflections, signal-to-noise ratio, and data completeness, can be used to 
assess the quality of the data. 
The intensity of the spots on an X-ray diffraction pattern is a function of the amplitude of the 
diffracted waves and the phase difference between them [242]. The amplitude can be 
calculated directly but phase information must be obtained by other means, such as with 
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multiple isomorphous replacement (MIR), multiwavelength anomalous dispersion (MAD) or 
molecular replacement (MR) approaches. Knowledge about the amplitude and phase 
information allows the determination of structure factors, which can allow the electron 
density map to be calculated. 
MIR and MAD are used when no related structures have been solved. Both techniques 
require the acquisition of X-ray diffraction data sets of the native protein, and of heavy atom 
derivatives [244]. Heavy atom derivatives are achieved by soaking the protein in a buffer 
containing ions of a heavy atom, such as mercury or platinum, or co-crystallising the protein 
with such agents. For the purpose of MIR, the heavy atoms bind to the protein structure, and 
the resultant crystal is said to be isomorphous if it is of the same conformation and unit cell 
dimensions as the native protein. A comparison of the differences in the two data sets allows 
the location of the heavy atoms in the protein to be determined, and this is used as the basis 
for calculating the phase information. One heavy atom derivative can give two possible 
solutions for the phase, but using a second heavy atom derivative allows the calculation of a 
true, unique solution. In MAD, heavy atom derivatives provide interpretable changes to the 
phases when the datasets are collected at different wavelengths. 
MR can be used when a related protein is available to be used as an approximate model of the 
unknown structure [245]. A root mean square deviation (RMSD) of 1.5Å or lower between 
the search model and the target is generally considered to be suitable for MR. The model that 
is used is rotated and translated until its orientation and position in the unit cell is a suitable 
fit with the experimental data.  Structure factors from the oriented model are utilised to apply 
the phase information onto the experimental data set, which, along with the experimentally 
derived amplitudes, is used as a starting point to calculate a new electron density map by 
performing a Fourier transform [242].  
While MR already has a coordinate set with which to work, the output of MIR and MAD is 
just the map therefore the protein model must be built by introducing the amino acid residues 
into the map. Once a model of sufficient quality is generated, it undergoes successive cycles 
of processing during which its orientation, position, bond angles, bond lengths, atomic 
temperature factors and occupancies, and many other parameters are refined. The quality of 
the final model can be given by the Rwork, which is a measure of the discrepancy between the 
model and the data [246]. The less biased Rfree value is also measured by withholding a small 
subset of experimental data during refinement and evaluating how well the model generated 
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from the remainder of the dataset can predict the withheld data. Both the Rwork and Rfree 
values can be used to guide refinement and determine the appropriateness of the strategies 
employed. Although the Rfree value is typically a little higher than Rwork, both should be 
similar and any significant difference between the two is an indication of overfitting the 
model to the data. Other validation tools and metrics can also be used to assess the model, 
including MolProbity to determine protein geometry statistics [247], and the diffraction 
precision index (DPI) to determine the experimental precision of the atomic positions in the 
structure [248].  
Model building and refinement steps can often be accomplished by a single suite of 
programs, such as PHENIX [249]. If appropriate, ligands can also be placed into the 
structure, however smaller, non-covalently bound molecules may display a higher degree of 
thermal motion which begets ambiguous electron density and makes it difficult to 
conclusively surmise whether the ligand is present. Even if the ligand has been determined, it 
may yet be challenging to identify its preferred stereoisomer, orientation, tautomeric state, 
protonation state, or conformation, and other techniques, such as molecular dynamics and 
free energy calculations, may assist in validating or correcting the ligand binding pose [250]. 
The ligand aside, the active site residues generally display lower temperature factors and 
better electron density than other regions, particularly areas of high mobility such as flexible 
loops and side-chains [251].  
1.5.3 Docking 
Docking is a technique which can suggest plausible models of protein-ligand interactions. 
Although ligands themselves can be another protein, they are often small molecules that bind 
to a receptor site of the target protein and will henceforth be referred to as such for the 
purpose of this docking introduction. Docking can be used strategically throughout the drug 
discovery process from the early stages of hit identification, by virtual screening, right 
through to lead optimisation [252]. The two main steps involved in docking are the sampling 
of ligands in the receptor active site using a searching algorithm, and the ranking of these 
conformations with a scoring function [253].  
1.5.3.1 Receptor representation 
Docking methods can represent the receptor by atomic, surface and grid representations [252, 
254]. In atomic representations, each atom is characterised by its coordinates and atom type. 
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Due to the complexity of evaluating pair-wise atomic interactions, this is typically used for 
the final ranking steps. Surface representations map the topography of the surface by smooth 
concave, convex or saddle shapes, and guide docking by complementarily aligning the ligand 
and protein surfaces. Surface representations are typically used in protein-protein docking. 
Grid representations encode physicochemical features of a receptor surface as energy 
potentials on grid points. The most basic forms of grid points characterise van der Waals and 
electrostatic potentials. These pre-calculated grid points are the only representation of the 
protein that needs to be read during ligand scoring.  
1.5.3.2 Searching algorithms 
The potential binding modes of a ligand, also known as poses, are sampled within the active 
site [252]. Initially, rigid ligands were docked into rigid receptors, but this limited the 
likelihood of providing a satisfactory model of ligand binding and advancements now allow 
the option of utilising flexible ligands in flexible receptors [255]. Incorporating flexibility can 
be laborious, as even a relatively small molecule may contain many degrees of freedom in its 
conformations, therefore the most desirable approach requires a balance between time and 
computational power expended, and the search space that is explored [256]. Searching 
algorithms survey the potential energy landscape to determine the lowest global energy pose 
of the ligand [257]. The main categories of searching algorithms used are systematic, 
stochastic, and simulation based approaches [252].  
Systematic searches can be further divided into three methods: incremental construction, 
conformational ensemble, and exhaustive searches. For incremental construction approaches, 
the ligand is initially broken up into fragments of rigid and flexible regions [258]. The pose 
of the rigid core with high complementarity to the active site, should there be one, is 
anchored into the docked solution site, and the flexible parts of the ligand, defined by 
rotatable bonds, are then added onto this core in an incremental manner. The algorithms to 
anchor the core can differ between implementations, with steric complementarity, and 
interactions between the ligand and protein among the parameters employed [252]. 
Conformational ensemble methods use a pre-generated library of diverse conformations of 
ligands to represent ligand flexibility [259]. This ensemble of conformations can then be 
docked as rigid bodies. In exhaustive methods, all the rotatable bonds in a ligand are rotated 
systematically however to make the process practical (due to the possibility of a large number 
of rotatable bonds), the ligands are subject to constraints which filter conformations [260]. 
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Stochastic methods operate by creating random changes that rotate the bonds of the ligand, or 
translate and rotate the ligand as a whole [257]. These changes are then either accepted or 
rejected by criteria involving a probability function. Simple Monte Carlo algorithms employ 
this basic principle to converge towards the best pose. Genetic algorithms induce these 
random changes based on evolutionary principles, including survival of the fittest [261]. In 
this method, poses for ligand binding are randomly generated and the parameters are encoded 
as “chromosomes”. The chromosomes that pass a fitness function are subjected to 
“crossover”, which swaps encoded regions from one chromosome to the other, and 
“mutations”, which introduces random changes, in order to yield new chromosomes that 
propagate the solution towards the optimum pose. Tabu searches are another algorithm used 
to sample new conformational space [257]. After random movements in space, the poses are 
compared to previously recorded conformations. Sufficiently dissimilar conformations, as 
determined by RMSD calculations, are accepted as new solutions. A fourth approach is 
swarm optimisation or swarm intelligence, which is inspired by the collective behaviour of 
birds [262]. In this, changes to the ligand conformation are directed by information from the 
best poses of its neighbours and the whole population. 
Energy minimisation and molecular dynamics are examples of simulation methods. Energy 
minimisation searches the energy landscape and moves the system towards the local energy 
minimum, but it is unable to overcome barriers to determine further local minima and 
therefore may not find the global energy minimum. As a result, energy minimisation is often 
employed in conjunction to the previously discussed searching algorithms for each of the 
generated ligand conformations (or partial structures, in the case of incremental construction) 
[252]. Generally, these conformations need to yield an equal or lower energy state than the 
initial state to be accepted and taken forward [257]. Molecular dynamics simulates the 
movement of atoms in a system with thermodynamic considerations, such as temperature 
[262]. While all the degrees in freedom for both the ligand and the receptor can in theory be 
explored, this is limited practically by the feasibility of simulation times. Molecular dynamics 
also has a problem of being unable to cross high energy barriers within reasonable time 
periods and can become trapped in local energy minima. 
1.5.3.3 Incorporation of protein flexibility  
Instead of a binding site existing as a pre-formed rigid region, proteins are generally induced 
to change conformation by ligand binding. Modelling this in docking is difficult as large 
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molecules inherently have many degrees of conformational freedom, but some level of 
protein flexibility can be incorporated by utilising soft docking, side-chain flexibility, 
molecular relaxation, and protein ensemble docking [260].   
Soft docking is a simple and fast method that simulates a receptor flexibly accommodating a 
ligand by loosening restrictions, such as steric repulsions, in docking calculations and 
allowing a slight overlap between the protein and ligand [263]. However, only small 
conformational changes can and should be modelled with soft docking.  
Introducing side-chain flexibility to a rigid backbone is a way of allowing limited protein 
flexibility. Side-chain flexibility can be sampled continuously or discretely using rotamer 
libraries in independent simulations [260]  
The molecular relaxation approach is accomplished in two general steps [260]. The ligand is 
firstly allowed to dock near the protein with some overlap, as in the situation with soft 
docking. The complex is then relaxed or minimised using Monte Carlo or molecular 
dynamics simulations. This second step removes the overlap of the protein-ligand complex 
by displacement of the appropriate ligand atoms or, if the ligand is in a low energy pocket, a 
change in protein conformation [264]. While it may be a more time consuming approach, 
molecular relaxation allows both protein backbone and side-chain flexibility. 
Another method to include protein flexibility is docking into an ensemble of 
conformationally different protein structures instead of running multiple independent 
simulations [265]. A pioneering study in this approach used weighted average energies and 
geometries from experimentally derived protein structures [266]. In another approach, the 
FlexE tool aligns ensembles to merge similar areas while treating the dissimilar areas as 
alternative conformations that are considered simultaneously during docking [267]. 
Examination of the crystal structures of the receptor have also been used to identify the rigid 
and mobile portions of the ensemble [268]. Ensembles of receptor conformations can 
additionally be generated by in silico methods such as structure prediction techniques, Monte 
Carlo simulations, or molecular dynamics simulations [260].  
1.5.3.4 Scoring functions  
A scoring function evaluates the accuracy of the ligand conformations generated in the 
searching algorithms, and is required to distinguish correct poses from incorrect ones [260]. 
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A good scoring function must be able to validate poses observed experimentally, and ideally 
can rank ligand binding by affinity estimations [262]. The most accurate techniques to 
estimate free energy of binding and affinity can be computationally expensive and 
time-consuming, making them not feasible when docking many compounds. To ensure faster 
calculations, scoring functions are simplified and feature various assumptions [252]. 
Traditionally, the main categories of scoring function are force field-based, empirical, 
knowledge-based, and machine-learning functions. 
Force fields quantify the sum of protein-ligand interaction energy terms and internal ligand 
energy terms. Standard energy terms used in calculations include van der Waals and 
electrostatic terms, but force fields also contain additional terms such as hydrogen bonding 
and torsional energies [269]. The internal protein energy terms are often omitted to simplify 
calculations and reduce computational costs [270]. A lack of solvation and entropic terms, 
and an inability to treat long-range interactions due to distance cut-offs applied to 
non-bonded interactions, are among the main shortcomings of standard force fields, however 
various extensions of these force fields have addressed some of these issues. 
Empirical scoring functions approximate free energy of binding using weighted energy terms 
such as van der Waals, electrostatic, hydrogen bonding, hydrophobicity, and entropic terms 
[260]. The coefficients for these terms are obtained through a regression analysis of binding 
affinity data from a training set of protein-ligand complexes. As a result, empirical scoring 
functions can differ based on the terms considered and the protein-ligand structures used in 
the training set. Increasingly comprehensive datasets allow these scoring functions to 
accurately evaluate interactions of ligands outside of the training set. However there is a 
concern that experimental binding data collated for this approach may be measured 
inconsistently in different conditions, given the disparate laboratory origins [271].  
Knowledge-based scoring functions are derived from structural information of known 
protein-ligands complexes [262]. Interacting pairs of atoms in these complexes are 
statistically analysed to observe their frequencies of distribution in a training set, which can 
be used to describe the ideal geometry of protein-ligand atom pairs. A higher frequency than 
would be expected from random distribution indicates that the atom pair provides 
energetically favourable interactions for protein-ligand binding, while the opposite is 
assumed for a lower frequency [271]. Unlike empirical scoring functions, knowledge-based 
scoring functions do not require binding data, allowing a large training set to be procured 
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relatively easily [257]. Both empirical and knowledge-based functions use relatively simple 
terms and can be computationally fast. 
Nonparametric machine-learning approaches are an emerging trend that have displayed the 
capability to infer binding interactions that are otherwise difficult to model [272]. The main 
difference with this approach is that unlike other scoring functions, machine-learning scoring 
functions are not predetermined and therefore are not inherently constrained to particular 
modelling parameters and assumptions. Rather, the functional form of this method is derived 
directly from the data in an unbiased manner. As with approaches taken in QSAR, by 
encoding interactions with various descriptors, machine-learning techniques can be used to 
generate a statistical model capable of calculating protein-ligand binding scores [271].  
Because the different scoring functions have their own deficiencies, consensus scoring has 
also been employed to improve docking accuracy [252]. Rather than being a standalone 
scoring function, consensus scoring combines multiple scoring functions to evaluate the 
predicted pose. While this can potentially balance out errors derived from the scoring 
functions, it may also magnify errors if the terms used correlate between functions. 
1.5.3.5 Docking using the Glide program 
In the approach used by Glide for docking, the shape and properties of the active site are 
represented on grid points with several sets of fields that allow progressively more accurate 
scoring [273]. The grid points only need to be computed once for each receptor as they are 
calculated in a pre-processing step. Glide docking methodology for standard precision (SP) 
and extra precision (XP) docking can be represented by what is known as the docking funnel 
(Fig. 1-9). SP docking uses an exhaustive search of the torsional minima to find an initial set 
of conformations. These are put into clusters which contain one conformation of a common 
core and all the conformations of the rotatable side-chains, and are docked as a single object. 
An initial screen is performed to approximate the position and scoring of the conformations, 
to narrow down promising ligand poses. These ligands are minimised within the receptor 
active site using an OPLS force field, and a small number of the lowest energy poses go 
through a Monte Carlo simulation for the examination of the nearby torsional minima and 
refinement of the ligands. These poses are then rescored using the Emodel and GlideScore 
scoring systems. GlideScore approximates ligand binding free energy using an empirical 
scoring function with many terms that reward or penalise interactions, including force field 
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based terms (such as van der Waals and electrostatic energies). GlideScore is designed to 
separate strong and weak binding affinity compounds, and therefore is well suited to ranking 
poses of distinct ligands. In contrast, Emodel has more weighting towards the force field 
terms and is better at selecting the best pose from the conformers of a single ligand. Glide 
uses the two in combination, with Emodel to rank the best pose of a ligand, and Glidescore to 
rank different ligands. XP docking follows a similar methodology, however initially a docked 
molecule is fragmented and an incremental construction approach is taken to find better poses 
by anchoring the fragments and regrowing the ligand. XP docking also features additional 
scoring and refinement steps, thereby increasing complexity in pose selection [274]. XP 
docking penalises interactions more harshly than SP docking, giving it the capacity to remove 
false positives. As XP docking takes longer to perform, a typical workflow when dealing with 
large libraries of ligands is to start with SP docking to find the highest ranking poses and then 
to re-evaluate them with XP docking. 
 
 
 
 
 
 
 
 
 
 
Figure 1-9. A funnel representation of the Glide docking schematic. Figure adapted from Friesner et al., 
2004 [273]. 
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1.5.3.6 Validity of docking 
Docking can be assessed by examining how accurately it can replicate the binding mode of a 
ligand in a crystal structure. This comparison of the docked and experimental poses can be 
measured by calculating the heavy-atom RMSD, where a value < 2 Å is often considered to 
be a correct pose [275, 276]. Within 2 Å, details of important binding features can correlate 
well enough to be considered useful in drug design processes [275]. Comprehensive analyses 
of a variety of programs docking molecules into different protein targets found that the 
searching algorithms employed by some of these programs were very effective in 
reproducing the binding pose for the ligands analysed (i.e. there was a high percentage of 
ligands with at least one pose generated that had an RMSD < 2 Å for the different targets) 
[275, 276]. However, the corresponding scoring functions of each docking program were less 
able to identify the correct poses from those produced (i.e. the percentage of the highest 
scoring poses of the ligands having an RMSD < 2 Å was comparatively lower). Docking 
studies have also indicated that there can be significant variability in the effectiveness of 
different programs, with Glide and GOLD amongst the better performers [277]. While they 
can generally be globally effective, even the best performing programs display disparity 
when handling different targets [275, 276]. Therefore it is important to validate a docking 
protocol for a given program and protein before relying on the resulting calculations. 
1.5.4 Surface plasmon resonance 
1.5.4.1 Theory of the technique 
The commonly used configuration for SPR is known as the Kretschmann configuration, 
where a polarised light source is directed to the surface of a thin metal, such as gold, located 
at the interface of a high-refractive glass prism and low-refractive media, resulting in the light 
reflecting back onto a detector (Fig. 1-10) [278]. When the incident angle of the light is 
greater than the critical angle, total internal reflection will occur in the prism, and an 
evanescent wave is produced that penetrates through the interface by up to 300 nm [279-281]. 
At a particular angle, called the resonance angle, the light waves couple to and excite the 
delocalised electrons on the surface of the gold metal (i.e. surface plasmons), causing them to 
resonate. This is induced by a transfer of energy from the photons, resulting in the intensity of 
light that is reflected back to the detector sharply reducing to a minimum.  
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Figure 1-10. The Kretschmann configuration used for SPR: polarised light is sent through a glass prism, 
and reflected back onto a detector. The angle of incidence causing resonance in the surface plasmons is 
associated with a large dip in intensity of the reflected light (A). In an SPR experiment, the ligand is 
initially bound onto the sensor chip surface. As the analyte solution flows through, the analytes bind to the 
ligand and cause an increase in the refractive index which changes the resonance angle proportional to their 
mass (B). 
Changes to the resonance angle is what is measured in SPR detection methods, and they are 
expressed as “response units” (RU) [282]. As the evanescent wave extends a short distance 
into the lower-refractive media adjacent to the gold metal, the resonance angle is also 
proportionally sensitive to changes in the refractive index at the metal surface. The refractive 
index in turn changes proportionally due to the mass of the molecules attached to the gold 
surface, and therefore SPR can be used to measure the binding of molecules. 
1.5.4.2 Practical aspects of surface plasmon resonance 
As a detection method, SPR has been implemented in commercial apparatus since the 1990s, 
pioneered by the BIAcore system (GE Healthcare) [282]. SPR is fast, automated, and is 
suitable for identifying binding interactions, and determining the equilibrium constant, kinetic 
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rate constants (i.e. the association rate constant and the dissociation rate constant), and the 
thermodynamics of these interactions [283]. 
An SPR experiment is performed by initially capturing a molecule of interest, called the 
ligand, on the surface of the sensor chip. After ligand immobilisation, a solution of the 
analyte is allowed to flow through the channels to measure any interactions it has with the 
ligand. In protein-small molecule interactions, the protein is used as the immobilised ligand 
and the small molecules are passed over it. When studying protein-protein interactions, the 
choice of which protein to use as the ligand may be determined by multiple factors [284]. 
Using the larger protein as the analyte makes it easier to detect binding as changes in SPR 
signal is proportional to the mass changes on the surface. However, higher purity or lower 
availability of the protein could also be a decisive factor in the decision to use it as the ligand. 
Another important consideration is the manner in which the protein can be bound onto the 
sensor chip surface, and whether it contains any tags that can be used for this purpose. 
Sensor chips are available with varying surface chemistries, to cater for the capture of 
different types of ligands [282]. A commonly used design is a carboxymethylated dextran 
layer covalently attached to the chip surface, which allows immobilisation by covalent 
coupling of the ligand through amine, thiol, aldehyde or carboxyl groups. The chips may 
contain other moieties pre-immobilised onto this initial dextran layer, such as lipophilic 
groups, nitrilotriacetic acid, streptavidin, and recombinant protein A, protein G, and protein 
L, which enables immobilisation of lipid membranes, histidine-tagged proteins, biotinylated 
proteins, and antibodies, respectively. If none of these methods are suitable, antibodies 
recognising the ligand can be attached to the surface as an indirect means of immobilising the 
ligand. 
SPR measures the real-time kinetics of analyte binding, displaying the information in a 
sensorgram (Fig. 1-11). The injection of the analyte through the channels causes an increase 
in response if the analyte binds onto the immobilised ligand (association phase), until 
equilibrium is achieved. Following the end of the injection, analyte occupation of the ligand 
binding sites reduces (dissociation phase). Most sensor chips can be regenerated using agents 
which strip the analyte completely from the ligand, allowing the re-use of the chips with fresh 
analyte samples. 
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Figure 1-11. A sensorgram showing the components of analyte binding in an experiment: (A) The baseline 
response prior to analyte injection, (B) the association phase after analyte injection, with analyte binding 
offsetting dissociation, (C) steady-state when analyte binding and dissociation is at equilibrium, 
(D) dissociation phase when the analyte injection is stopped, (E) regeneration removes the analyte from the 
ligand and returns it to baseline.  
Not all interactions reach the state of equilibrium depicted in Fig. 1-11 in the time allotted for 
the experiment, however the curves produced during the association and dissociation phases 
can still be used to calculate the association rate constant (ka) and dissociation rate constant 
(kd), respectively [282, 283]. For simple interactions, the binding affinity, measured by the 
equilibrium constant (KD), is calculated by the ratio of kd/ka. In some instances, such as with 
fragment molecules, the association and dissociation of the analytes are too rapid to calculate 
the kinetic rate constants but steady-state can be achieved relatively easily (Fig. 1-12). The 
response at equilibrium can be plotted against the concentration of the analyte to measure KD. 
Measuring the KD over a range of temperatures allows the thermodynamics of the interaction 
(changes in enthalpy, entropy, and free energy) to be determined [285].  
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Figure 1-12. A sensorgram typical of fragment binding. The kinetic constants are unable to be calculated 
due to rapid association and dissociation of the fragments. However, the binding affinity can be measured 
by the response at steady-state for a series of concentrations. 
1.5.4.3 Advantages and disadvantages of surface plasmon resonance 
A wide variety of interactions of interest can be analysed in real-time using SPR to measure 
their binding kinetics and thermodynamics [206]. SPR can also be used on a larger scale in 
drug discovery as it can be used for screening compounds and validating hits by 
characterising their binding. Compared to screening by other biophysical methods such as 
NMR and X-ray crystallography, SPR consumes 10 – 1000-fold less protein. This is 
contributed to by the ability to regenerate sensor chips by washing away the analyte, allowing 
the reuse of the immobilised ligand. Additionally, the protein that is used in SPR can be 
devoid of any additional modifications or tags, allowing the protein to be closer to the native 
system.  
SPR can offer rapid analysis and screening, with a typical fragment library able to be 
screened in a matter of days. Multiple channels on the chips can also increase screening 
efficiency as multiple proteins or conditions are able to be tested simultaneously. There is a 
concern that analytes can exhibit non-specific binding, particularly when dealing with small, 
promiscuous fragments, however this can be minimised by complementing the immobilised 
target protein with a blank immobilisation and a reference protein immobilisation on separate 
channels [286].  
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Another important consideration is that SPR requires the use of a running buffer which 
accounts for the baseline response to the immobilised ligand [206]. It is necessary to match 
the analyte solution buffer with the running buffer or else the difference in refractive index 
will create large amounts of noise and may be a source of false positives. This is particularly 
the case with high-refractive index solvents such as DMSO, where a slight mismatch can 
cause a large bulk shift in SPR response. 
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Chapter 2 Implications of kynurenine aminotransferases in the context of 
schizophrenia................................. 
2.1 Preface 
Schizophrenia is a complex neuropsychiatric disease in which there is a lack of clear 
understanding of the processes involved in the aetiology of the condition. Many hypotheses 
have been proposed over the years to explain the development of the disease, including 
theories based on genetic, environmental and biochemical factors. Antipsychotic drugs have 
been developed since the 1950s to treat psychoses, but they themselves may come with 
significant adverse effects and primarily work by managing positive symptoms [1]. The range 
of symptoms associated with schizophrenia can include delusions, hallucinations, 
disorganised speech and behaviour, flattened affect, poverty of speech, avolition, and 
neurocognitive deficits, and the manifestation of these symptoms also typically results in 
markedly lower ability to self-care, and social and occupational dysfunction [2]. In addition 
to their poor tolerability, current antipsychotic drugs have limited effectiveness in treating 
negative and cognitive symptoms of schizophrenia, which are aspects of the disease 
associated with an increased likelihood of hospital admissions and increased duration of stay 
[3]. Therefore, there is substantial reason to pursue new avenues for the treatment of 
schizophrenia. 
This literature review chapter will focus more comprehensively on the KAT enzymes, from 
their structure to their function, and will discuss the links between KAT, KYNA and 
schizophrenia, and the role of KAT inhibitors in the context of treating schizophrenia and/or 
cognitive impairment. 
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Kynurenine Aminotransferases and the Prospects of Inhibitors for the 
Treatment of Schizophrenia 
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Abstract: Schizophrenia is a complex neuropsychiatric disorder with limited treatment options and 
highly debilitating symptoms, leading to poor personal, social, and occupational outcomes for an af-
flicted individual. Our current understanding of schizophrenia suggests that dopaminergic and glutama-
tergic systems have a significant role in the pathogenesis of the disease. Kynurenic acid, an endoge-
nous glutamate antagonist, is found in elevated concentrations in the prefrontal cortex and cerebrospi-
nal fluid of patients with schizophrenia, and this affects neurotransmitter release in a similar manner to previously ob-
served psychotomimetic agents, such as phencyclidine, underlining the molecular basis to its link in schizophrenia patho-
physiology. Kynurenic acid is a breakdown product of tryptophan degradation, through a transamination process mediated 
by kynurenine aminotransferase (KAT) enzymes. There are four KAT homologues reported, all of which are pyridoxal 5’-
phosphate-dependent enzymes. All four KAT isoforms have been analysed structurally and biochemically, however the 
most extensive research is on KAT-I and KAT-II. These two enzymes have been targeted in structure-based drug design 
as a means of normalising raised kynurenic acid levels. The most potent KAT-I inhibitors and KAT-II inhibitors include 
phenylhydrazone hexanoic acid derivatives and a pyrazole series of compounds, respectively. KAT inhibitors have been 
shown to be effective in reducing kynurenic acid production, with accompanying changes in neurotransmitter release and 
pro-cognitive effects seen in animal studies. This review will discuss the characteristics pertaining to the different KAT 
isoforms, and will highlight the development of significant KAT inhibitors. KAT inhibitors have great potential for thera-
peutic application and represent a novel way in treating schizophrenia. 
Keywords: BFF-122, BFF-816, KAT, KAT inhibitor, kynurenic acid, kynurenine, kynurenine aminotransferase, PF-04859989, 
phenylhydrazone, schizophrenia. 
INTRODUCTION
Schizophrenia 
Schizophrenia is a debilitating, neuropsychiatric disorder 
caused by environmental and genetic factors, and character-
ised by chemical imbalances [1]. The prevalence of schizo-
phrenia is approximately 1% worldwide, and it accounts for 
a profound burden both at the individual and public health 
level [2]. This burden arises from the significant clinical 
symptoms of schizophrenia, as it manifests with positive 
symptoms such as delusions, hallucinations, motor dysfunc-
tion, and thought disorder, negative symptoms such as flat-
tened affect, social withdrawal, apathy, and anhedonia, as 
well as cognitive dysfunction [3]. 
The debilitating nature of these symptoms leads to poor 
outcomes and leaves patients with a reduced capacity for 
*Address correspondence to this author at the Faculty of Pharmacy A15,
The University of Sydney, Sydney NSW 2006, Australia; 
Tel: +61(2)9036 6569; Fax: +61(2)9351 4391
E-mail: bret.church@sydney.edu.au
#Equal first authors 
self-care and assimilation into the community [4]. Social and 
family relationships are strained for a majority of patients to 
some degree, while 24% of patients were described as being 
mild-to-moderately impaired in their ability to work and a 
further 16% were more extensively impaired [4]. Employ-
ment rates for individuals with schizophrenia, though differ-
ing between countries (ranging from 10-30%), are much 
lower than the general population [5]. In addition to this, 
individuals with schizophrenia notably lack self-esteem, and 
face stigma and discrimination arising from perceptions of 
those that are mentally ill [4]. 
Schizophrenia also has a quite pronounced overall effect 
on mortality, as it causes a reduction on life expectancies by 
up to 10-25 years [6]. A leading cause of death in patients 
with schizophrenia is suicide [7], and up to half of the pa-
tients with schizophrenia will attempt suicide in their life-
time with up to 13% completing the suicide [7]. 
The impact of schizophrenia extends beyond the individ-
ual, as families and/or caregivers supporting an affected in-
dividual must change lifestyle habits and face possible eco-
nomic challenges [4]. The financial burden of schizophrenia 
© 2015 Bentham Science Publishers 
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is also significant on a national level as schizophrenia is 
among the most costly mental illnesses in developed nations, 
as a result of both direct health care costs and indirect costs. 
The latter, for example, includes costs associated with pro-
ductivity and time loss by patients and caregivers [8,9]. 
All this greatly underlines the desire and prospective im-
pact of research into treating the condition. Current antipsy-
chotic therapy is well known to cause extrapyramidal effects 
and metabolic dysregulation, affecting patient adherence 
[10], and mainly improve positive symptoms with limited 
effects on negative symptoms and cognitive impairment [3]. 
This is an issue as negative symptoms in particular are sig-
nificantly involved in the reduced quality of life, diminished 
employment opportunities and maintenance of personal rela-
tionship [11,12]. Therefore, other avenues of treating schizo-
phrenia must be actively explored to further improve this 
situation. 
Hypotheses of Schizophrenia 
Dopamine Hypothesis 
The pathogenesis of schizophrenia has not been fully es-
tablished, but several theories have been proposed over the 
years. The first substantial hypothesis involved dopaminergic 
neurotransmission, as many symptoms associated with 
schizophrenia are thought to be mediated by dopaminergic 
systems, particularly through the mesolimbic and mesocorti-
cal pathways [13]. Dopaminergic hyperfunction in the stria-
tum and nucleus accumbens was hypothesised as one under-
lying cause, and was consistent with typical antipsychotic 
agents ameliorating positive, psychotic symptoms almost 
exclusively by blocking dopamine D2 receptors [2,14]. The 
theory gained more credence by the post-mortem examina-
tion of the brains of patients with schizophrenia showing an 
apparent increase in D2 receptors [15], however subsequent 
findings have suggested that an increase of D2 receptors in 
the striatum and nucleus accumbens is a result of antipsy-
chotic drug action [16]. Nevertheless the theory remains 
largely accepted. Further, it is thought that the negative 
symptoms of schizophrenia are suggestive of dopaminergic 
hypofunction in the prefrontal cortex [2], and possibly occurs 
simultaneously alongside dopaminergic hyperfunction via 
separate dopamine neuronal projection pathways to give rise 
to the clinical presentation of schizophrenia [2]. 
Increasingly, however, it is believed that the dopamine 
hypothesis does not account for the disease state alone. 
GABAergic Hypothesis 
The GABAergic system has also been linked based on 
evidence for GABAergic neuron loss in the cortex and the 
hippocampus of brains in patients with schizophrenia. The 
levels of the key enzyme responsible for GABA biosynthe-
sis, glutamic acid decarboxylase, was shown to be reduced in 
the prefrontal cortex of individuals with schizophrenia 
[17,18]. Deficits of the expression of GABA transporter-1 
protein [19] and the calcium binding protein, parvalbumin 
[20], were also seen in patients. Alterations to the axonal 
terminus of GABAergic chandelier cells [21] and the deficits 
in glutamic acid decarboxylase, GABA transporter-1, and 
parvalbumin in patients with schizophrenia suggest that the 
Current Medicinal Chemistry, 2015, Vol. 22, No. 24     2903 
GABAergic system may be implicated and could contribute 
to cognitive dysfunction [20,22]. 
Glutamatergic Hypofunction 
The glutamatergic hypofunction hypothesis is regarded 
as a developing model of schizophrenia, and originates from 
the observation of the activity of phencyclidine (PCP) on the 
N-methyl-D-aspartate (NMDA) glutamate receptor subtype.
Antagonism of the NMDA receptor in humans by PCP was
shown to induce positive and negative symptoms, and cogni-
tive impairment [23]. Similarly it has been shown that the
NMDA antagonist ketamine produced a range of positive
and negative symptoms, and cognitive impairments, when a
low dose perfusion was administered to healthy volunteers
[24].
Furthermore, reduced glutamate levels seen in the cere-
brospinal fluid of patients with schizophrenia [1] is suppor-
tive of this theory. Glutamatergic hypofunction is suggested 
to lead into a secondary dysfunction of dopamine transmis-
sion that is associated with schizophrenia. Increases in do-
pamine release in the nucleus accumbens has been seen with 
the subchronic administration of PCP in animal models, 
along with reduced dopamine release in the prefrontal cortex 
[25]. This mechanism of NMDA antagonist induced dopa-
mine hyperfunction and hypofunction (Fig. 1) suggests a 
feasible means by which the glutamatergic system is associ-
ated with both the positive and negative symptoms [2,26]. 
Glutamatergic hypofunction could also lead to the re-
duced GABAergic function seen in schizophrenia. Glutamic 
acid decarboxylase and GABA transporter protein down 
regulation in the cerebral cortex of rats treated with dizocil-
pine, an NMDA antagonist, mimicked the deficits in expres-
sion of these proteins in patients with schizophrenia [27]. 
The relationship between the glutamatergic and GABAergic 
systems was further highlighted by a study showing a de-
crease in density of glutamic acid decarboxylase containing 
interneurons that co-expressed the NMDA NR2A subunit in 
patients with schizophrenia [28]. 
Kynurenic Acid Hypothesis 
On this basis, kynurenic acid (KYNA), an endogenous 
NMDA antagonist [29], can be implicated in schizophrenia. 
KYNA is also a non-competitive antagonist of the α7-
nicotinic acetylcholine receptor [30] and may also implicate 
itself in cognitive deficits by affecting cholinergic neuro-
transmission [31]. This is all of significant interest as ele-
vated KYNA levels have been observed in the cerebrospinal 
fluid [32] and prefrontal cortex [33] of patients with schizo-
phrenia; an elevation that is independent of antipsychotic 
medication use. 
KYNA is a breakdown product in tryptophan metabolism 
(Fig. 2), and up to 99% of excess dietary tryptophan is me-
tabolised through the kynurenine pathway, with the remain-
der forming serotonin and melatonin [34]. KYNA does not 
readily cross the blood-brain barrier, therefore local produc-
tion in astrocytes accounts for the majority of brain KYNA 
levels [35]. KYNA production is mediated through the irre-
versible transamination of L-kynurenine by kynurenine 
aminotransferase (KAT) enzymes [36]. Of the four known 
KAT enzymes, KAT-II occurs in the highest proportion in 
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Fig. (1). Proposed “accelerator”/”brake” mechanism of glutamatergic control of dopamine release. A. Inhibitory pathway (brake): glutamate 
stimulates GABA release by acting on NMDA receptors, which causes basal inhibition of dopamine release. KYNA antagonises NMDA re-
ceptors to reduce inhibition of dopamine release (thereby increasing release). B. Activating pathway (accelerator): Glutamate causes basal 
stimulation of dopamine release. KYNA antagonises NMDA receptors to reduce stimulation of dopamine release. The predominant system in 
the nucleus accumbens is A. and in the prefrontal cortex it is B., leading to dopamine hyperfunction and hypofunction, respectively [2,26]. 
rat and human brain tissue [37]. Inhibiting KAT enzymes, 
particularly KAT-II, therefore can reduce brain KYNA lev-
els, making the enzymes a viable target in treating the ele-
vated KYNA levels seen in patients with schizophrenia. 
Kynurenine Aminotransferase and KYNA 
The kynurenine aminotransferase (KAT) isoforms are 
enzymes involved in the major degradation pathway of 
tryptophan (Fig. 2). Through a series of steps, L-tryptophan 
gets converted into L-kynurenine which is a substrate of the 
KAT enzymes. The KAT isoforms use pyridoxal 5’-
phosphate (PLP) as a cofactor to transfer an amino group 
from L-kynurenine onto an α-keto acid (Fig. 3), to convert 
it into kynurenic acid (KYNA) [38]. KYNA primarily dis-
plays antagonist activity to the allosteric glycine site on 
NMDA receptors [14,39], with some activity at the AMPA 
[30], kainate and α7-nicotinic receptors [40], and the glu-
tamate recognition sites on NMDA receptors at higher con-
centrations [41]. Due to its inhibitory actions and the diver-
sion of potentially neurotoxic tryptophan metabolites being 
formed such as 3-hydroxykynurenine and quinolinic acid 
(Fig. 2), and subsequent prevention of excitotoxic attacks, 
KYNA is neuroprotective [36] and also has anticonvulsant 
effects [42, 43]. Despite these beneficial effects, KYNA 
levels are found elevated in the brains of patients of 
schizophrenia suggesting that normalised levels are re-
quired to avert disease. 
Four KAT isoforms have currently been identified and 
characterised, and all are expressed in the mammalian brain 
to different levels throughout the body [44]. 
KAT-I 
Also known as glutamine transaminase-K or cysteine 
conjugate β-lyase-I, KAT-I has a very broad range of sub-
strates (Table 1A) [45,46], the most potent of which include 
glutamine and phenylalanine. As such, these amino acids 
may competitively inhibit KAT-I activity towards producing 
kynurenine. KAT-I is mainly expressed peripherally in the 
liver and kidneys [47], and optimal pH for KAT-I tends to-
wards the more alkaline end of the range 7.5-9 [36]. KAT-I 
also displays β-lyase activity [48]. 
KAT-II 
KAT-II was first known as aminoadipate aminotrans-
ferase, and is also versatile in binding different amino acid 
substrates (Table 1B) [49]. The greatest activity is displayed 
towards aminoadipate, kynurenine, methionine and gluta-
mate [49]. In contrast to KAT-I having an optimum pH 
which is alkaline, KAT-II activity is highest at neutral pH. 
KAT-II is the most abundant isoform in the rat brain [37] 
and its activity is also relatively unaffected by higher con-
centrations of other competing substrates, suggesting that its 
action on kynurenine at physiological concentrations and pH 
accounts for the majority of KYNA synthesis in the brain 
[50]. KAT-II is also important in the major, aminoadipate 
pathway of lysine metabolism [49].
KAT-III 
Also known as cysteine conjugate β-lyase-II, KAT III 
shares high sequence identity to the KAT-I gene [51] and 
also acts on a similar range of substrates (Table 1C) [52], as 
evidenced in mice. The greatest activity includes action on 
glutamine, histidine, methionine and phenylalanine. Again 
similar to KAT-I, with mouse KAT-III, optimum activity 
was at alkaline pH of 9-10. 
KAT-IV 
Originally known as mitochondrial aspartate aminotrans-
ferase or glutamic-oxaloacetic transaminase-II, KAT-IV was 
a mitochondrial transaminase that had KAT activity [37]. 
Mouse studies have been used to determine KAT-IV sub-
strate activity (Table 1D) [53]. KAT-IV is considered to 
have a role in the synthesis of glutamate in the brain, gluta-
mate entry into the citric acid cycle, and the malate-aspartate 
shuttle [36]. KAT-IV seems to display most KAT activity of 
the four isoforms in the mouse brain, with a pH optimum of 
8, and may hence have an important role in human brain 
KYNA formation at physiological kynurenine concentrations 
and pH [37]. 
Structure of KAT Isoforms 
The KAT isoforms are homodimers belonging to the fold 
type I family of PLP-dependent enzymes [54]. The subunits 
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Fig. (2). Kynurenine pathway of tryptophan degradation. Tryptophan is metabolised through indoleamine 2,3-dioxygenase and 
kynurenine formylase, to form the precursor kynurenine. Kynurenine branches through kynurenine 3-monooxygenase and kynureninase to 
form the excitotoxic 3-hydroxykynurenine and quinolinic acid. Another branch by the KAT enzymes converts kynurenine into the neuro-
protective KYNA. 
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Fig. (3). PLP-dependent transamination reaction. A. Formation of the active site from PLP and lysine. B. Mechanism of the first half of the 
transamination reaction. 
contain an N-terminal arm, a large domain which hosts the 
PLP-binding site and consists of an α /β/α-fold, and a small 
domain comprising mainly the C-terminal (Fig. 4). Both 
subunits of the enzyme contribute an active site which are 
located at the interface of the two monomers [36], and a 
PLP-binding site is situated near the active site for each 
monomer [38]. 
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Table 1. Amino acid substrates and α-keto acid acceptors enabling KAT-I (A) [45,46], KAT-II (B) [49], KAT-III (C) [52] and KAT-
IV (D) [53,56] activity. *Represents substrates that the KAT isoforms display relatively higher potency towards. 
Substrates α-keto Acid as Amino Group Acceptors 
A. KAT-I
Asparagine, arginine, alanine, L-3-(1-napthyl)alanine, 
aminobutyrate, cysteine, 5S-(1,2-dichlorovinyl)-L-
cysteine, 5-S-cysteinylDOPA, 5-S-cysteinyl-dopamine, S-
(1,1,2,2-tetrafluoroethyl)-L-cysteine, *glutamine, glycine, 
histidine, kynurenine, leucine, lysine, methionine, Se-
methylselenocysteine, *phenylalanine, tryptophan, tyro-
sine, serine 
Glyoxylate, ρ-hydroxyphenylpyruvate, indo-3-pyruvate, α-
ketoadipate, α-ketobutyrate, α-ketocaproic acid, α-
ketoglutarate, α-ketoisoleucine, α-ketoleucine, α-keto-
methylthiobutyric acid, α-ketovalerate, α-ketovaline, mer-
captopyruvate, oxaloacetate, phenylpyruvate, pyruvate 
B. KAT-II 
Alanine, *aminoadipate, aminobutyrate, *glutamate, glu-
tamine, 3-hydroxykynurenine, *kynurenine, leucine, 
*methionine, phenylalanine, tryptophan, tyrosine
Glyoxylate, ρ-hydroxyphenylpyruvate, indo-3-pyruvate, α-
ketoadipate, α-ketobutyrate, α-ketocaproic acid, α-
ketoglutarate, α-ketoisoleucine, α-ketoleucine, α-keto-
methylthiobutyric acid, α-ketovalerate, α-ketovaline, mer-
captopyruvate, oxaloacetate, phenylpyruvate, pyruvate 
C. KAT-III
Alanine, aminobutyrate, asparagine, cysteine, *glutamine, 
glycine, *histidine, 3-hydroxykynurenine, kynurenine, 
lysine, *methionine, *phenylalanine, serine, tryptophan, 
tyrosine 
Glyoxylate, ρ-hydroxyphenylpyruvate, indo-3-pyruvate, α-
ketobutyrate, α-ketocaproic acid, α-ketoglutarate, α-
ketoisocaproic acid, α-keto-methylthiobutyric acid, α-
ketovalerate, mercaptopyruvate, oxaloacetate, phenylpyru-
vate, pyruvate 
D. KAT-IV
*Aspartate, asparagine, cysteine, *glutamate, 3-
hydroxykynurenine, kynurenine, methionine, phenyla-
lanine, tryptophan, tyrosine 
Glyoxylate, ρ-hydroxyphenylpyruvate, indo-3-pyruvate, α-
ketobutyrate, α-ketocaproic acid, α-ketoglutarate, α-keto-
methylthiobutyric acid, α-ketovalerate, mercaptopyruvate, 
oxaloacetate, phenylpyruvate, pyruvate 
 Important conserved features for PLP-binding includes 
the formation of the cofactor’s Schiff-base link with a cata-
lytic lysine group, an aspartate residue hydrogen bonding to 
the nitrogen atom of the PLP pyridine [36,47], a tyrosine 
residue forming hydrogen bonds to PLP via the phenolate 
moiety, and pi-stacking interactions of an aromatic residue 
onto the cofactor [47]. 
 Another conserved feature of the active site is an arginine 
residue which forms a salt-bridge to the α-carboxyl of the 
substrate, enabling the substrate’s α-amino group to be posi-
tioned in a favourable orientation near the PLP catalytic cen-
ter [47,53]. Crystal structures are available of the human 
versions of KAT-I and KAT-II, whereas mouse versions 
only are available for KAT-III and KAT-IV. 
KAT-I Structure 
 In KAT-I, the PLP cofactor is covalently linked to Lys-
247 residue in the binding pocket of the subunit [55] (Fig. 5). 
The aspartate residue hydrogen bonding with the PLP pyri-
dine nitrogen is Asp-213 for KAT-I [55]. The PLP binding 
site is partly formed from the interface of both subunits, but 
the bottom of the site is built by residues from the monomer 
it is located in [55]. 
The substrate binding site of KAT-I consists of a hydro-
phobic crown formed by aromatic residues such as Tyr-63, 
His-279, Phe-278, Tyr-101, Phe-125 and Trp-18 [55], in 
which the substrate side chain rests in. This can account for 
the efficiency of KAT-I transamination of relatively hydro-
phobic amino acids such as leucine and tryptophan [36]. 
KAT-II Structure 
The residue binding covalently to PLP in KAT-II is Lys-
263, and Asp-230 binds to the pyridine nitrogen. Contrasting 
to the other isoforms, KAT-II is unique in that the catalyti-
cally essential N-terminal region undergoes domain swap-
ping [47]. The N-terminal region arising from the large do-
main of each subunit projects to the opposite subunit (Fig. 4) 
and provides several points of contact between the subunits, 
and helps shape the PLP-binding sites [47]. In contrast, the 
N-terminal regions of the other KAT isoforms help build the
small domain and active site of the same subunit it buds from
[36].
The hydrophobic pocket present in KAT-I is mostly ab-
sent in KAT-II. In its place, there are more polar and neutral 
amino acids for where the substrate side chain binds to, in-
cluding Ile-19, Arg-20, Leu-40, Tyr-74, Tyr-142, Leu-293 
and Ser-143 [36] (Fig. 6). The lack of Trp-18 and the re-
placement of Phe-278 with Leu-293 also makes the binding 
pocket in KAT-II more accommodating in terms of width 
[36]. 
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Fig. (4). Structure of the KAT isoforms. A. human KAT-I (PDB ID 3FVS), B. human KAT-II (PDB ID 2R2N), C. mouse KAT-III (PDB ID 
3E2Y), D. mouse KAT-IV (PDB ID 3PD6). The enzymes consist of two subunits, depicted by different colours. The small and large domain 
in one sub unit is depicted by blue and green, respectively. Figures adapted from Han et al. (2010). All three-dimensional structural figures in
this review were drawn using PyMOL 
Fig. (5). The active site of hKAT-I showing the hydrophobic crown (see text), A. L-phenylalanine (PDB ID 1W7M) and B. indole acetic acid 
(IAC; PDB ID 3FVU) in approximately the same orientation. The active site is shown in its co-crystallised location at the KAT-I active site. 
L-phenylalanine is shown with carbons in yellow, and PLP complex in magenta. The majority of the binding sites are from one monomer, but
Tyr-63 and Phe-278 are contributed by the second monomer of the homodimer. In the IAC bound structure, a glycerol molecule is also bound
at the active site with hydrogen bonds to an IAC carboxy O and the backbone N of Gly-36, and hydrophobic bonds from Gln-35 and Phe-37,
and His-279 of the other monomer . This glycerol is not shown in the figure to aid clarity of the IAC binding.
in KAT-I, which is replaced by polar and neutral amino acids. A 
wider active site also allows larger substrates to accommodate into 
the site. 
KAT-III Structure 
In mouse KAT-III, PLP binds covalently to Lys-281 and 
interacts with Asp-247 [52]. Mouse KAT-III shares struc-
tural similarities to human KAT-I based on the high se-
quence identity of 53% [36], featuring an active site aromatic 
crown made up of Tyr-160, Tyr-312, and Tyr-98 residues 
which give it similar substrate activity. The aromatic crown 
in KAT-III is however relatively more hydrophilic, making 
the enzyme comparatively better in the transamination of 
less hydrophobic amino acids than KAT-I [52]. 
KAT-IV Structure 
Lys-279 is covalently attached to PLP in mouse KAT-IV, 
and Asp-243 also interacts with the cofactor [56]. Like KAT-
II, the active site has more polar and neutral residues includ-
ing Ile-44, Asn-215, Arg-287, Tyr-96, Ser-317, giving it a 
substrate profile similar to KAT-II [56]. 
Targeting KAT 
The evidence relating to KYNA levels is for bidirectional 
activity. Morris water tests and other cognitive function tests 
in rats and mice have shown that reductions in KYNA levels 
are associated with improved cognitive performances [57-
60]. Increases in KYNA by application of kynurenine in 
A.hKAT-I B.hKAT-II C. hKAT-III D.hKAT-IV
A.   B. 
Fig. (6). The active site of hKAT-II with kynurenine, with carbons 
shown in yellow, and the cofactor in its PMP form, in magenta 
(PDB ID 2R2N). Here, L-kynurenine is shown in its co-crystallised 
location at the KAT-II active site. The amino acids with an atom 
within 5.0 Å of the L-kynurenine and the cofactor were chosen for 
display. In KAT-II, there is a lack of the hydrophobic crown present 
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adult rats [61-63] and younger rats [64,65] have shown that it 
causes cognitive impairments resembling that in schizophre-
nia. Adolescent rats treated with kynurenine were also found 
to be susceptible to impaired social behaviour [66]. 
Other effects of targeting KAT is in regards to KYNA 
being a potent agonist for the aryl hydrocarbon receptor, 
which is implicated in a number of functions including a role 
in immune surveillance [67]. Reducing KYNA levels and 
thereby decreasing its activity on the aryl hydrocarbon recep-
tor could reduce the ability of the receptor to dampen im-
mune surveillance, and this could be problematic given pos-
sible autoimmune links to schizophrenia [68]. 
Another aspect to consider is the metabolic pathway in-
volved in kynurenine production. The use of a kynurenine 
3-monooxygenase inhibitor has been shown to prevent the
conversion of kynurenine to 3-hydroxykynurenine (Fig. 2),
and shunt the pathway towards producing more KYNA
[69,70]. Blocking the KAT enzymes could shift the meta-
bolic pathway towards producing the metabolites 3-
hydroxykynurenine and quinolinic acid, both of which are
neurotoxic [71,72]. However a number of studies involving
knock-out mice [73] and KAT-II inhibitors [74,75] have
shown reductions in KYNA without significant changes in
3-hydroxykynurenine or quinolinic acid levels.
In patients with schizophrenia, determining the relative 
levels of kynurenine metabolites showed that the KYNA/3-
hydroxykynurenine ratio [76] was initially lower compared 
to healthy controls, and subsequently increased, largely due 
to reduced 3-hydroxykynurenine concentrations, after an-
tipsychotic treatment. These results reaffirm the relevance 
of an imbalance in kynurenine metabolites having a role in 
schizophrenia [76,77] but, conversely, other studies have 
indicated no significant difference in 3-hydroxykynurenine 
levels between patients with schizophrenia and controls 
after treatment [78]. Nevertheless, any inhibitor of KAT 
must also be evaluated on its potential to increase the neu-
rotoxic arm of the pathway and change the balance of the 
metabolites. 
Hence, although there is substantial evidence of the link 
between KYNA and cognitive function, attention must be 
given to elucidate the other possible impacts of KYNA re-
duction. 
Targeting KAT I or KAT II? 
It is unclear whether specifically KAT-I or KAT-II, or 
both should be targeted for the treatment of schizophrenia. 
Current evidence suggests that KAT-II is more involved in 
KYNA synthesis in the mammalian brain [37]. However, 
KAT-I has been found to be significantly elevated in the 
cerebellum of post mortem brains of patients with schizo-
phrenia, implicating its involvement as well [79]. KAT-I’s 
broader substrate specificity, however, may give it a more 
varied role than KAT-II [47], and as KAT-II is the dominant 
isotype in rat and human brain tissue [37], it can be reasoned 
that KAT-II would be the main contributor in raising KYNA 
levels in the cerebrospinal fluid and thus should be the tar-
geted isoform. Despite this, KAT II has not been convinc-
ingly proven to be up-regulated or overactive in patients with 
schizophrenia, with some evidence indicating there may be 
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no significant difference in KAT-II activity in the prefrontal 
cortex of brains in patients with schizophrenia compared to 
controls [80]. 
DEVELOPMENT OF KAT INHIBITORS
Indole Derivatives 
The earliest studies were on KAT-I. Knowledge of 
KAT-I substrates which act as competitive inhibitors sug-
gest that an aromatic ring and a carboxylic acid are impor-
tant functional groups for binding [1]. Based on trypto-
phan and indole-3-pyruvic acid, four similar indole de-
rivatives were selected. These derivatives had an absence 
of α-amino and α-keto groups to ensure that they were not 
substrates of the enzyme. All six compounds (Fig. 7) were 
assayed to measure KAT-I inhibition [48], and were 
found to inhibit the enzyme effectively. Indole-3-
propionic acid (IC50: 0.14 ± 0.20 mM) and DL-indole-3-
lactic acid (IC50: 0.22 ± 0.22 mM) were more potent than 
the substrates tryptophan and indole-3-pyruvic acid in 
inhibiting KAT-I [48], and were identified as potential 
suitable lead candidate inhibitors. 
Of the compounds discussed, the crystal structure of in-
dole-3-acetic acid is available and shows that the compound 
inserts into a hydrophobic pocket formed by Tyr-63, His-
279, Phe-278, Tyr-101, Phe-128 with its carboxylic moiety 
forming bonds with an Arg-398 residue (Fig. 5b) [48]. 
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Fig. (7). Structure of six inhibitors of KAT-I. 
Indole and Phenylhydrazone Derivatives 
More recent work has shown a new series of more potent 
compounds that are suitable as leads [1]. Compounds of in-
dole and phenylhydrazone derivatives (Table 2) were tested. 
The most potent indole based molecule was a bromo-
substitute (2b) with an IC50 of 271 ± 51 μM, while the 3- and 
4-chlorophenylhydrazone hexanoic acid derivatives (1a and
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1f) were significantly more potent (IC50: 20 ± 14 μM and 
IC50: 20 ± 8 μM, respectively). 
The experiment showed the impact of substituents on the 
phenylhydrazone hexanoic acid derivatives. An electron 
withdrawing nitro group of the phenyl ring (1c) decreased its 
potency (IC50: 179 ± 43 μM) in comparison to a methyl sub-
stituent (1d) in its place (IC50: 33 ± 6 μM). In contrast, 
halogen groups greatly improved the potency of inhibitors 
(1abfg); the lowest IC50 of these halogen containing com-
pounds was 1g with a value of 34 ± 20 μM [1]. 
The 3- and 4-chlorophenylhydrazone hexanoic acid de-
rivatives represents a new series of KAT-I inhibitor lead 
compounds that are approximately 6-7 fold more potent than 
the previously described indole-3-propionic acid compound. 
Table 2. Chemical structure and IC50 values (μM) of phenyl-
hydrazone and indole based inhibitors of KAT-I. 
Data taken from Akladios et al. (2012) [1].
H
N
N
O O
O
OH
Y
X
CH3
Phenylhydrazone derivatives (1a-g)
NH
O
OH
X
Y
O
OH
Indole derivatives (2a-e)
Compounds X Y IC50 ± SD (μM) 
1a Cl H 20 ± 8 
1b Br H 21 ± 15 
1c NO2 H 179 ± 43 
1d CH3 H 33 ± 6
1e OCH3 H 43 ± 4 
1f H Cl 20 ± 14 
1g I H 32 ± 20 
2a Cl H 293 ± 29 
2b Br H 271 ± 51 
2c NO2 H 666 ± 74 
2d CH3 H > 1000
2e OCH3 H > 6000
S-ESBA 
The first notable KAT-II specific inhibitor was evalu-
ated by Pellicciari et al., (2006) [81]. Interest in sulfonylal-
kyl-substituted benzoylalanine derivatives due to the fa-
vourable size, hydrophilic/hydrophobic and hydrogen 
bonding characteristics of the moiety, led to the develop-
ment of D,L-4-(ethylsulfonyl)benzoylalanine and the active 
enantiomer S-4-(ethylsulfonyl)benzoylalanine (S-ESBA) 
(Fig. 8). In rat enzyme studies, S-ESBA selectively inhib-
ited KAT activity with no effect on the enzymes 
kynurenine 3-monooxygenase and kynureninase [75], 
which are part of the tryptophan metabolism pathway (Fig. 
2). Inhibitory action on the latter two enzymes, should it 
exist, could promote the tryptophan metabolism pathway 
back towards producing more KYNA, so it is desirable to 
not inhibit these enzymes to ensure that KYNA production 
isn’t increased. S-ESBA was further characterised and 
found to inhibit KAT-II selectively (IC50: 6.1 μM) and did 
indeed reduce rat brain kynurenic acid levels when the 
compound was administered [81]. However follow on stud-
ies have shown that the inhibitory effects of S-ESBA on 
recombinant human KAT-II was 10-20 fold less than that 
observed in rat KAT-II, attributed to subtle differences in 
the catalytic site of the enzymes [82]. 
Rat studies have shown that the administration of S-
ESBA, to block KAT-II activity and acutely reduce KYNA 
synthesis in the hippocampus, led to an increase in extracel-
lular glutamate levels [58], which is consistent with KYNA 
inducing effects on the glutamatergic system. This also cor-
related with an increase in cognitive function found in S-
ESBA administered rats in comparison to controls, as deter-
mined by a Morris water maze test. Application of S-ESBA 
and KYNA together confirmed the counteracting effect of 
KYNA, as it diminished the pro-cognitive effects of S-
ESBA. Similar results were seen with chronic reduction of 
KYNA synthesis by KAT-II knock-out mice [57]. In other 
rat studies, S-ESBA has also been shown to increase brain 
acetylcholine [83], dopamine [74], and GABA levels [84], 
which also have established roles in cognitive performance 
[31]. 
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O
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D,L-4-(ethylsulfonyl)benzoylalanine S-4-(ethylsulfonyl)benzoylalanine
Fig. (8). Structure of KAT-II inhibitors ESBA, and S-ESBA (the 
active enantiomer). 
These results show that inhibiting KAT-II activity may 
counterbalance the neurotransmitter imbalances and cogni-
tive impairment that is associated with elevated KYNA lev-
els and schizophrenia. 
BFF-122 
The activity of (S)-(-)-9-(4-aminopiperazin-1-yl)-8-
fluoro-3-methyl-6-oxo-2,3-dihydro-6H-1-oxa-3a-azaphena-
lene-5-carboxylic acid (BFF-122) (Fig. 9) tested in vitro us-
ing rat brain homogenate showed that it inhibited KAT activ-
ity without affecting kynurenine 3-monooxygenase activity 
(Fig. 2) [75]. Tests with rat liver preparations of KAT iso-
forms showed selective activity towards KAT-II [75]. In vivo 
rat experiments replicated the effectiveness of BFF-122 in 
inhibiting KAT and reducing KYNA synthesis in the stria-
tum [75]. Experiments with recombinant human KAT-II 
showed that BFF-122 was extremely potent with an IC50 of 
approximately 1 μM [85]. 
75
Review of KAT Inhibitors Current Medicinal Chemistry, 2015, Vol. 22, No. 24     2911 
N
N
NH2
F
N
O
OOH
O
BFF-122
Fig. (9). Structure of KAT-II inhibitor, BFF-122. 
In vitro testing of brain slices confirmed KAT-II inhibi-
tion of BFF-122 and showed that it was able to normalise an 
increase in KYNA induced inhibition of α7-nicotinic recep-
tors and NMDA receptors [86]. Unlike the extensively stud-
ied S-ESBA, animal behavioural studies for this compound 
are still lacking. 
The crystal structure of BFF-122 in complex with human 
KAT-II (PDB ID 2XHI) shows that the inhibitor forms a 
covalent adduct with the PLP cofactor, which irreversibly 
inhibits the KAT enzyme (Fig. 10) [85]. While other human 
KAT isoforms are too narrow and rigid to accommodate 
BFF-122, KAT-II displays plasticity allowing it to accom-
modate bulkier compounds than might have been simply 
anticipated, reaffirming the possibility of exploiting struc-
tural differences to develop specific inhibitors [85]. 
Fig. (10). The active site of hKAT-II with BFF-122, with carbons 
shown in yellow, and the cofactor in its PLP form, in magenta 
(PDB ID 2XH1). The amino acids with an atom within 5.0 Å of the 
L-kynurenine and the cofactor were chosen for display.
Hydroxamate and Pyrazole Compounds 
The search for a more potent, brain-penetrable KAT-II 
inhibitor led to the discovery of the cyclic hydroxamate 
compound (3S)-3-amino-1-hydroxy-3,4-dihydroquinolin-
2(1H)-one (PF-04859989) (Fig. 11) from a high through-
put screen [87]. With high potency for human KAT-II, in 
the nanomolar range (IC50: 23 nM), the compound showed 
selectivity towards KAT-II over KAT-I, KAT-III, and 
KAT-IV (IC50: 22, 11, and > 50 μM, respectively). The 
pharmacokinetic properties and the simplicity of the 
molecule give it great potential as a lead compound. PF-
04859989 forms a covalent adduct to the PLP cofactor 
and irreversibly inhibits the enzyme (PDB ID 3UE8), 
similar to BFF-122 [87]. 
N
OH
O
NH2
PF-04859989
Fig. (11). Structure of brain penetrable KAT-II inhibitor, PF-
04859989. 
Structure activity relationship studies showed that the 
(S)-enantiomer of PF-04859989 is ten-fold more potent, and 
a free hydroxamic acid group is necessary for inhibitory ac-
tion. Addition of methyl groups on the piperidine ring also 
reduces potency by interfering with the formation of the in-
hibitor-PLP adduct [87]. 
Evaluating substituents on the aromatic ring suggested 
that adding large substituents to R1 and R4 made the com-
pound significantly less potent (Table 3) due to unfavourable 
steric interactions with KAT-II. Smaller substituents such as 
R1 or R4 = F are relatively tolerable, but still reduce potency. 
Small substituents on the R2 and R3 position are less sensi-
tive to a decrease in potency as measured by IC50 values. 
Potency measured by the second order rate constant Kinact/Ki, 
which is considered to be more relevant for irreversible in-
hibitors, shows that the small substituent added onto R2 (4f-
h) may actually increase potency [87]. 
In vivo testing of PF-04859989 in rats by subcutaneous
injection displayed that the compound is brain-penetrant and 
reduces KYNA concentrations by 50% approximately one 
hour after dosing; a decrease that is returned to normal 
twenty hours after the dose [87]. Further experiments have 
shown that the molecule is capable of restoring nicotine-
evoked glutamatergic signalling suppressed from elevated 
KYNA levels [88]. Amphetamine and ketamine challenges, 
which mimic impairments in schizophrenia, were used to 
induce auditory gating deficits in rats and these were shown 
to be prevented by PF-04859989 administration [59]. In-
creased performance with sustained attention tasks was also 
seen in rats following administration of PF-04859989, as 
well as improvements in working memory tasks and spatial 
memory tasks in ketamine-challenged rats and non-human 
primates, respectively [59]. Altogether, this shows that PF-
04859989 can improve cognitive symptoms by inhibiting 
KAT-II and lowering KYNA concentrations. 
Using PF-04859989 as a scaffold, further analogues were 
analysed (Table 4: 5a-c) to develop one with superior po-
tency [89]. IC50 data was again shown to not be able to dif-
ferentiate between the analogues, however Kinact/Ki revealed 
that compounds 5a and 5b were more potent (Kinact/Ki: 
31,700 and 26,800 M-1 s-1, respectively, compared to PF-
04859989 Kinact/Ki: 18,500 M
-1 s-1). This led to the design of 
5c, a compound that is 4-5 fold more potent (Kinact/Ki: 
129,000 M-1 s-1). The increase in potency seen in 5a and 5b 
is due to an additional van der Waals interaction with Ile-19, 
and an additional lipophilic interaction between the aryl 
group and a hydrophobic pocket formed by Leu-293, respec-
tively (PDB IDs are 4GE4 and 4GE7 (Fig. 12), respectively). 
Compound 5c displays the latter entry of the benzyl group 
into the hydrophobic pocket, but has different stabilising 
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Table 3. Structure activity relationships of PF-04859989 analogues. Potency of the compounds is measured by IC50 (nM) and 
Kinact/Ki (M
-1
 s
-1
). Data taken from Dounay et al. (2012) [87].
NH2
O
OH
N
R1
R2
R3
R4
Hydroxamate derivatives
Compound R
1
R
2 
R
3 
R
4 
IC50 (nM) Kinact/Ki (M
-1
 s
-1
) 
PF-04859989 H H H H 23 18,500
4a F H H H 40 5310
4b OMe H H H 572 21.3
4c Cl H H H 252 42.0
4d Me H H H 1050 -
4e CF3 H H H 174 541
4f H Cl H H 29 28,300
4g H Me H H 37 33,400
4h H OMe H H 22 31,700
4i H H Cl H 36 19,000
4j H H Me H 30 11,900
4k H H CF3 H 29 15,300
4l H H H F 45 6680
4m H H H Cl 349 9.5
4n H H H Me 319 -
4o H H H OMe 179 1940
4p H H H CF3 >10,000 -
interactions with Arg-20 (adjacent to Ile-19), which anchors 
the inhibitor-PLP complex and enhances potency [89] (PDB 
ID 4GE9). 
Experiments in vivo showed that the increased potency of
5b compared to PF-04859989 in rats resulted in reduced 
KYNA levels to a significantly longer and greater extent at 
the same dose. 5c however was shown to not lower KYNA 
levels regardless of dose in rats due to higher CYP450-
mediated clearance of the compound as a result of a rela-
tively more lipophilic core [89,90]. 5c was redesigned as a 
series of pyrazole analogues (Table 4: 6a-h) to provide better 
physicochemical parameters [90]. The addition of a benzyl 
substituent (mirroring 5b) to the 5-position of the ring 
showed improvements in potency from 6a to 6b. Further 
substituents and minor changes did not improve potency 
significantly (6c-e). The aromatic carbon was then added 
onto the nitrogen at the 6-position (6f-h) with the expectation 
that it would still project into the previously described hy-
drophobic pocket of the enzyme. Compound 6g showed po-
tency comparable to 5c (Kinact/Ki: 112,000 M
-1 s-1). Interest-
ingly, the isomeric compound of 6h was significantly less 
potent (Kinact/Ki: 8580 M
-1 s-1), which highlights the impor-
tance of the atoms in the pyrazole ring itself in determining 
the effectiveness of this compound as an inhibitor [90]. 
The crystal structure of 6g (PDB ID 4GEB) shows that 
the potency difference between the isomers 6g and 6h is 
likely a result of 6g being able to interact with a water mole-
cule in the active site of the enzyme and project the 5-
position, unsubstituted carbon into a lipophilic pocket de-
fined by Tyr-74, while 6h would not be able to interact with 
the water molecule and has a nitrogen in the 5-position 
which is projected into the lipophilic pocket instead [90]. 
6g, having similar potency to 5c, was confirmed to have 
more desired lipophilic characteristics. 6g is less lipophilic 
and measurements from a human liver microsome assay 
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Table 4. Structures and potency of PF-04859989 derivatives and variants as measured by IC50 (nM) and Kinact/Ki (M
-1 
s
-1
). Data
taken from Tuttle et al. (2012) (5a-c) [89] and Dounay et al. (2013) (6a-h) [90].
Compound Structure IC50 (nM) Kinact/Ki (M
-1
 s
-1
) 
PF-04859989 
NH2
O
OH
N
 
23 18,500
5a 
NH2
O
OH
NO
 
22 31,700
5b 
NH2
O
OH
N
O
23 26,800
5c 
NH2
O
OH
NO
 
37 129,000
6a 
NH2
O
OH
NN
N
329 -
6b 
NH2
O
OH
NN
N
64 16,000
6c 
NH2
O
OH
NN
N
H3C
O
66 8710
6d 
NH2
O
OH
N
N
N
F
F
F
74 7920
6e 
NH2
O
OH
N
N
N 23 16,200
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(Table 4) contd…. 
Compound Structure IC50 (nM) Kinact/Ki (M
-1
 s
-1
) 
6f 
NH2
O
HO
N
N
N
47 10,500
6g 
NH2
O
OH
NN
N
25 112,000
6h 
NH2
O
OH
N
N
N
85 8580
Fig. (12). The active site of hKAT-II with PF-04859989 derivative, with carbons shown in yellow, and the cofactor in its PLP form, in ma-
genta (PDB ID 4GE7). The amino acids with an atom within 5.0 Å of the L-kynurenine and the cofactor were chosen for display. Labels for 
Gly-38, Gly-39, Gly-116, and Ser-117 were removed (amino acids still shown) for clarity. 
showed that CYP-mediated clearance was significantly re-
duced [90]. Clinical applications of these analogues with 
animal behavioural studies have not yet been reported. 
BFF-816 
BFF-816 (Fig. 13) was discovered after a search directed 
at finding a KAT-II inhibitor that was orally active [60]. In 
rat liver homogenate, the IC50 of BFF-816 was determined to 
be 13.4 ± 0.2 μM [60]. 
A 30 mg/kg oral dose in rats showed an acute, reversible 
reduction in KYNA levels by approximately 30% and an 
increase in dopamine levels by 50-70% in the striatum each 
day, for five days, without evidence of tolerance [60]. In the 
rat hippocampus, a 30 mg/kg oral dose saw a reduction in 
KYNA levels by approximately 25% and an elevation in 
glutamate levels by 60%, and these results were duplicated 
when KYNA and glutamate levels were measured in the 
prefrontal cortex [60]. Behavioural experiments using the 
Morris water maze tests found that rats receiving an oral 
dose of BFF-816 had enhanced cognitive performance in 
comparison to controls [60]. Again, these experiments dem-
onstrate that translation of inhibitors reducing KYNA levels, 
increasing key neurotransmitter levels, and improving cogni-
tive function, into compounds which are brain-penetrant and 
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orally active, is occurring [60]. However, pharmacokinetic 
and pharmacodynamics parameters of BFF-816 have not 
been reported in detail. 
N
O
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Fig. (13). Structure of orally active KAT-II inhibitor, BFF-816. 
KAT-III and KAT-IV Inhibitors 
S-ESBA (Fig. 8) was also used to examine the inhibition 
of mouse KAT homologues, which showed that the mole-
cule, while still selective towards KAT-II, was less obvi-
ously so than what has been observed in rat studies. S-ESBA 
displayed some capability to inhibit KAT-IV [74]. 
Intensive research on developing specific KAT-III and 
KAT-IV inhibitors is lacking. However, structural and bio-
chemical analyses of mouse KAT-III [52] (PDB ID 3E2Y) 
and KAT-IV [53,56] (PDB ID 3PD6) establishes ground-
work to advance in this area. 
CONCLUSION 
As KYNA is found elevated in patients with schizophre-
nia and is produced by the transamination activity of KAT 
enzymes, these enzymes are targets in the search for avenues 
to treat this debilitating condition. 
The most potent KAT-I inhibitors in the literature are the 
phenylhydrazone hexanoic acid derivatives (Table 2: 1a and 
1f), but these have potencies in the micromolar range and 
require further optimisation of potency to be developed into 
a drug. For KAT-II inhibitors, 6g (Table 4) of the pyrazole 
series had nanomolar potency and had favourable physico-
chemical properties compared to the compounds from which 
it was derived. Although it had comparatively lower potency, 
BFF-816 is significant in that it has shown a desired clinical 
effect and is orally active. 
The clinical relevancy of KAT inhibitors primarily comes 
from in vivo administration of KAT-II inhibitors, rather than 
anything else. KAT inhibitors, in general, have been repeat-
edly shown to reduce KYNA production in the brain. This 
KYNA reduction has also corresponded with an increase in 
key neurotransmitter activity, chiefly in the glutamatergic, 
dopaminergic and cholinergic systems. In animals it is further 
shown that these effects also correlate to an improvement in 
cognition. This is promising considering that current antipsy-
chotic medications mainly ameliorate the positive symptoms 
of schizophrenia. The negative and cognitive symptoms of 
schizophrenia can have a tremendous impact on patient wel-
fare, and cause occupational and social impairment, and so 
any treatments that can potentially assist with these symp-
toms, whether as stand-alone treatments or as an adjunct to 
the positive symptom-treating antipsychotics, will therefore 
have significant impact in treating schizophrenia. 
With the structural and biochemical properties of the 
KAT-I and KAT-II isoforms comprehensively characterised, 
there is great potential in developing more lead molecules for 
KAT inhibitors. 
FUTURE DIRECTIONS 
Inadequate treatment options for schizophrenia necessi-
tates the closer analysis of mechanisms underpinning the 
pathogenesis of schizophrenia, as this could provide more 
tailored medicines. KAT inhibitors are touted as possible 
treatments in schizophrenia, especially for the less well 
treated negative symptoms and cognitive impairment. 
KAT-I and KAT-II are thought to be primarily responsi-
ble for KYNA production in the brain, and the most exten-
sive research has been done on these isoforms. However 
there are still only a limited number of potential leads, and 
even fewer that have the adequate kinetics and efficacy nec-
essary to be pushed into trials in the near future. 
KAT-III and KAT-IV have not had their roles as well es-
tablished, but nevertheless there is potential for their rele-
vance in brain kynurenic acid production. Presently there are 
no three-dimensional structures established for the human 
versions of these enzymes and there are no compounds tar-
geted at specifically inhibiting these isoforms, both of which 
would be of interest. 
Developing more, selective inhibitors against each iso-
form can help tailor the clinical effect depending on the ex-
tent of inhibition of KAT activity that is warranted, as the 
enzymes may perform to different requirements. More selec-
tive inhibitors of the KAT subtypes can also inform our un-
derstanding of the pathogenesis. Evidence is accruing that 
the symptoms of schizophrenia are treated by the KAT-II 
inhibitors, S-ESBA, PF-04859989 and BFF-816. The recent 
discovery of BFF-816 shows promise in finding efficacious, 
orally active KAT-II inhibitors. 
ABBREVIATIONS 
3 HAO = 3 hydroxyanthranilate oxidase 
GABA = γ-aminobutyric acid
IAC = indole acetic acid
IDO = indoleamine 2,3 dioxygenase 
KAT = kynurenine aminotransferase
KMO = kynurenine 3-monooxygenase
KYNA = kynurenic acid
L-KYN/KYN = L-kynurenine/kynurenine
NMDA = N-Methyl-D-aspartic acid
PCP = phencyclidine
PLP = pyridoxal 5’-phosphate
PMP = pyridoxamine 5’-phosphate
S-ESBA = (S)-(4-ethylsulfonyl)benzoylalanine
TDO = tryptophan 2,3dioxygenase. 
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Chapter 3 Fragment-based drug design approaches to developing kynurenine 
aminotransferase-II inhibitors 
3.1 Preface 
The development of inhibitors for the KAT enzymes has been guided by structure and 
ligand-based drug design approaches, and from these works some different scaffolds have 
emerged for the creation of KAT-II inhibitors. Utilising fragment-based methodologies for 
drug design is an increasingly interesting approach, with successes observed in many 
different contexts over a relatively short period of time [1].  FBDD has not been previously 
used for designing KAT-II inhibitors, therefore the work in this chapter sought to determine 
if FBDD techniques were feasible for developing novel KAT-II inhibitors. The use of SPR 
for both the identification of hits from a fragment library screening, and hit validation, is 
discussed, and some of the pitfalls associated with this technique for this purpose are 
addressed. This approach, when combined with inhibition assays (method validation in 
Appendix A) using the hits, successfully generated leads which can be used as novel 
scaffolds for producing different classes of inhibitors to those currently existing. Molecular 
docking (method validation in Appendix C) was also used to predict and discuss the binding 
modes of the identified leads. Due to the potentially promiscuous nature of fragment 
molecules, molecular docking was also used to assess the fidelity of the top hits at the active 
site of KAT-II, whereby it was shown that the fragment hits displayed more favourable 
interactions in the active site than at other sites of the protein (Appendix C.4).  
Supplementary material for the article contained within this chapter is located in 
Appendix E.1. 
3.2 References 
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Introduction
Fragment-based drug design utilizes low-molecular weight 
fragments, typically less than 300 Da, as initial leads for the 
development of drugs.1 Libraries of fragment molecules are 
usually orders of magnitude smaller than those used in 
high-throughput screening, but the total chemical space for 
fragments is much smaller, enabling it to be sampled more 
efficiently.2 Because of their simplicity, fragments have a 
greater chance of binding to enzymes and can generate a 
higher rate of “hits” in a screen.3 Fragment binding repre-
sents a foothold at the start of the difficult process of drug 
discovery, but its potential has been translated with some 
success with several targets of interest.4 Fragments offer 
greater versatility in being able to be optimized due to start-
ing leads being relatively smaller.3 However, because of 
their size, they tend to bind with low affinity to their targets, 
and hence a sensitive biophysical detection method must be 
used, such as x-ray crystallography, nuclear magnetic reso-
nance (NMR), mass spectrometry, or surface plasmon reso-
nance (SPR).2
In approaches guided by SPR, a target is immobilized on 
a sensor chip surface and any changes in the refractive 
index upon binding of test compounds can be observed and 
are measured.5 The SPR approach consumes less protein 
than other biophysical screening methods, can rapidly 
provide the kinetics of interactions, and offers flexibility in 
allowing multiple channels to be available for referencing 
or running experiments against different targets in parallel.5 
However, some pitfalls with SPR can arise from using sol-
vents, particularly DMSO, which has a high refractive 
index, as it can cause a bulk shift in response if the solvent 
concentration in the sample is mismatched with the running 
buffer, and may introduce false positives.6
Kynurenine aminotransferase-II (KAT-II) is a pyridoxal 
5′-phosphate (PLP)-dependent homodimer and is one of four 
KAT isoforms in mammals.7 Each KAT-II subunit contains a 
large domain, a small domain containing the C-terminus, and 
an N-terminal arm, and the interface of the two subunits is 
where the active site and PLP binding sites are hosted.7,8 
KAT-II is clearly differentiated structurally from the other 
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Abstract
Kynurenine aminotransferase-II (KAT-II) is a pyridoxal 5′-phosphate (PLP)–dependent enzyme that acts in the tryptophan 
metabolic pathway by catalyzing the transamination of kynurenine into kynurenic acid (KYNA). It is one of four isoforms 
in the KAT family, of which it is the primary homologue responsible for KYNA production in the mammalian brain. 
KAT-II is targeted for inhibition as KYNA is implicated in diseases such as schizophrenia, where it is found in elevated 
concentrations. Previously, many different approaches have been taken to develop KAT-II inhibitors, and herein fragment-
based drug design (FBDD) approaches have been exploited to provide further lead compounds that can be designed into 
novel inhibitors. Surface plasmon resonance (SPR) was used to screen a fragment library containing 1000 compounds, of 
which 41 hits were identified. These hits were further evaluated with SPR, and 18 were selected for inhibition studies. 
From these hits, two fragments, F6037-0164 and F0037-7280, were pursued and determined to have an IC50 of 524.5 (± 
25.6) μM and 115.2 (± 4.5) μM, respectively. This strategy shows the viability of using FBDD in gleaning knowledge about 
KAT-II inhibition and generating leads for the production of KAT-II inhibitors.
Keywords
inhibitors, fragments, screening, surface plasmon resonance, kynurenine aminotransferase
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isoforms in that it has a relatively larger, less hydrophobic 
binding pocket, and also the N-terminal arm undergoes domain 
swapping as it projects from one subunit into the opposite sub-
unit, helping shape the active site.9
The KAT isoforms catalyze the irreversible transamination 
of kynurenine to kynurenic acid (KYNA), a step in the trypto-
phan metabolic pathway.10 The KAT-II transamination mecha-
nism is thought to occur first, with kynurenine entering into the 
active site by a conformational fold of N-terminal residues and 
generating a π-cation interaction with Arg-20 (Suppl. Fig. 
S1).10 The carboxyl of kynurenine acts as a salt bridge and 
interacts with Arg-399, while the amine group also forms 
hydrogen bonds with Asn-202 and Gly-39, and together these 
residues assist in anchoring the substrate in the correct confor-
mation for transamination within the active site. PLP is cova-
lently attached to Lys-263 by an internal aldimine bond that is 
later broken during the enzymatic reaction.10
The product of this reaction, KYNA, is an N-methyl-d-
aspartic acid (NMDA)11,12 and an α7-nicotnic acetylcholine 
receptor antagonist13 that plays a role in cognitive function. 
KYNA was found elevated in the cerebrospinal fluid14 and 
prefrontal cortex15 of patients with schizophrenia, and 
KAT-II, thought to be responsible for producing most 
KYNA in the brain,16 has had inhibitors developed against it 
with the potential to ameliorate these effects. Existing KAT-II 
inhibitors include the reversible inhibitors S-ESBA,17 BFF-
816,18 and NS-150219 and the irreversible inhibitors 
PF-0485998920 and BFF-122,21 which have their irrevers-
ibility derived from the formation of a covalent adduct 
between the primary amine of the inhibitor and PLP.20,22 
The KAT-II inhibitors have the ability to reduce KYNA lev-
els while increasing levels of neurotransmitters involved in 
cognitive function, such as glutamate,18,23 acetylcholine,24 
dopamine,25 and GABA.26 KAT-II inhibitors have also dem-
onstrated in animal studies that they can improve spatial 
learning and memory.18,23,27
In this study, we aimed to screen a 1000-fragment library 
against KAT-II using SPR to find potential binding hits. 
These hits were validated by evaluating them in different 
concentrations to minimize the potential for false positives, 
and any fragment hits advancing further were evaluated for 
their inhibitory ability using a high-performance liquid 
chromatography (HPLC) inhibition assay. The possible 
binding mechanisms of the fragments hits are discussed 
with a view to aiding the design process of KAT-II inhibi-
tors, and also using these hits as the basis of new leads for 
new inhibitors.
Materials and Methods
General Procedures
Commercially available reagents were used without addi-
tional purification unless otherwise stated. The fragment 
library (1000 wells, each containing 1 mg of a fragment 
compound) was purchased from Life Chemicals (Ontario, 
Canada). Phosphate-buffered saline (PBST; pH 7.4 with 0.05% 
Tween 20) was purchased from Sigma-Aldrich (Sydney, 
Australia). SPR reagents (40 mM EDC, 10 mM sulfo-NHS, 
10 mM sodium acetate, 1 M ethanolamine HCl, pH 8.5) were 
purchased from Bio-Rad Laboratories (Gladesville, Australia). 
Methanol and DMSO were purchased from Thermo Fisher 
Scientific (Scoresby, Australia).
The SPR screening protocol was prepared with the Biacore 
T200 control software, measurements were performed using 
the Biacore T200 with a CM5 sensor chip, and the results were 
analyzed with the Biacore T200 evaluation software (GE 
Healthcare Life Sciences, Sydney, Australia).
The IC50, reported with standard error, was determined 
using GraphPad Prism v7.02 software (GraphPad, La Jolla, 
CA), by developing a nonlinear regression fit of the data 
collected from the inhibition assays. Images of docked 
compounds were generated by the PyMOL Molecular 
Graphics System (Schrodinger LLC, Cambridge, MA).
Protein Preparation
The recombinant KAT-II protein was expressed and puri-
fied in our lab as previously described.28
Initial Fragment Binding SPR Screen against 
KAT-II
Prior to performing the SPR experiments, the solutions 
were filter sterilized for 10 min at 25 °C. KAT-II was diluted 
to a concentration of 320 µg/mL using sodium acetate (pH 
4.5). The Biacore T200 compartment temperature was con-
trolled at 25 °C, and the flow rate was set to 10 µL/min. 
Using a 1:1 mixture of 400 mM EDC and 100 mM sulfo-
NHS, two flow cells on a CM5 sensor chip (contains a car-
boxymethylated dextran surface) were activated. Flow cell 
1 contained a blank immobilization (PBST buffer injec-
tion), and flow cell 2 had the prepared KAT-II sample 
injected. The two flow cells were deactivated using an 
injection of 1 M ethanolamine.
The analytes (fragment library samples) were prepared 
in running buffer (PBST with 5% DMSO) to a final concen-
tration of 20 µM and loaded into a 96-well plate. The ana-
lytes were injected using a flow rate set to 30 µL/min, a 
contact time of 30 s, and a dissociation time of 30 s, with an 
extra 50% DMSO wash performed after each injection. 
Solvent correction was performed at the start and end of the 
experiment, and also after every 50 cycles, to account for 
the use of DMSO in the analyte sample preparation and the 
running buffer. The positive control (20 µM NS-1502) and 
the blank control (running buffer) were injected every 30 
cycles.
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Analytes were prepared in running buffer (PBST with 5% 
DMSO) in a concentration series from 6.25 to 100 µM. The 
analytes were injected onto the CM5 sensor chip using a 
flow rate of 30 µL/min, a contact time of 90 s, and a disso-
ciation time of 90 s, with an extra 50% DMSO wash per-
formed after each injection. Solvent correction was 
performed before and after the analyte injections and also 
every 50 cycles.
Fragment Lead Evaluation Using HPLC Inhibition 
Studies and IC50 Determination
The KAT-II inhibition assay was performed as previously 
described.19 KAT-II (0.5 µg) was incubated at 37 °C in a 50 
µL reaction mixture containing 50 µM PLP, 5 mM 
α-ketoglutarate, and 5 mM l-kynurenine in PBS, pH 7.4, 
and the inhibitor studied (200–500 µM in the initial lead 
screening and 1–2000 µM for IC50 determination).This 
reaction was terminated after 10 min by adding formic acid 
(0.8 M) in a 1:1 ratio. Fifty microliters of this mixture was 
diluted to 1 mL with water, which was analyzed by HPLC 
using a C18 reverse-phase column with a 50% (v/v) water 
and 50% (v/v) methanol mobile phase. Kynurenine and 
KYNA were measured with UV detection at a wavelength 
of 330 nm.
Computational Docking of Inhibitor Compounds 
at the Active Site of KAT-I and KAT-II
The crystal structure of human KAT-I (PDB ID: 3FVU29) 
and KAT-II (PDB ID: 2R2N30) was downloaded from the 
Protein Data Bank. Docking was performed as follows, 
both with and without PLP in the active site. The protein 
was optimized and minimized using the protein prepara-
tion wizard in Maestro v10.4.017 (Schrodinger LLC), 
and water molecules not participating in the reaction 
were removed. LigPrep (Schrodinger LLC) was used to 
prepare the fragment and inhibitor ligands, using the 
OPLS-200531 force field. The active site grid was deter-
mined by the location of kynurenine, the natural sub-
strate, in the PDB file in KAT-II, and the cocrystallized 
inhibitor, indole-3-acetic acid, in KAT-I. The ligands 
were docked with XP (extra precision) docking32 using 
Glide (Schrodinger LLC).
Data Availability
The data generated and analyzed during the current study 
are available in the Figshare repository (https://figshare 
.com/projects/Fragment_Screening_of_Human_Kynure 
nine_Aminotransferase-II/28293).
Results and Discussion
Preliminary Fragment Binding Screen on KAT-II 
Using SPR
SPR was used to identify potential KAT-II-inhibiting lead 
molecules from a fragment library containing 1000 com-
pounds. The fragment library was synthesized to be diverse 
and has an average molecular weight of 223 Da (with a 
range of 84–300 Da). An initial consideration with using 
fragment molecules in SPR is their inherent lower response. 
The theoretical response limit is dictated by the equation 
Rmax = MWan/MWlig*RL*Sm, where Rmax is the analyte bind-
ing ability, MWan and MWlig are the molecular weights of 
the analyte and ligand, RL is the ligand immobilization lev-
els, and Sm is the stoichiometric ratio of the interaction. This 
necessitates that higher ligand binding on the sensor chip is 
required in fragment binding than it otherwise would be 
required in, for example, protein–protein interactions. In 
our experiment, KAT-II was bound onto a CM5 sensor chip 
by amine coupling and achieved approximately 20,000 RU, 
which enabled us to elicit a noticeable response from the 
fragments. All the fragment molecules and positive control 
(NS-1502) were injected at a concentration of 20 µM, and 
the running buffer (PBST with 5% DMSO) was used as a 
blank control. After correcting for DMSO and subtracting 
the reference channel, the data were adjusted to show the 
relative response of the analytes in comparison with the 
positive and blank controls (Fig. 1).
The screening of the 1000 fragment compounds was 
done over different days, using samples loaded into a 
96-well plate for each run. One negative aspect that was
evident from the experiment was the effect the duration of
each run (approximately 8–10 h per well plate) had on the
quality of the results. Notably, there seemed to be a slight,
but increasing, negative shift in response by the blank con-
trol as time progressed in some of these runs. Given that
between runs the blank control had a normal response at the
beginning (before slowly drifting), and given that the posi-
tive control seemed to be consistent throughout the runs, the
response described is likely not as a result of chip or ligand
instability. Instead, it is thought that there was mismatch in
the running buffer and the blank control over time. The rela-
tive adjustment to the blank control can hence potentially
positively skew the response of the fragments in that par-
ticular run and produce false positives (a graphical example
of this can be seen in Fig. 2).
The cutoff used from the initial screen included those 
fragments that achieved a relative response of 85%+ of the 
positive control, NS-1502. In total, 41 fragments were 
selected for more extensive investigation with SPR to pro-
vide more accurate information on their binding and hence 
maximize chances of true positives while ensuring that any 
false results were eliminated.
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The 41 fragments were prepared in a concentration series 
from 6.25 to 100 µM and analyzed using multicycle kinetics 
(Suppl. Fig. S2A–C). NS-1502 was also prepared in the 
same concentration and used as a positive control.
With increasing concentration, a concomitant increase in 
response can be expected from each fragment. Hence, some 
fragments could immediately be discarded as they did not 
respond in this way, and likely arose from binding nonspe-
cifically or simply as a result of the experimental conditions, 
such as requiring DMSO, which has a high refractive index 
and could result in false data if not treated with care. 
Removing these fragments from further consideration, there 
were 26 fragments remaining from which we could identify 
those truly most suitable. These fragments were compared 
with NS-1502, and 18 fragments were selected for a greater 
response to KAT-II than the positive control. Eight out of the 
18 fragments were observed to have a similar structural moi-
ety, with an aromatic ring fused to a five-membered ring 
(Suppl. Fig. S3).
HPLC Enzyme Assay Screening and IC50 
Determination
Out of the 1000 compounds in the fragment library, the 18 
selected fragments were determined to be the best binding 
to KAT-II, as determined by SPR, but this did not necessar-
ily indicate that they would be inhibitory. An HPLC inhibi-
tion assay was required to measure the inhibitory ability of 
these fragments at one concentration.
As seen in Supplemental Table S1, 15 of the selected 
fragments did not exhibit inhibition of KAT-II or did so only 
weakly. Fragments by nature can be highly indiscriminate 
in their binding, and it is possible that some of these com-
pounds bound to off-target locations when they were elicit-
ing a response to SPR. However, two fragments (F0037-7280 
and F6037-0164) were pursued for further study as evi-
dence showed that they were inhibitors of KAT-II. F3412-
0030 was a third fragment that seemed to inhibit KAT-II 
relatively well; however, given the high level of structural 
similarity to F0037-7280, this fragment was not followed 
up initially.
F6037-0164 and F0037-7280 were prepared in a concen-
tration series from 1 to 2000 µM. F6037-0164 was found to 
have an IC50 of 524.5 (± 25.6) µM (Fig. 3A). By varying the 
concentration of PLP in the reaction mixture, F6037-0164 
was found to be reversible (data not shown), like NS-1502.19 
In these same inhibition assay conditions, NS-1502 has an 
IC50 of 315 µM, so the IC50 determined for F6037-0164 is a 
promising lead for a reversible inhibitor.
F0037-7280 was found to have an IC50 of 115.2 (± 4.5) 
µM (Fig. 3B). Unlike NS-1502 and F6037-0164, changing 
PLP concentration did not seem to have an effect on F0037-
7280 inhibition (data not shown), suggesting that it may act 
irreversibly or in a noncompetitive manner with respect to 
the cofactor. However, the primary cause of irreversible 
inhibition in KAT-II inhibitors is the formation of a covalent 
adduct via a primary amine in the inhibitor, forming an 
external aldimine bond with PLP, which F0037-7280 would 
be unable to achieve.
Both of these compounds structures have a resemblance 
to a phthalimide core, with F0037-7280 differing in having 
the aromatic ring two carbon lengths distant from the 
Figure 1. A plot of the SPR response of the initial 
1000-fragment screen against KAT-II. Depicted are the blank 
control (green triangles), positive control (red triangles), 
fragments (blue circles), and cutoff (red dashed line). The plot 
has been subtracted with the blank and normalized with the 
controls. The diagram was produced using GraphPad Prism 
v7.02.
Figure 2. SPR responses of fragments (blue circles) from 
one run after normalization of the blank buffer control (green 
triangles). A mismatch in the blank buffer control and running 
buffer over time appears to skew the response of the fragments 
in a positive gradient. Diagram was produced using GraphPad 
Prism v7.02.
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succinimide-like moiety, and with F6037-0164 having an 
imidazole ring instead of a succinimide. Both fragments 
extend toward an aromatic ring but differ in the length of the 
molecule, with F6037-0164 being significantly bulkier. 
Based on the features of these compounds, and knowledge of 
the specific atomic interactions kynurenine has in the active 
site, it may be possible to predict the manner in which these 
fragments bind.
Binding Conformation of the Fragments
In both the three-dimensional structure and the docking in 
KAT-II with PLP, kynurenine is observed to favor the aro-
matic ring forming π-cation interactions with Arg-20, and 
the carboxyl group forming a salt bridge with Arg-399 
(Suppl. Fig. S1). The amine group also forms hydrogen 
bonds with Asn-202 and Gly-39, which, in addition to the 
carboxyl, helps situate it in the correct conformation within 
the active site. On the basis of modeling, a similar confor-
mation is expected with F0037-7280, with the benzene moi-
ety situated adjacent to Arg-20 and the succinimide moiety 
forming hydrogen bonds with Arg-399, Asn-202, and Gly-
39 (Fig. 4A). F6037-0164 is similar, with the benzimid-
azole core near Arg-20 and the carbonyl hydrogen bonding 
to Arg-399 and Asn-202 (Fig. 5A). As F6037-0164 is bulk-
ier, the remainder of the molecule curves back around in the 
binding pocket to avoid clashing with PLP. F3412-0030 is 
also a potential hit that was not explored and docks corre-
spondingly to the structurally similar F0037-7280, but with 
fewer notable interactions (Suppl. Fig. S4).
F0037-7280 docking calculations were also performed 
in KAT-II with PLP removed, and no significant change in 
the docking pose was observed (Fig. 4B). This is consistent 
with the F0037-7280 binding being unaffected by the pres-
ence of PLP, as was observed in the HPLC assay when a 
range of PLP concentrations in the reaction mixture were 
used but inhibition was very similar. These observations 
contrast with those of F6037-0164 (Fig. 5B) and NS-1502 
(Fig. 6A,B), which have a different proposed pose and dock 
near and interact with Lys-263, the residue normally 
involved in covalently binding to PLP, in the absence of the 
cofactor. Unlike F0037-7280, the inhibitory ability of these 
compounds decreases with increasing PLP concentrations, 
and hence they are in competition with it and may take up a 
less favorable conformation within the active site or get dis-
placed completely when PLP levels are increased. Estrogen 
disulfate, another relatively strong inhibitor of the KAT 
enzymes,33 also has been reported to compete with PLP, and 
it has been argued that its inhibitory action occurs by com-
peting for the binding site with the apoenzyme form of 
KAT.34 A similar mechanism of inhibition is conceivable for 
F6037-0164 and NS-1502.
The ability of F0037-7280 and F6037-0164 to inhibit 
KAT-II can be seen to be a consequence of the interactions 
they could have with key amino acid residues within the 
active site. Of particular importance seems to be the pres-
ence of an aromatic ring near the entry point of the active 
site, situated adjacent to Arg-20, whether alone (seen in 
F0037-7280) or as part of a system of rings (seen in F6037-
0164). Moieties that can exploit hydrogen bonding interac-
tions with Arg-399, Asn-202, and Gly-39, such as the 
carbonyl groups in F0037-7280 and F6037-0164, are also 
very important for binding.
The unique features of KAT-II, in particular its wider 
active site and flexible N-terminal arm, can be exploited in 
the development of selective inhibitors. The bulkiness of a 
ligand has been observed to be a significant determinant of 
selectivity as larger compounds can be more readily accom-
modated in the KAT-II active site. In contrast, there is more 
steric hindrance in the narrower, rigid active sites of the 
Figure 3. (A) Inhibitory activity of F6037-0164 in a dose-dependent format on KAT-II (IC50 = 524.5 [± 25.6] μM, R
2 = 0.92). (B)
Inhibitory activity of F0037-7280 in a dose-dependent format on KAT-II (IC50 = 115.2 [± 4.5] μM, R
2 = 0.97). The data used were from
at least three sets of tests. The diagram was produced using GraphPad Prism v7.02.
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Figure 5. F6037-0164 docked into the active site of KAT-II. The amino acids with an atom within 5.0 Å of F6037-0164 (yellow) were 
chosen for display. (A) F6037-0164 docked into KAT-II with PLP (magenta) present. Residues Leu-40, Pro-41, Ser-143, Gly-144, and Gln-
289 were removed for clarity. The carbonyl forms a bifurcated hydrogen bond (yellow dashes) with Asn-202 and Arg-399. (B) F6037-0164 
docked into KAT-II with PLP removed. Residues Leu-40, Gly-144, and Gln-289 were removed for clarity. The carbonyl forms hydrogen 
bonds with Asn-202. The nitrogen in the imidazole ring forms hydrogen bonds with Tyr-142. Images were generated with PyMOL.
Figure 4. F0037-7280 docked into the active site of KAT-II. The amino acids with an atom within 5.0 Å of F0037-7280 (yellow) were 
chosen for display. (A) F0037-7280 docked into KAT-II with PLP (magenta) present. Residue Leu-40 was removed for clarity. One 
carbonyl on the succinimide ring forms a hydrogen bond (yellow dashes) with Gly-39, and the second carbonyl forms a bifurcated 
hydrogen bond with Asn-202 and Arg-399. The succinimide nitrogen forms hydrogen bonds with Arg-399 (yellow dashes). (B) F0037-
7280 docked into KAT-II with PLP removed. Residues Ser-17 and Gln-289 were removed for clarity. The succinimide carbonyl forms 
a bifurcated hydrogen bond with Asn-202 and Arg-399. The succinimide nitrogen forms a salt bridge (yellow dashes) with Arg-399. 
Images were generated with PyMOL.
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other KAT isoforms.22,35 The docking of F6037-0164 
showed that in KAT-II, even as an elongated compound, it 
can be enclosed in the active site; however, in KAT-I this 
fragment directs more toward the surface of the enzyme 
(Suppl. Fig. S5). This suggests that KAT-II selectivity may 
be invoked by incorporating more bulk and rigidity into the 
structure, as the whole molecule may not be contained 
within the active site of KAT-I. F0037-7280 is a much 
smaller molecule and has more potential to be optimized in 
the future with similar considerations.
The design of selective KAT-II inhibitors remains an 
important endeavor. KYNA, thought to be predominantly 
produced by KAT-II in the brain, is a downstream product 
of tryptophan degradation and is implicated in normal cog-
nitive function; however, it is also found to be elevated in 
patients with schizophrenia. KAT-II inhibitors, which 
reduce KYNA levels, notably have been shown to have 
positive effects on cognitive function in animal models. To 
aid in the improvement of existing inhibitors and in the 
development of new KAT-II inhibitors, in this study we 
screened a library of fragments compounds using SPR. 
From the screening and subsequence inhibition assay, we 
have found two fragments, F0037-7280 and F6037-0164, to 
pursue as lead KAT-II inhibitor compounds.
The most important protocol design consideration that 
became evident during this work was ensuring that the sol-
vent concentration was controlled in the samples and the 
running buffer for use in SPR. As DMSO has a high refrac-
tive index, a mismatch during its use can cause a large bulk 
shift in response and confound the data. This situation is 
likely more problematic in a long screening run, as we 
found that for extended runs the mismatch between the two 
grew. To overcome this, it would be more advisable to split 
the runs into smaller ones with freshly made samples and 
running buffer. In the work presented here, the false posi-
tives were eliminated by running the fragment hits in a con-
centration series and reevaluating the SPR curves generated. 
This method, however, adds an additional step to the proto-
col; hence, an initial minimization of the effect of DMSO 
would be more beneficial in terms of time.
The fragment-based screening found 18 hits from the 
SPR experiments. Despite many of these hits being poor 
inhibitors, they can potentially be developed into more 
potent leads as they are proven KAT-II binders. Evidence 
suggests that three of the hits are already strongly inhibi-
tory, with F6037-0164 and F0037-7280 actively pursued 
and F3412-0030 in consideration for future research. 
Analyzing the interactions with which F0037-7280 and 
Figure 6. NS-1502 docked into the active site of KAT-II. The amino acids with an atom within 5.0 Å of NS-1502 (yellow) were 
chosen for display. (A) F6037-0164 docked into KAT-II with PLP (magenta) present. Residues Leu-40, Ser-143, Gly-144, and Gln-289 
were removed for clarity. The carboxyl forms hydrogen bonds (yellow dashes) with Asn-202 and Arg-399. The phthalimide carbonyls 
form hydrogen bonds with Gly-39 and Tyr-142, respectively. The phthalimide aromatic ring forms π-π interactions (green dashes) 
with Tyr-74. (B) NS-1502 docked into KAT-II with PLP removed. Residues Leu-40, Ser-143, Gly-144, and Gln-289 were removed for 
clarity. The carboxyl moiety forms hydrogen bonds with Asn-202 and Arg-399. The aromatic ring has π-π interactions with Tyr-142 
and π-cation interactions (blue dashes) with Lys-263. Images were generated with PyMOL.
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F6037-0164 may bind, it appears that the important features 
in KAT-II binding and inhibition include interactions with 
Arg-20, Arg-399, Asn-202, and Gly-39 for reversible inhi-
bition. It also appears that a smaller compound, such as 
F0037-7280, may be noncompetitive with respect to the 
cofactor PLP, whereas a larger compound, such as F6037-
0164, may be partially competitive with PLP (along with 
the substrate kynurenine) in binding to the apoenzyme.
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Chapter 4 Estrogen inhibition of kynurenine aminotransferases 
4.1 Preface 
More traditional SBDD methods were also utilised to develop KAT-II inhibitors, 
underpinned by the work presented in this chapter. The basis of the approach taken came 
from observations of estrogens inhibiting enzymes in the kynurenine pathway and other 
PLP-dependent enzymes, with particularly strong inhibition by the sulfate ester forms of the 
steroid compounds [1]. Experimental work with aspartate aminotransferase and estrogen 
phosphates suggested that the potency of these steroid compounds could be due to 
17-position substituents [2]. It should also be noted that there are sexual dimorphic 
considerations for some diseases, including schizophrenia. Therefore, studying the influence 
of estrogens on pathways linked to these diseases, including the kynurenine pathway 
enzymes, is in itself a valuable exercise. 
The work in this chapter was designed to test the KAT inhibition of various steroids 
(estradiol, estradiol 3-sulfate, estradiol disulfate, estrone 3-sulfate) in the HPLC inhibition 
assay established for KAT inhibitors (method validation in Appendix A), thereby allowing a 
comparison with existing inhibitors as well as each other. The second aspect of this work was 
to surmise whether there is an increase in potency towards KAT inhibition by the sulfate 
forms of the steroids, and, if so, whether the positioning of the sulfate moieties on the steroid 
compounds has a bearing on KAT inhibition. In a similar manner to that utilised for the 
KAT-II inhibitor, NS-1502 (Appendix B), SPR was used to help ascertain the binding ability 
of estradiol disulfate. Molecular docking (method validation in Appendix C) was also 
employed to predict the binding mode of the different steroid compounds in KAT-II and 
discuss how and why the position of the sulfates may affect its ability to inhibit the protein. 
Docking calculations were also performed to predict the binding of the steroid compounds in 
other important enzymes of the kynurenine pathway, as part of the rationalisation of the 
potential mechanism by which these compounds may influence the pathway beyond KAT-II 
(discussed in Appendix C.3). The primary conclusions from the work described in this 
chapter had a strong influence in the development of the KAT-II inhibitors discussed in 
Chapter 5.  
Supplementary material for the article contained within this chapter is located in 
Appendix E.2. 
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Inhibition of human kynurenine 
aminotransferase isozymes by 
estrogen and its derivatives
Gayan S. Jayawickrama1, Alireza Nematollahi1, Guanchen Sun1, Mark D. Gorrell  2  
& W. Bret Church  1
The kynurenine aminotransferase (KAT) enzymes are pyridoxal 5′-phosphate-dependent homodimers 
that catalyse the irreversible transamination of kynurenine into kynurenic acid (KYNA) in the 
tryptophan metabolic pathway. Kynurenic acid is implicated in cognitive diseases such as schizophrenia, 
and several inhibitors have been reported that selectively target KAT-II as it is primarily responsible 
for kynurenic acid production in the human brain. Not only is schizophrenia a sexually dimorphic 
condition, but women that have schizophrenia have reduced estrogen levels in their serum. Estrogens 
are also known to interact in the kynurenine pathway therefore exploring these interactions can yield 
a better understanding of the condition and improve approaches in ameliorating its effects. Enzyme 
inhibitory assays and binding studies showed that estradiol disulfate is a strong inhibitor of KAT-I and 
KAT-II (IC50: 291.5 μM and 26.3 μM, respectively), with estradiol, estradiol 3-sulfate and estrone sulfate 
being much weaker (IC50 > 2 mM). Therefore it is possible that estrogen levels can dictate the balance of 
kynurenic acid in the brain. Inhibition assay results and modelling suggests that the 17-sulfate moiety in 
estradiol disulfate is very important in improving its potency as an inhibitor, increasing the inhibition by 
approximately 10–100 fold compared to estradiol.
Schizophrenia has a prevalence of approximately 1% worldwide1,2, and is a major societal and individual health bur-
den owing to the debilitating nature of the positive symptoms (such as hallucinations, delusions), negative symp-
toms (such as social withdrawal, flattened affect), and cognitive dysfunction that is associated with this condition3. 
Sexual dimorphism has been described for the age of onset of schizophrenia in several studies4–6. Males typi-
cally have been shown to have an earlier onset, with a peak in those aged 15–25 years6. In comparison, the onset 
for females peak in the ages of 20–29 years6. The relatively lower incidence of schizophrenia in females during 
adolescence corresponds to a time of major hormonal changes, including that of increasing estrogen levels7. 
A smaller secondary peak for late onset schizophrenia has also been observed in females aged 45–49 years6 which 
again coincides with a period of estrogen change in women, with this time it being a drop in estrogen levels dur-
ing menopausal transition8,9. The association of estrogen deficits in schizophrenia has been supported by molec-
ular, animal and clinical studies. Several studies have identified increased severity of schizophrenia or surrogate 
measures of schizophrenia associated with low circulating estrogen levels10,11. In women with schizophrenia, 
reduced levels of serum estradiol has been reported in all phases of their menstrual cycle and although some 
reduction in estrogen is known to be associated with some antipsychotic medications, for which mechanisms 
leading to hypoestrogenism are known, it is thought that the reduction in women with schizophrenia exists inde-
pendently of medication10,11.
The estrogen hormones primarily play an important role in growth and development, however they also dis-
play additional functions including influencing the breakdown of tryptophan. Tryptophan is an essential amino 
acid that must be acquired through the diet. In its unbound form, tryptophan is able to cross the blood brain 
barrier12 where it is a precursor for the serotonin pathway and the kynurenine pathway (Fig. 1).
Up to 99% dietary tryptophan may be metabolised through the complex kynurenine pathway13. This path-
way includes a family of pyridoxal 5′-phosphate (PLP)-dependent enzymes called kynurenine aminotrans-
ferase (KAT)14, of which there are four KAT isoforms in mammals. Between them, they are responsible for the 
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irreversible transamination of kynurenine (KYN) to kynurenic acid (KYNA), using PLP as a cofactor (Fig. 2)15. 
The KAT enzymes are homodimers and each subunit includes an N-terminal arm, a large domain containing the 
PLP-binding site, and a small domain containing the C-terminus14,16.
Examination of the structural details of the transamination mechanism of kynurenine with KAT-II identifies 
the significance of some regions (Fig. 3). The side-chain of Arg-20 has a π-cation interaction with the aromatic 
ring of kynurenine, which is the location around which there is a conformational fold of the N-terminal region 
residues and therefore seemingly controls the entry point of the substrate into the active site15. Arg-399 acts as a 
salt bridge and interacts with the carboxyl of the kynurenine thereby anchoring the neighbouring amine group of 
the substrate in the active site, and this is also assisted by the side chains of Asn-202 and Gly-39 forming hydrogen 
bonds with the amino acid group. Lys-263 is important in the transamination process as it is responsible for situ-
ating PLP by an internal aldimine linkage, which is later broken during the transamination process15.
Figure 1. The kynurenine pathway. The first step is rate-limiting, involving tryptophan getting cleaved by 
indoleamine 2,3-dioxygenase (IDO1/IDO2; EC 1.13.11.52) or tryptophan 2,3-dioxygenase 2 (TDO2; EC 
1.13.11.11) to form N-formylkynurenine. Kynurenine formamidase (EC 3.5.1.9) metabolises this further into 
L-kynurenine, where it is converted into either kynurenic acid by kynurenine aminotransferases (KAT; EC 
2.6.1.7), 3-hydroxykynurenine (3-HK) by kynurenine 3-monooxygenase (EC 1.14.13.9), or anthranilic acid by 
kynureninase (EC 3.7.1.3). 3-HK can be metabolised into xanthurenic acid by KAT, or 3-hydroxyanthranilic 
acid (3-HANA) by kynureninase. The latter is also a product that is formed by anthranilate 3-monooxygenase 
(EC 1.14.16.3) acting on anthranilic acid. Downstream of 3-HANA, quinolinic acid is formed and this 
progresses into nicotinamide metabolism which produces nicotinamide adenosine dinucleotide (NAD). The 
transamination of kynurenine to kynurenic acid by the KAT enzymes is denoted in red. Figure adapted with 
permission from Jayawickrama, et al.24.
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KYNA, the product of the transamination, is an N-methyl-D-aspartic acid (NMDA)17,18 and an α7-nicotinic 
acetylcholine receptor antagonist19 that plays a role in cognitive function. KYNA has been shown to have anticon-
vulsive properties20,21 and this, alongside its antagonistic activity of the excitatory NMDA receptor, allows KYNA 
to be considered neuroprotective. However, KYNA has also been found elevated in the cerebrospinal fluid22 and 
prefrontal cortex23 of patients with schizophrenia. Therefore, among the contributing aetiologies on the patho-
genesis of schizophrenia, which includes the dopamine, GABAergic and glutamatergic hypotheses24, KYNA has 
also been implicated. Developing KAT inhibitors, to reduce KYNA levels, has been pursued as a potential means 
of ameliorating the effects of schizophrenia25.
S-ESBA, BFF-122, PF-04859989, BFF-816 (Fig. 4) are KAT-II inhibitors that have demonstrated a proficiency in
reducing KYNA levels in rat homogenates and dialysates26–29, and often simultaneously increase the levels of the key 
neurotransmitters, glutamate29,30, acetylcholine31, dopamine32, and GABA33, which have recognized roles in cognitive 
function18. Supplementing this, the use of S-ESBA, BFF-816 and PF-04859989 on rats and, in the case of the latter inhib-
itor, also on non-human primates, have shown that these inhibitors may improve memory and spatial learning29,30,34.
All these inhibitors referred to, and the recently synthesised NS-150235 (Fig. 4), have been designed to selec-
tively target the KAT-II isoform as it is thought to be the main KAT that is responsible for synthesising KYNA in 
the brain36. While very potent, BFF-122 and PF-04859989 were found to act through an irreversible inhibitory 
Figure 2. PLP-dependent transamination reaction. (a) The active site is formed from PLP (red) and Lys-263 
(blue). (b) The transamination process which irreversibly converts kynurenine (brown) into kynurenic acid 
(brown); PLP is regenerated in this process via an α-ketoacid acceptor. Figure adapted with permission from 
Jayawickrama, et al.24.
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mechanism by forming a covalent adduct with PLP28,37. However the later inhibitors, BFF-816 and NS-1502, 
pursued reversibility in their design, which may be preferable due to the ubiquitous nature of PLP-dependent 
enzymes in the body. Over 300 PLP-dependent enzymes exist and potentially deactivating these could cause 
adverse effects, as has been seen previously with the development of dyskinesias and increasing death rates in 
patients with Parkinson’s disease following the introduction of carbidopa into their medication regimen38,39.
Steroid compounds, such as estrogens, and their sulfate and phosphate esters forms, have activity on various 
PLP-dependent enzymes40,41, including those in the kynurenine pathway. In rat kidney and liver homogenates, 
they were shown to reversibly inhibit kynureninase42,43, kynurenine monooxygenase44, and KAT40,45, and induce 
tryptophan 2,3-dioxygenase 2 (TDO2)46–48, although other evidence refutes TDO2 induction49. This discrepancy 
might arise from inhibition of enzymes such as kynureninase and KAT by estrogens, thereby causing a build-up 
of kynurenine. As kynurenine is the measured, downstream product of TDO2 activity, a build-up of kynurenine 
can potentially give an appearance of TDO2 induction in a tissue homogenate.
The effects of estrogen on the kynurenine pathway metabolites have been observed in women. Relative to 
controls, young women taking oral contraceptives have increased excretion of kynurenine pathway metabolites, 
including kynurenine, xanthurenic acid, 3-hydroxykynurenine, 3-hydroxyanthranilic acid and quinolinic acid, 
after they were given a tryptophan load50–54. These changes are caused by the estrogen component in the oral con-
traceptives, as women administered progestogen alone do not display increased excretion of these metabolites55,56. 
Similarly, elevated metabolite excretory patterns were displayed during pregnancy57 and in ovulation in the men-
strual cycle58, both correlating with rising estrogen levels.
Owing to the sexual dimorphism in schizophrenia and the observed links between the kynurenine path-
way and schizophrenia, exploring the relationship between estrogen and the kynurenine pathway will aid in 
the molecular understanding of this pathway and its associated conditions in which variations occur. In our 
current study, our goal was to accurately establish the inhibitory capacity of estradiol, estradiol 3-sulfate, estradiol 
disulfate and estrone sulfate (Fig. 5) directly on recombinant human KAT-I and KAT-II. By means of surface 
Figure 3. Kynurenine in the active site of KAT-II. The amino acids with an atom within 5.0 Å of kynurenine 
(yellow), and PLP (magenta), were chosen for display. Residue Tyr-142 was removed for clarity. The aromatic 
ring of kynurenine forms pi-pi interactions (green dashes) with Tyr-74, and pi-cation (blue dashes) interactions 
with Arg-20. The carboxyl moiety forms a salt bridge (yellow dashes) with Arg-399, and the neighbouring 
amine group forms hydrogen bonds with Asn-202 (yellow dashes). Image generated with PyMOL67.
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plasmon resonance (SPR) and modelling we were able to further characterise the probable binding mechanics of 
the important estrogen metabolites. A detailed study of the binding will aid in the drug design process of KAT-II 
inhibitors.
Results and Discussion
HPLC Inhibition Assay of Estrogens on KAT-I and KAT-II. Estradiol, estradiol 3-sulfate and estrone 
sulfate were found to not be good inhibitors of human KAT-I at the concentrations used (IC50: >2 mM). Estradiol 
disulfate displayed relatively good inhibitory capacity and had an IC50 of 291.5 (±19.6) μM (Fig. 6a).
Similar to KAT-I, Estradiol and estradiol 3-sulfate were not very good inhibitors of human KAT-II (IC50: 
>2 mM). Estrone sulfate also could not be fully profiled and hence its IC50 is approximately ~2 mM. Estradiol
disulfate however was found to inhibit KAT-II comparatively well, with an IC50 of 26.3 (±1.4) μM (Fig. 6b),
and also it was determined that this inhibition is reversible. This was demonstrated by varying the concentra-
tion of PLP in the reaction mixture which resulted in the inhibition caused by estradiol disulfate reducing as
PLP concentration increased, representing competition with it. This contrasts with irreversible inhibitors,
such as PF-04859989, where the inhibitory activity remains unchanged with varying PLP cβoncentrations (see
Supplementary Table S1).
Previously the inhibition profiles of the known reversible inhibitor NS-1502 (IC50: 315 μM), and irreversible 
inhibitors BFF-122 (IC50: 15–20 μM) and PF-04859989 (1–3 μM) on KAT-II have been measured35. Our IC50 
for the reversible estradiol disulfate suggests that it inhibits KAT-II strongly by the standards of the previously 
reported inhibitors, as it compares in magnitude to the irreversible inhibitor, BFF-122.
Our results indicate that the disulfate ester of estradiol had a strong, reversible, inhibitory capacity for both 
KAT-I and KAT-II, while estrone sulfate was a weak inhibitor of KAT-II only. Relatively, estradiol and estradiol 
3-sulfate did not inhibit either enzyme significantly. These results suggest that having a sulfate moiety on the
17-position of estradiol could be important for inhibitory potency. The addition of a 3-sulfate group onto estra-
diol did not alter inhibitory potency whereas estradiol disulfate, which additionally contains a 17-sulfate group, 
displayed markedly improved inhibition. However, the importance of the 17-sulfate can only be inferred as estra-
diol 17-sulfate was not tested directly.
Figure 4. Chemical structures of KAT-II inhibitors S-ESBA, BFF-122, PF-04859989, BFF-816, and NS-1502. 
The reversible inhibitors are drawn in blue; the irreversible inhibitors are in red.
102
www.nature.com/scientificreports/
SCIeNTIFIC REPORTS | 7: 17559  | DOI:10.1038/s41598-017-17979-7
Surface Plasmon Resonance Analysis of Estradiol Disulfate on KAT-II. SPR was employed 
to evaluate the binding profile of estradiol disulfate on KAT-II. KAT-II was bound to a CM5 chip by amine 
coupling (achieving approximately 8000 RU). Estradiol disulfate was injected at increasing concentrations 
(170 nM–43750 nM) and the corrected, reference subtracted data displayed that estradiol disulfate interacted with 
KAT-II in a dose-dependent manner, and it had rapid association and dissociation with KAT-II. Due to the nature 
of this interaction, kinetic analyses could not be performed to directly evaluate the association and dissociation 
rate constants. Instead, a steady state affinity model was fitted with this data which showed that estradiol disulfate 
binds with a KD of 5.05 × 10−6 (chi2: 0.481) (see Supplementary Fig. S1), comparable to SPR measurements of 
NS-1502 interacting with KAT-II (KD: 7.2 × 10−6, chi2: 0.34)35. The KD suggests that estradiol disulfate binds with 
affinity as strong as that would be expected from a compound that is neither irreversible nor very tightly binding.
Computational Docking of Estrogen Compounds on KAT-II. Computational docking showed that 
estradiol disulfate displays the best potential for affinity with KAT-II at the active site, with a G score of −8.0 Kcal/
mol (see Supplementary Table S2). Estradiol is oriented with the aromatic, A ring forming a pi-cation interaction 
with Arg-20, while the C and D rings project towards Arg-399 and Asn-202, with the 17-hydroxyl hydrogen 
bonding with Arg-399. (see Supplementary Fig. S2). This pose mirrors the interactions of the natural substrate, 
kynurenine, and KAT-II, where the aromatic ring in kynurenine has an analogous interaction with Arg-20 and 
the carboxyl forms a salt bridge with Arg-399 and helps orientate it in the active site15. By binding similarly, estra-
diol is likely to directly compete in the active site with the substrate and cause some competitive inhibition. This 
was seen in the inhibition assay results, but ultimately the inhibition by estradiol was relatively weak.
Estrone has a similar pose, with the 17-ketone group hydrogen bonding with the Arg-399 and Asn-202 
side-chains (see Supplementary Fig. S3). Like Arg-399, Asn-202 is typically involved in orientating kynurenine 
in the active site by forming hydrogen bonds with the amino acid group in kynurenine15. Estradiol 3-sulfate (see 
Supplementary Fig. S4) and estrone sulfate (see Supplementary Fig. S5) are also similarly situated, with the sulfate 
at the 3-position forming hydrogen bonds with the Arg-20. As with estradiol, these poses reflect the way in which 
kynurenine interacts with the active site but the compounds themselves were not strongly inhibitory.
The docking of estradiol 17-sulfate showed differences in that the 17-sulfate group is extended more towards 
the Lys-263 side-chain and forms a hydrogen bond with it (see Supplementary Fig. S6). Estradiol disulfate dis-
played a mix of features of all the estrogen compounds, with the 3-sulfate position hydrogen bonding with Arg-20 
and the 17-sulfate position hydrogen bonding with the Asn-202 and Lys-263 residues (Fig. 7).
Experiments with phosphorylated estrogens have shown that adding a phosphate moiety onto the 17-position, 
in comparison to the 3-position, improves the potency of the molecule in inhibiting the PLP-dependent aspartate 
aminotransferase41. A similar result, displaying the importance of 17-position sulfate moieties, was also observed 
in the inhibition assays with the KAT enzymes. The docking suggesting that the 17-sulfate on estradiol disul-
fate and estradiol 17-sulfate binding to Lys-263 is in accordance with this. Lys-263 is a catalytically significant 
side-chain as it binds to PLP, which is important in the regular activity of KAT (Fig. 2). This, along with the hydro-
gen bonding with Asn-202 and Arg-20, suggests that estradiol disulfate interacts with many key residues in the 
active site that would normally interact with the substrate and the cofactor.
Figure 5. Scaffold of estrogen compounds. X is off the 3-carbon position. Y is off the 17-carbon position. The 
four rings are labelled A, B, C, D, respectively.
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Materials and Methods
General Procedures. Commercially available reagents were used without additional purification unless 
otherwise stated. estradiol, estradiol 3-sulfate sodium salt, estradiol 3,17-disulfate dipotassium salt, estrone sul-
fate potassium salt were purchased from Sigma-Aldrich (Sydney, Australia). Methanol and dimethyl sulfoxide 
(DMSO) were purchased from Thermo Fisher Scientific (Scoresby, Australia). PBST (phosphate buffered saline, 
pH 7.4 with 0.05% Tween 20) was purchased from Sigma, and SPR reagents (40 mM EDC, 10 mM sulfo-NHS, 
10 mM sodium acetate, 1 M ethanolamine HCl, pH 8.5) were purchased from Bio-Rad Laboratories (Gladesville, 
Australia).
SPR binding affinity measurements were performed using the Biacore T200 with a CM5 sensor chip (GE 
Healthcare Life Sciences, Sydney, Australia). The experiment was prepared and obtained with the Biacore T200 
Control Software, and analysed with the Biacore T200 Evaluation Software.
GraphPad Prism v7.02 software59 was used to develop a nonlinear regression fit of the data collected in the 
inhibition assays. The IC50 is reported with the standard error.
Protein Preparation. The expression and purification of recombinant KAT-I and KAT-II protein was com-
pleted as previously described60,61.
HPLC Inhibition Studies Using Recombinant Human KAT. The KAT inhibition assay was based on 
that described previously35. 0.7 µg of KAT-I or KAT-II was incubated at 37 °C for 10 minutes in a 50 µL reaction 
mixture containing PLP (50 µM), α-ketoglutarate (5 mM), L-KYN (5 mM) in PBS, pH 7.4, and the inhibitor stud-
ied (1–2000 µM). Following incubation, the reaction was terminated by adding formic acid (0.8 M) in a 1:1 ratio. 
50 µL of the mixture was transferred into a vial with 950 µL of water for HPLC analysis.
Figure 6. Inhibition assays of estradiol disulfate on KAT. (a) Inhibitory activity of estradiol disulfate in a dose-
dependent format on KAT-I (IC50: 291.5 (±19.6) μM, R2 = 0.95). (b) Inhibitory activity of estradiol disulfate in a 
dose-dependent format on KAT-II (IC50: 26.3 (±1.4) μM, R2 = 0.98). Both plots used data from at least 3 sets of 
tests. Diagrams were produced using GraphPad Prism v7.0259.
104
www.nature.com/scientificreports/
SCIeNTIFIC REPORTS | 7: 17559  | DOI:10.1038/s41598-017-17979-7
The production of KYNA was measured using HPLC with UV detection at a wavelength of 330 nM, using a 
C18 reverse-phase column, and 50% (v/v) water and 50% (v/v) methanol mobile phase. The data was collected 
in triplicate.
Surface Plasmon Resonance Binding Assay. Prior to performing the SPR experiments, the solutions 
were filter sterilised for 10 min at 25 °C. KAT-II was diluted to a concentration of 350 µg/mL using sodium ace-
tate (pH 4.5). The Biacore T200 compartment temperature was controlled at 25 °C and the flow rate was set to 
10 µL/min. Using a 1:1 mixture of EDC (400 mM) and sulfo-NHS (100 mM), two flow cells on a CM5 sensor chip 
(containing a carboxymethylated dextran surface) were activated. Flow cell one contained a blank immobilisa-
tion (PBST buffer injection) and flow cell two had the prepared KAT-II sample injected. The two flow cells were 
deactivated using an injection of 1 M ethanolamine.
The analyte, estradiol disulfate, was prepared in running buffer (PBST with 5% DMSO) in a concentration 
series from 170 nM-43750 nM. The analytes were injected in a multicycle kinetics mode using a flow rate set to 
30 µL/min, contact time of 90 seconds and a dissociation time of 300 seconds, with an extra 50% DMSO wash per-
formed after each injection. Solvent correction was performed before and after the estradiol disulfate injections, 
and also every thirty cycles, to account for the use of DMSO in the analyte sample preparation and the running 
buffer. The data was collected in triplicate.
Computational Docking of Estrogen Compounds at the Active Site of KAT-II. The human KAT-II 
crystal structure (PDB ID: 2R2N62) was downloaded from the Protein Data Bank. The PLP cofactor was removed 
as it is thought to compete with the ligands in the active site rather than being present simultaneously. The protein 
preparation wizard was used in Maestro (version 10.4.017) to optimise and minimise the protein, and hydrogen 
atoms were added and water molecules not participating in the reaction were removed. The ligands were prepared 
Figure 7. Estradiol disulfate docked into the active site of KAT-II. The amino acids with an atom within 5.0 Å of 
estradiol (yellow) were chosen for display. Residues Tyr-142 and Gly-144 were removed for clarity. The 3-sulfate 
group of estradiol disulfate forms hydrogen bonds (yellow dashes) with Arg-20, and the 17-sulfate group forms 
hydrogen bonds (yellow dashes) with Asn-202 and Lys-263. Image generated with PyMOL67.
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using LigPrep63, using the OPLS-2005 force field64. The active site was defined by the location of the existing (and 
natural substrate of KAT) ligand, kynurenine, in the PDB file. The ligands were then docked using the Glide dock-
ing program65, with XP (extra precision) docking66.
Data Availability. The data generated and analysed during the current study is available in the Figshare 
repository (https://figshare.com/projects/Inhibition_of_human_kynurenine_aminotransferase_isozymes_by_
estrogen_and_its_derivatives/24823).
Conclusions
KYNA, a metabolite in the tryptophan metabolic pathway, is produced by the KAT enzymes, of which KAT-II is 
thought to be the isoform that produces the majority of KYNA in the human brain. KYNA is found elevated in the 
brain of patients with schizophrenia, and is therefore implicated in the condition. Low circulating estrogen levels 
are also associated with the onset and severity of patients with schizophrenia. The activity of the KAT enzymes 
has been previously studied with estrogens and estrogen conjugates to determine their inhibitory ability, but in 
rat homogenates only.
We have found estradiol disulfate to be the most potent amongst the group of derivatives inhibiting KAT 
activity, with some activity also displayed by estrone sulfate. Despite showing inhibition, estradiol and estradiol 
3-sulfate were, relatively, the weaker inhibitors. In combination with molecular docking studies, this shows that
increased potency for KAT-II inhibition for estrogens is mainly derived from the 17-sulfate moiety. This can
also be exploited in the design of novel KAT-II inhibitors, and also contribute to the improvement of existing
inhibitors.
Changes in estrogen levels induced by oral contraceptives, pregnancy and the menstrual cycle can influence 
the tryptophan metabolic pathway. Estrogens have the ability to be formed in the brain analogous to that of 
peripheral tissues, and have a similar capacity to being metabolised as a consequence of enzymatic activity in the 
brain. Owing to the inhibitory capability of the steroids, and particularly their sulfate derivatives, the distribution 
of the metabolic enzymes in the brain may dictate the potential for these compounds to inhibit the KAT enzymes. 
Consequently, this will affect the production of tryptophan metabolites, including that of KYNA, in the brain.
Ultimately, steroid dysfunction in schizophrenia may not be confined to estrogen dysfunction alone, and is it 
possible that many steroid hormones and their metabolites are involved. There are multiple pathways in which 
estrogen may be affecting the brain but a role involving the NMDA receptor antagonist KYNA is potentially a 
significant one, which may be consistent with the kynurenic acid hypothesis of schizophrenia as a lack of KAT 
inhibition by estrogen derivatives in the brain can cause an imbalanced oversupply of KYNA.
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Chapter 5 Structure-based drug design approaches to developing kynurenine 
aminotransferase-II inhibitors 
5.1 Preface 
From the work discussed in Chapter 4, it was identified that estradiol disulfate is a much 
more effective inhibitor of KAT compared to the other estrogens tested, and its increased 
potency was identified to be derived primarily from the sulfate on the 17-position of the 
estrogen. The work in this chapter details the use of this knowledge to develop novel KAT-II 
inhibitors. The starting scaffold that was used for this work was the KAT-II inhibitor, 
NS-1502, previously designed in our lab [1]. The binding mode of NS-1502 was predicted 
through the use of molecular modelling (method validation in Appendix C) and knowledge of 
the manner by which ligands typically bind into the KAT-II active site.  Based on this, 
additions were made to the starting scaffold in order to mimic the 17-sulfate of estradiol 
disulfate in an effort to produce significantly more potent inhibitors. The inhibitors developed 
from this work were used in co-crystallisation experiments that provided crystals from which 
the highest resolution KAT-II crystal structure has been described to date (Appendix D). 
Supplementary material for the article contained within this chapter is located in 
Appendix E.3. 
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2016;21(7). 
 
 
109
5.3 Article 4: Improvement of kynurenine aminotransferase-II inhibitors guided by 
mimicking sulfate esters 
PMID: 29689093, PLoS One. 2018 Apr 24;13(4):e0196404. 
DOI: 10.1371/journal.pone.0196404. 
110
RESEARCH ARTICLE
Improvement of kynurenine
aminotransferase-II inhibitors guided by
mimicking sulfate esters
Gayan S. Jayawickrama, Alireza Nematollahi, Guanchen Sun¤, William Bret Church*
Group in Biomolecular Structure and Informatics, Faculty of Pharmacy, The University of Sydney, Sydney,
New South Wales, Australia
¤ Current address: Fountain Biotech, Sydney, New South Wales, Australia
* bret.church@sydney.edu.au
Abstract
The mammalian kynurenine aminotransferase (KAT) enzymes are a family of related iso-
forms that are pyridoxal 5’-phosphate-dependent, responsible for the irreversible transami-
nation of kynurenine to kynurenic acid. Kynurenic acid is implicated in human diseases such
as schizophrenia where it is found in elevated levels and consequently KAT-II, as the iso-
form predominantly responsible for kynurenic acid production in the brain, has been tar-
geted for the development of specific inhibitors. One class of compounds that have also
shown inhibitory activity towards the KAT enzymes are estrogens and their sulfate esters.
Estradiol disulfate in particular is very strongly inhibitory and it appears that the 17-sulfate
makes a significant contribution to its potency. The work here demonstrates that the effect
of this moiety can be mirrored in existing KAT-II inhibitors, from the development of two
novel inhibitors, JN-01 and JN-02. Both inhibitors were based on NS-1502 (IC50: 315 μM),
but the deliberate placement of a sulfonamide group significantly improved the potency of
JN-01 (IC50: 73.8 μM) and JN-02 (IC50: 112.8 μM) in comparison to the parent compound.
This 3–4 fold increase in potency shows the potential of these moieties to be accommodated
in the KAT-II active site and the effect they can have on improving inhibitors, and the envi-
ronments in the KAT-II have been suitably modelled using docking calculations.
Introduction
Kynurenic acid (KYNA) is a metabolite formed in the kynurenine pathway of tryptophan
catabolism (Fig 1), produced when kynurenine is irreversibly transaminated into KYNA by
the kynurenine aminotransferase (KAT) enzymes [1]. KYNA is an antagonist of the glycine
and glutamate binding sites of NMDA receptors [2, 3], the α-amino-3-hydroxy-5-methyl-
4-isoxazole propionic acid (AMPA) receptor [4], and kainate receptors [5]. By inhibiting the
activity of these glutamatergic receptors and preventing excitotoxic attacks, as well as diverting
the pathway from the formation of neurotoxic metabolites (such as 3-hydroxykynurenine and
quinolinic acid), KYNA can be considered neuroprotective. KYNA also may have antagonistic
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Fig 1. Tryptophan metabolism through the kynurenine pathway. Tryptophan metabolism proceeds through
kynurenine in multiple branches, which includes the formation of KYNA by the KAT enzymes.
https://doi.org/10.1371/journal.pone.0196404.g001
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effects on the α7-nicotonic acetylcholine receptors [6], which can play a role in glutamate and
dopamine modulation, and also displays antioxidant [7] and anticonvulsive [8, 9] capabilities.
Despite this ability to be neuroprotective, elevated KYNA levels have been observed in the
prefrontal cortex [10] and cerebrospinal fluid [11] of patients with schizophrenia, suggesting
that a balance is necessary to prevent adverse events, particularly with regards to cognitive
function. Animal studies have shown that lowering KYNA levels by application of KAT-II
inhibitors increases glutamate [12, 13], acetylcholine [14], dopamine [15] and GABA [16] lev-
els, for which roles in cognition have been established, and improves the performance of mem-
ory and spatial learning in rats and non-human primates [12, 13, 17]. A similar profile, with
increased glutamate release and cognitive improvements, was also observed in KAT-II knock-
out mice [18]. These pro-cognitive effects from KAT-II inhibition was neutralised by the
administration of KYNA [13].
There are four isoforms of KAT, differing in structure and substrate specificities. KAT-I
and KAT-III contain an aromatic crown present in the active site that enables the transamina-
tion of relatively hydrophobic substrates. In comparison, KAT-II and KAT-IV contain more
neutral and polar amino acids, and KAT-II in particular is able to accommodate larger struc-
tures in the active site due to its flexible N-terminal region which helps construct the active site
of the opposite subunit [19]. Individual KAT activity may also contrast greatly between species
of animals, as for example the liver and kidney KAT activity of rats were significantly higher
than the corresponding activity in cats [20].
The KAT isoforms are widely distributed in tissues, including the liver, kidney and brain
[21]. KAT-II is thought to be the isoform predominantly responsible for the synthesis of
KYNA in the brain, preferentially within astrocytes [22, 23]. KAT-I is relatively versatile with
broader substrate recognition, making its activity less specific to KYNA synthesis [24]. By
these considerations, KAT-II is targeted for the design of inhibitors to reduce brain KYNA lev-
els. KAT-II is a homodimer of the fold type 1 family of pyridoxal 5’-phosphate (PLP)-depen-
dent enzymes [25] and each of the subunits contain a large domain which has the PLP-binding
site, a small domain containing the C-terminus, and an N-terminal arm [1]. The interface of
the subunits houses an active site and the PLP-binding site is nearby for each subunit [1, 26].
PLP is covalently attached to Lys-263 of the enzyme by a Schiff base linkage [27]. When
kynurenine enters the active site, this link is broken and a new aldimine bond is formed
between PLP and the α-amine group of kynurenine [28]. This α-amino group is transferred
onto the PLP, forming pyridoxamine phosphate (PMP), and KYNA is also produced from the
remains of the substrate by spontaneous closure of its ring. PMP then transfers the α-amino
group to an α-keto acid co-substrate to regenerate into the PLP form.
Arg-20 is another notable residue in the active site, with its side chain having pi-cation
interactions with the aromatic ring of kynurenine (Fig 2) [26]. This region of the N-terminal
residues allows the entry of the substrate into the active site by undergoing a conformational
change. Asn-202 and Gly-39 forms hydrogen bonds with the amine group, and Arg-399 forms
a salt bridge with the carboxyl group in kynurenine, and in doing so these residues help anchor
the substrate in the necessary orientation within the active site [26].
Previous KAT-II inhibitors include S-ESBA, BFF-122, PF-04859989, BFF-816 and NS-1502
(S1 Fig). S-ESBA was designed by using kynurenine as a scaffold and adding an ethylsulfonyl
substituent, which confers selectivity by increasing steric bulk and disqualifying it from occu-
pying the relatively inflexible KAT-I [24]. The phenyl amino group was also removed from the
scaffold, which eliminated the ability of KAT-II to transaminate it, rendering it inert and
therefore inhibitory [30]. BFF-122, which shares a high similarity to the fluoroquinolone, levo-
floxacin, may also derive its selectivity from steric bulk that is accommodated by KAT-II [31].
Both BFF-122 and PF-04859989 feature heterocyclic ring systems and a primary amine group,
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the latter of which confers a mechanism of irreversible inhibition as it is observed to form a
covalent adduct with PLP [31, 32]. NS-1502 combined features of these three inhibitors by
incorporating a phthalimide core to resemble BFF-122 and PF-04859989, and adding an aro-
matic amino acid branch which resembled S-ESBA to improve the potency further [33].
Fig 2. Kynurenine in the KAT-II active site. The amino acids within 5.0 Å of kynurenine (green) were chosen for display, with PLP in magenta and
residue Tyr-142 removed for clarity. Depicted is the aromatic ring forming pi-pi interactions (green dashes) with Tyr-74 and pi-cation interactions
(blue dashes) with Arg-20. A hydrogen bond (yellow dashes) between the amine group and Asn-202, and a salt bridge (yellow dashes) formed between
the carboxyl and Arg-399 helps anchor kynurenine in the correct conformation for transamination. Image generated with PyMOL [29].
https://doi.org/10.1371/journal.pone.0196404.g002
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Notably NS-1502 was designed to be reversible by the omission of the primary amine group
present in BFF-122 and PF-04859989. Although irreversible inhibitors may be suitable in
many instances, as PLP is a cofactor used by hundreds of enzymes, there is rationale in creat-
ing reversible inhibitors that specifically target KAT-II as opposed to PLP. This approach may
be important to avoid the prospects of adverse events caused by depleting the cofactor or
inhibiting off-target enzymes. Such concerns appear to be borne out by the use of carbidopa in
patients with Parkinson’s disease, as it is able to permanently deactivate PLP, and is associated
with the development of dyskinesias and increasing death rates [34, 35].
Steroid compounds, such as estrogen and sulfate esters of estrogen, have also been shown
to inhibit a variety of PLP-dependent enzymes [36], including the KAT enzymes. Typically it
has been reported that unconjugated steroids such as estradiol and estrone have a lower
potency in inhibiting KAT from rat kidney in comparison to the sulfate ester forms [37]. The
disulfate esters of estrogens, such as estradiol disulfate and diethylstilbestrol disulfate, were the
most potent of these, while estrone sulfate was inhibitory at higher concentrations [37]. Similar
results were found with phosphate esters, with estradiol diphosphate being very inhibitory
towards rat kidney KAT [38]. The steroid phosphate compounds were also tested on another
PLP-dependent enzyme, aspartate aminotransferase, with the phosphate groups appearing on
different positions in the steroid structure. From this work, it was found that the phosphate
group on the 17-position, as opposed to the 3-position, yielded the compound inhibiting with
the greatest potency [38]. Similar results have been inferred in our lab, where a sulfate in the
17-position, instead of the 3-position, appears to increase the potency of the sulfated estrogen
compounds inhibiting KAT-II [39]. From molecular docking, it is predicted that the increased
potency may derive from the 17-sulfate forming hydrogen bonds with key residues in the
active site, including, Asn-202 and Lys-263 [39].
In our current study, our goal was to use NS-1502 with a mind to improve its inhibitory
capability further using detailed structural knowledge about the manner in which sulfated
estrogens derive their potencies. Using an inhibition assay, we were able to evaluate the
potency of two novel, reversible KAT II inhibitors, JN-01 and JN-02.
Results and discussion
For the design approach to improving this inhibitor, we took the core of NS-1502 and strategi-
cally mimicked sulfated estrogens when synthesising JN-01. Due to the considerations from
the inhibitor synthesis protocol, the sulfate moiety was replaced by a sulphonamide group, and
the carboxyl present in NS-1502 was omitted. Evidence suggested that in the inhibitor estradiol
disulfate, the sulfate on the 17-position, located on the end opposite to its aromatic ring (S2
Fig), was most important for its potency. Molecular docking predicted that the phthalimide
core of NS-1502 (Fig 3) corresponded to the location of the aromatic ring of both kynurenine
(Fig 2) and estradiol disulfate (S3 Fig). Therefore in designing JN-01, the rationale was to
introduce a sulfonamide group onto the end opposite to the phthalimide core of NS-1502, so
that it occupies the same location as the 17-sulfate of estradiol disulfate, where it can similarly
exploit interactions with important nearby residues such as Asn-202 and Lys-263. Overall, JN-
01 was also designed to ensure that it retained a length comparable to estradiol disulfate (Fig
4), with the difference coming from the relative sizes of the sulfonamide and the sulfate group.
JN-02 was designed with a similar concept in mind to JN-01, however the length of the
compound was further increased, by an ethyl chain, which better reflected the size of NS-1502,
while still incorporating the other features of JN-01 and estradiol disulfate. Although it is
unquestionably larger than estradiol disulfate, JN-02 is flexible and can be accommodated to
interact with similar active site residues.
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The inhibition assay was previously performed on KAT-II with racemic NS-1502, BFF-122,
and PF-04859989, which determined their IC50 to be 315 μM, 15–20 μM and 1–3 μM, respec-
tively [33]. By varying the concentration of PLP in the assay conditions, NS-1502 was found to
be reversible. When PLP concentration was increased, the inhibition caused by NS-1502
decreased as it competed with it. This contrasts with the irreversible inhibitor PF-04859989,
which displayed similar inhibition as PLP concentration changed [33].
Fig 3. NS-1502 docked into the KAT-II active site. The amino acids within 5.0 Å of NS-1502 (green) were chosen for display. Residues Ser-143, Gly-
144, and Gln-289 were removed for clarity. The carboxyl group forms hydrogen bonds (yellow dashes) with Asn-202 and Arg-399, and the aromatic
ring has pi-pi interactions (green dashes) with Tyr-142 and pi-cation interactions (blue dashes) with Lys-263. Image generated with PyMOL [29].
https://doi.org/10.1371/journal.pone.0196404.g003
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Relative to NS-1502, JN-01 and JN-02 displayed improved potency towards inhibiting
KAT-II, with an IC50 of 73.8 μM (Fig 5A) and 112.8 μM (Fig 5B), respectively. The IC50 of
both inhibitors for KAT-I in this assay is beyond the maximal concentration tested (2 mM),
therefore they are considered to be selective towards KAT-II. Additionally, both inhibitors
were found to be reversible. This reaffirms what was seen previously with estradiol disulfate
and estradiol diphosphate where the 17- sulfate or 17-phosphate groups improved the inhibi-
tory potency of the molecule, as these moieties were mirrored in JN-01 and JN-02 with the use
of a sulfonamide group and similarly improved inhibition greatly from the parent compound,
NS-1502.
Estradiol disulfate and estradiol has also been tested using this assay in these conditions and
inhibits KAT-II with an IC50 of 26.3 μM and>2 mM, respectively [39]. The apparent increase
in potency for KAT-II inhibition is 100-fold comparing estradiol disulfate and estradiol,
whereas it is approximately 3–4 times for JN-01 and JN-02 in comparison to NS-1502. The
absolute value for the IC50 is also lower for estradiol disulfate than it is for JN-01 and JN-02,
suggesting that there also remains ample area for improvement in these new inhibitors. Two
such areas that have been identified includes the lack of the carboxyl that was present in NS-
1502 but not the new inhibitors, and also the sulfate present in estradiol disulfate being substi-
tuted by a sulfonamide moiety in the new inhibitors. The reintroduction of the carboxyl group
Fig 4. Comparative lengths of the structures when fully extended. Distances measured in the 3D conformer of the compounds, generated from
LigPrep at the time of preparation for docking, from the first carbon atom (A) in each compound to the carbon from which the carboxyl branches off
(B), the furthest carbon atom (C), or the sulfur atom in the sulfate/sulfonamide groups (D).
https://doi.org/10.1371/journal.pone.0196404.g004
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and the replacement of the sulfonamide with the sulfate could maximise the number and
strength of the hydrogen bonds formed with the residues in the active site. Molecular docking
of NS-1502, JN-01, JN-02, and NS-1502 with a sulfate (JN-03) reinforces this.
Docking into KAT-II suggests that the best binding pose for NS-1502 has the phthalimide
core situated near Arg-20, with the carboxyl forming hydrogen bonds with Arg-399 and Asn-
202, and the lone six-membered aromatic ring forming pi-pi interactions with Tyr-142 and pi-
cation interactions with Lys-263 (Fig 3). When JN-01 is docked, the phthalimide is orientated
in a similar location, and the sulfonamide group has hydrogen bonding interactions with Asn-
202 and Lys-263 (Fig 6). The whole of JN-02 docks in a similar pose to NS-1502, while lacking
the carboxyl interactions but gaining an additional hydrogen bond between the sulfonamide
and Gln-118 (Fig 7). Both JN-01 and JN-02 displayed the potential of this binding pocket, near
Lys-263, in accommodating the sulfonamide moieties.
Considering NS-1502 and estradiol disulfate, the key interactions these two inhibitors have
with the active site are with Arg-399, Asn-202 and Lys-263. A carboxyl on JN-02, branching
off the same location as it does in NS-1502, would retain the positioning required to interact
with Arg-399 and Asn-202, whilst the flexibility of JN-02 allows the sulfonamide group to also
interact with residues near Lys-263. The docking of JN-03 was performed for the purpose of
considering all these interactions (Fig 8). For JN-03, as with the others, the phthalimide core is
oriented next to Arg-20. The carboxyl group forms hydrogen bonds with Arg-399 and Asn-
202, just as it does in NS-1502, a feature that was not prevalent in either JN-01 or JN-02. In
place of the sulfonamide, the sulfate forms many hydrogen bonding interactions with the
nearby residues including that of Tyr-74, Gln-118, Lys-263, and Arg-270.
It has been argued that the ability of sulfated estrogens to inhibit KAT is derived from a
reversible reaction with the apoenzyme form of the protein, and it competes with PLP for the
binding to the apoenzyme [37]. As mentioned previously, NS-1502, JN-01 and JN-02 displayed
a similar competition with PLP to that seen for the estrogens, as they had reduced inhibition
when PLP concentration increased. This work demonstrates that the potency of these types of
inhibitors can be improved by introducing moieties, such as the sulfonamide or sulfate groups,
to form stronger bonds within the active site and out-compete PLP for the apoenzyme. The
notion that these moieties could be accommodated in the inhibitor binding region was proven
Fig 5. Dose-dependent inhibition of KAT-II. Inhibition assays with 0.5 μg KAT-II incubated for 10 min at 37 ˚C in a 50 μL reaction mixture
containing 50 μM PLP, 5 mM α-ketoglutarate, 5 mM L-kynurenine and the inhibitor studied. The reaction was terminated with 0.8 M formic acid and
analysed using HPLC. Experiments were performed as independent replicates, and figures were produced using GraphPad Prism v7.02 [40] (A) JN-01
inhibition (IC50: 73.8 (95% CI: 66.3–81.8) μM, R2: 0.91). (B) JN-02 inhibition (IC50: 112.8 (95% CI: 100.8–126.1) μM, R2: 0.92).
https://doi.org/10.1371/journal.pone.0196404.g005
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to be correct by the assay results, although the docking of the compounds suggest that the
intricate detail in which they bind can vary depending on the flexibility of each structure.
Materials and methods
General procedures
Commercially available reagents were used without additional purification unless otherwise
stated. 4,5-dichlorophthalic anhydride, 4-aminobenzenesulfonamide, and 4-(2-aminoethyl)
benzenesulfonamide were purchased from Sigma-Aldrich (Sydney, Australia). 1H-NMR (400
MHz) and 13C-NMR (101 MHz) spectroscopy was obtained using a Gemini 400-MR NMR
Fig 6. JN-01 docked into the KAT-II active site. The amino acids within 5.0 Å of JN-01 (green) were chosen for display. Residues Ser-143, Gly-144,
and Gln-289 were removed for clarity. The oxygen atoms in the sulfonamide form hydrogen bonds (yellow dashes) with Asn-202 and Lys-263, and the
aromatic ring has pi-pi interactions (green dashes) with Tyr-74. Image generated with PyMOL [29].
https://doi.org/10.1371/journal.pone.0196404.g006
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spectrometer (Varian, Palo Alto, CA, USA), using DMSO-d6 as NMR solvent. Low-resolution
ESI-MS was measured on an amaZon SL (Bruker Daltonics, Bremen, Germany). High resolu-
tion ESI-MS was performed on an Apex Ultra Fourier Transform Ion Cyclotron Resonance 7
T Mass Spectrometer (Bruker Daltonics, Bremen, Germany). The mass spectra were obtained
by direct infusion electrospray ionization and are reported as mass to charge ratio (m/z) and
Fig 7. JN-02 docked into the KAT-II active site. The amino acids within 5.0 Å of JN-02 (green) were chosen for display. Residues Ser-143, Gly-144,
and Gln-289 were removed for clarity. The amine in the sulfonamide forms hydrogen bonds (yellow dashes) with Gln-118, and the carbonyl in the
phthalimide rings forms a hydrogen bond with Tyr-142. The aromatic ring has pi-pi interactions (green dashes) with Tyr-142 and pi-cation interactions
(blue dashes) with Lys-263. Image generated with PyMOL [29].
https://doi.org/10.1371/journal.pone.0196404.g007
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relative intensity (%). The estimated purity for the synthesised inhibitors is> 93%, with the
final yield approximately 70%. HPLC was performed using a CBM-20A Shimadzu HPLC sys-
tem (Kyoto, Japan), with an Ascentis C18 HPLC column (particle size: 10 μm, length: 25 cm,
internal diameter: 4.6 mm) purchased from Sigma-Aldrich (Sydney, Australia). The inhibition
assay data was modelled with a nonlinear regression fit of the log[inhibitor] vs. normalised
response (using a variable slope) in GraphPad Prism v7.02 software [40], and the IC50 is
reported with 95% confidence intervals.
Fig 8. JN-03 docked into the KAT-II active site. The amino acids within 5.0 Å of JN-03 (green) were chosen for display. Residues Ser-143, Gly-144,
and Gln-289 were removed for clarity. The sulfate forms hydrogen bonds with Tyr-74, Gln-118, Lys-263, and Arg-270, and the carboxyl moiety forms
hydrogen bonds with Asn-202 and Arg-399. The aromatic ring has pi-cation interactions (blue dashes) with Lys-263. Image generated with PyMOL
[29].
https://doi.org/10.1371/journal.pone.0196404.g008
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Protein preparation
The recombinant KAT-II protein was expressed in E. coli Rosetta 2 cells with a hexa-histidine
tag, and purified using nickel nitrilotriacetic acid column chromatography in our lab as previ-
ously described [41]. Recombinant KAT-I was expressed in Spodoptera frugiperda insect cells,
precipitated using ammonium sulfate, and purified in a high salt ion exchange column as pre-
viously described [42].
Synthesis of JN-01
A solution of 4,5-dichlorophthalic anhydride (2.5 mM) and 4-aminobenzenesulfonamide (2.5
mM) in glacial acetic acid (7 mL) was stirred and heated under reflux for 4 h. The product, 4-
(5,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzenesulfonamide (JN-01), was
recovered by precipitation using cold water and ethanol, filtered and dried. 1H-NMR (400
MHz, DMSO-d6): δ 8.33 (s, 2H), 7.98 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.6 Hz, 2H), 7.48 (s, 2H).
13C-NMR (101 MHz, DMSO-d6): δ 125.69 (C-14,17), 126.43 (C-8,12), 127.49 (C-9,11), 131.55
(C-3,4), 134.44 (C-7), 137.66 (C-15,16), 143.51 (C-10), 164.91 (C-2,5) (S1 Appendix); HRE-
SIMS: 424.97 m/z [C14H8N2O4S1Cl2 + CH3OH + Na]+ (Calcd. 424.974171) (S2 and S3
Appendices).
Synthesis of JN-02
A solution of 4,5-dichlorophthalic anhydride (2.5 mM) and 4-(2-aminoethyl)benzenesulfona-
mide (2.5 mM) in glacial acetic acid (7 mL) was stirred and heated under reflux for 4 h. The
product, 4-(5,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl benzenesulfonamide
JN-02, was recovered by precipitation using cold water and ethanol, filtered and dried.
1H-NMR (400 MHz, DMSO-d6): δ 8.17 (s, 2H), 7.71 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 8.1 Hz,
2H), 7.30 (s, 2H), 3.84 (t, J = 7.1 Hz, 2H), 2.99 (t, J = 7.1 Hz, 2H). 13C-NMR (101 MHz,
DMSO-d6): δ 33.30 (C-8), 38.89 (C-7), 125.28 (C-16,19), 125.76 (C-11,13), 129.19 (C-10,14),
131.43 (C-3,4), 137.32 (C-17,18), 142.32 (C-12), 142.37 (C-9), 165.85 (C-2,5) (S4 Appendix).
Inhibition studies using recombinant human KAT-I and KAT-II
0.5 μg of KAT-I or KAT-II was incubated at 37 ˚C for 10 min in a 50 μL reaction mixture con-
taining 50 μM PLP, 5 mM α-ketoglutarate, 5 mM L-kynurenine in PBS, pH 7.4, with the inhib-
itor being studied (1–2000 μM) dissolved in DMSO. Equal volume of formic acid (0.8 M) was
added to terminate the reaction, and 50 μL of this mixture was diluted to 1 mL. Kynurenine
and KYNA produced during the reaction was analyzed by HPLC using a C18 reverse-phase
column, with 50% (v/v) methanol and 50% (v/v) water used as the mobile phase, and with an
injection volume of 20 μL. The column temperature was 20 ˚C. Kynurenine and KYNA were
detected by UV detection at a wavelength of 330 nm. The retention time for kynurenine and
KYNA were 2.5 mins and 3.5 mins, respectively.
Docking of inhibitors into KAT-II
A crystal structure of human KAT-II (PDB ID: 2R2N [27]) was downloaded from the Protein
Data Bank. 2R2N is a high resolution human KAT-II structure (1.95 Å) with the ligand, kynur-
enine, already occupying the active site. The PLP cofactor was removed from the active site of
the protein as there was evidence it competed with the ligands in the inhibition studies. Opti-
misation and minimisation of the protein was performed using the Impref utility in IMPACT
(Schrodinger LLC) and the OPLS-2005 [43] force field, and hydrogen atoms were also added
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and water molecules not involved in the reaction were removed, using the protein preparation
wizard in Maestro version 10.4.017 (Schrodinger LLC). The active site was determined by the
location of kynurenine in the crystal structure. The ligands were prepared using LigPrep [44],
using the OPLS-2005 force field, and were docked using Glide [45] with XP docking [46]. Both
enantiomers of NS-1502 and JN-03 were docked, with the best scoring pose represented in the
figures.
Conclusions
KAT-II inhibitors have been shown to reduce the production of KYNA, increase neurotrans-
mitter release and improve memory tasks in animals [12, 13, 17]. Other compounds, particu-
larly sulfate esters of estrogens, have also been shown to be very adept in inhibiting the KAT
enzymes [37]. For sulfated estrogens, the 17-sulfate position appears to be very important in
comparison to their unconjugated parent estrogens in this potency for inhibition, with dock-
ing also suggesting that it interacts with key active site residues [39].
Using the information derived from these estrogens, and the template of the previously
designed reversible inhibitor NS-1502, we have synthesised two new inhibitors, JN-01 and
JN-02. Notably, JN-01 and JN-02 differ from NS-1502 with the addition of a sulfonamide moi-
ety, which seems to improve inhibition by approximately 3–4 fold, with an IC50 of 73.8 (± 3.9)
μM and 112.8 (± 6.1) μM, respectively. This finding suggests that knowledge gleaned from sul-
fated estrogens binding can help improve the potency of current inhibitors. A sulfate (or like-
minded) moiety can be placed to mimic the interactions of the 17-sulfate in estradiol disulfate,
and greatly improve potential inhibition.
Supporting information
S1 Fig. Structures of existing KAT-II inhibitors.
(TIF)
S2 Fig. Structure of estradiol disulfate.
(TIF)
S3 Fig. Estradiol disulfate docked into the KAT-II active site. The amino acids within 5.0 Å
of estradiol disulfate (green) were chosen for display. Residues Tyr-142 and Gly-144 were
removed for clarity. The 3-sulfate forms hydrogen bonds (yellow dashes) with Arg-20 and the
17-sulfate forms hydrogen bonds with Asn-202 and Lys-263. Image generated with PyMOL
[29].
(TIF)
S1 Appendix. 1H-NMR and 13C-NMR results for JN-01.
(PDF)
S2 Appendix. HRESIMS results for JN-01.
(PDF)
S3 Appendix. HRESIMS results for JN-01.
(PDF)
S4 Appendix. 1H-NMR and 13C-NMR results for JN-02.
(PDF)
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Chapter 6 Conclusions and future directions 
6.1 Summary 
Abnormalities in the activity of the kynurenine pathway enzymes and metabolites have been 
associated with many disease states, including those that affect the CNS. The main 
metabolites in this pathway that have had relatively substantial study are the neuroactive 
ones, which primarily include 3-HK, 3-HAA, QUIN, and KYNA, and variations to these 
metabolite levels are observed in neurological diseases. KYNA, although it is generally 
considered to be the neuroprotective metabolite due to its antagonism of excitatory receptors, 
anticonvulsive effects, and antioxidant effects, has been observed to be reduced in patients 
with neurodegenerative diseases such as AD, HD and PD. KYNA has also been observed 
elevated in patients with schizophrenia, and animal studies have shown that this increase can 
be accompanied by cognitive impairment and reduced neurotransmitter release. The balance 
of this evidence suggests that homeostatic levels of the metabolite are important to avert 
disease and maintain regular function. The KYNA hypothesis of schizophrenia suggests that 
inhibition of the KAT enzymes might be valuable to limit KYNA production. The KAT 
enzymes are responsible for the conversion of KYN to KYNA in the body, and they include a 
family of four isoforms (KAT I-IV). The primary isoform responsible for KYNA production 
in human and other mammalian brains is thought to be KAT-II. The work in this thesis 
largely pertains to the development and analysis of selective KAT-II inhibitors by several 
means. 
Chapter 1 describes the background information which relates to this study, broadly including 
details of the kynurenine pathway, its role in disease, and how it is affected by steroid 
compounds. The chapter also discusses core approaches to drug design used in this study, 
such as the SBDD and FBDD approaches, and describes the key techniques that have been 
used as part of these processes, including enzyme inhibition assays, X-ray crystallography, 
computational docking, and SPR. Chapter 2 is a literature review with a narrower scope on 
KAT inhibition and its relevance in schizophrenia, and the symptoms of the disease. A 
description of the history and analysis of KAT-II inhibitors is covered extensively in this 
chapter.  
Chapter 3 is chiefly about the use of a FBDD approach to develop novel KAT-II inhibitor 
leads. As part of this process, SPR was used to identify hits from a fragment library of 
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compounds. Inhibition assays were then used to clarify the inhibitory capabilities of these 
hits, and this yielded two novel compounds, F0037-7280 (IC50: 115.2 μM), and F6037-0164 
(IC50: 524.5 μM), that could contribute to the approach of designing further KAT-II 
inhibitors. Docking was used in an effort to consider the binding of these fragments and 
propose mechanisms by which they would act. An interesting observation from this work was 
that F6037-0164 inhibition was readily reversed by the addition of PLP while F0037-7280 
inhibition was not, despite the latter not having any apparent ability to form an irreversible, 
covalent adduct with PLP. This could indicate that it is possible to manufacture effective 
inhibitors which can compete with either cofactor binding or substrate binding.  
Chapters 4 and 5 were parts of a larger investigation to find KAT-II inhibitors using SBDD 
methods. The presented work in Chapter 4 investigated the inhibitory ability of estrogen and 
estrogen derivatives, and from this it was determined that estradiol disulfate was the form of 
estrogen that was by far the most potent (KAT-II IC50: 26.3 μM).  It was hypothesised from 
the inhibition assays and through docking that it is the 17-sulfate moiety of the molecule, 
rather than the 3-sulfate, that is most responsible for its potency, due to interactions it forms 
with the catalytically important Lys-263. This active site lysine residue is conserved amongst 
the KAT family of enzymes as it is the site of covalent PLP bonding and, consequently, it has 
a very significant role in KAT activity. Chapter 5 took this work of Chapter 4 further and 
applied it to develop other novel KAT-II inhibitors, JN-01 (IC50: 73.8 μM) and JN-02 (IC50: 
112.8 μM), using the most potent, designed, reversible inhibitor available, NS-1502 (IC50: 
315 μM), as a scaffold. The sulfonamide moiety that is present in both JN-01 and JN-02 had 
been deliberately added to mimic the effect of the 17-sulfate on the estradiol disulfate, and 
resulted in the production of two potent, reversible inhibitors that had a 3-4 fold improvement 
in IC50, compared to NS-1502. 
Related work from this study is also provided in Appendices A-D. Appendix A has some core 
results pertaining to the validity of using the KAT-II assays to measure inhibition or enzyme 
activity, and also features the KAT-II enzyme kinetics measured from the assay. Appendix B 
is a brief extract from Journal Article 6, which is not provided in totality in the thesis, 
involving the use of SPR to determine the high affinity binding of NS-1502 to KAT-II 
(KD: 7.2 x 10
-6
). Appendix C describes the validation procedure for the computational 
docking used throughout the study and features an extensive coverage of docking results not 
provided elsewhere in the thesis. A particular focus is on the docking of estrogens into 
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enzymes in the kynurenine pathway, including TDO, IDO, kynureninase, KAT-I, and 
KAT-II, which suggested that if the estrogens were to actually inhibit all of these enzymes, 
they would do so in distinct ways (arising from whether inhibition is or could be independent 
of the cofactor). In addition, the fragment library compounds tested in Chapter 3 were docked 
with KAT-II to ascertain if the hits generated from SPR were likely to bind elsewhere, other 
than the active site, however the results indicated that this was not the case. Appendix D 
describes the attempt to co-crystallise KAT-II with the inhibitors, estrogen disulfate, JN-01 
and JN-02. The result of this work has been deposited in the Protein Data Bank (PDB) with 
the identification 6D0A. 6D0A surprisingly lacks the presence of the expected inhibitor and 
PLP cofactor, and instead features an active site that is apparently relatively closed off due to 
the positioning of the guanidine group of the Arg-20 residue. Appendix D also discusses the 
similarities and differences between deposited KAT-II structures, including important 
modelling considerations such as the conformation of proline residues and other significant 
amino acids. Many of the deposited KAT-II structures feature cis non-proline residues and 
twisted peptides, which are most likely attributable to modelling errors and for which there is 
no evidence for in 6D0A. From the KAT-II crystal structures that are available to date, 6D0A 
has the highest resolution and the most accurately determined atomic coordinates, and 
features as the model with the best structural validation statistics.  
6.2 Future work 
The development of the novel KAT-II inhibitors, JN-01 and JN-02, demonstrates that the 
current scaffolds of KAT inhibitors can be improved in potency by the addition of moieties 
resembling the sulfates in estradiol disulfate. Regarding JN-01 and JN-02 themselves, though 
they are potent, reversible inhibitors, it is necessary to perform many studies to get a full 
characterisation of these compounds before it is proven that they can be taken further in the 
development cycle. The other novel inhibitor leads that came from this study were the 
fragment compounds, F0037-7280 and F6037-0164. These two compounds are at an earlier 
stage of drug development and require additional optimisation steps before being subjected to 
further studies. Importantly, the fragment-based studies showed the viability of a different 
approach to developing KAT-II inhibitors. Further studies utilising this approach for the 
identification of other novel scaffolds, from which KAT-II inhibitors can be produced, would 
be significant from a drug design perspective. 
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The solved crystal structure from this work, PDB ID 6D0A, was observed to be without 
ligands or the cofactor. Additional trials to pursue co-crystallisation of KAT-II with the 
newly designed inhibitors could be performed, to determine if the apoenzyme form of 
KAT-II is to be expected when they are involved and how persistent the closed active site is 
in the apoenzyme. The inhibitors and fragments co-crystallised with KAT-II could also 
clarify whether it is possible to produce inhibitors which work by separate means, by 
inhibiting either the cofactor or the substrate only. Many of the deposited KAT-II crystal 
structures likely contain structural errors or have poor model validation statistics in 
comparison to 6D0A. There should be an endeavour to provide further high quality models 
that would greatly enhance the structural understanding of the mechanisms of inhibition.  
A little removed from the drug design work is further analysis of estrogen inhibition in the 
kynurenine pathway. Estrogen variation in humans is expected not only between the different 
sexes, but also per individual, whether it is on a yearly, monthly or daily basis. Because of the 
potential role of the kynurenine pathway metabolites in disease, knowledge of how they may 
fluctuate depending on estrogen levels may aid in the understanding and treatment of disease. 
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Appendix A Validation of and indicative experiments from the inhibition assay 
A.1 Inhibition assay protocol 
The KAT-II inhibition assays, including instrumentation used, are described thoroughly in 
section 5.3.4. A brief summary of the steps involved is described below: 
- 0.5 µg KAT-II and the inhibitor studied (1 – 2000 µM) was incubated for 10 minutes 
at 37 °C in 50 μL of reaction mixture (50 µM PLP, 5 mM α-ketoglutarate, 
5 mM KYN in PBS, pH 7.4). Negative controls contained neither KAT-II nor the 
inhibitor, while positive controls and activity assays contained KAT-II but not the 
inhibitor. 
- The reaction was terminated by the addition of 0.8 M formic acid in a 1:1 ratio. 50 μL 
was transferred into a vial containing 950 μL of water for detection using HPLC at a 
wavelength of 330 nm. 
A.2 Linearity of kynurenic acid production 
Prior to the use of the inhibition assay in the studies, KYNA production was assessed by 
allowing an uninhibited reaction to occur with samples taken over the course of 30 minutes 
(Fig. A-1). The production of KYNA was measured to be linear with respect to time over this 
period, and therefore the use of a 10 minute incubation time was validated for subsequent 
experiments as it ensured that the reaction velocity was consistent throughout the 
experiments. 
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Figure A-1. The KYNA production curve. Samples were taken after 5, 10, 15, 20, 25 and 30 mins of 
KYNA production and analysed using HPLC. The areas under the curve for the KYNA peaks display a 
clear linear relationship with time over this period (R
2
 = 0.9975) 
A.3 Standard curves of kynurenine and kynurenic acid 
Standard curves were produced for both KYN and KYNA by preparing pure samples of each 
compound at varied concentrations, and analysing their respective HPLC peaks at a 
wavelength of 330 nm (Fig. A-2). There is a strong linear correlation between the 
concentration of KYN or KYNA in each sample and the area under the curve (AUC) of their 
respective peaks. The standard curves therefore enable meaningful comprehension of the 
AUC data collected from the HPLC analysis of samples in the inhibition studies, as the linear 
regression equation used to model the curves can be used to convert AUC data into KYN and 
KYNA concentrations. 
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Figure A-2. KYN and KYNA standard curves detected at 330 nm. Plots of the AUC vs. concentration 
were modelled by linear regression for both (A) KYN (R
2
 = 0.9995) and (B) KYNA (R
2
 = 0.9985). The 
experiments were performed in triplicate. 
A.4 Kinetics of kynurenine aminotransferase-II 
Although the KAT enzymes can be described by double displacement reactions, it is possible 
to measure the kinetics of its reaction with KYN as a pseudo-single substrate reaction by 
ensuring that the co-substrate, PLP, is kept constant at saturating conditions while varying 
only the concentrations of KYN (0.15 mM – 20 mM) in the reaction mixture [1]. The exact 
concentration of KYN used and the concentration of KYNA produced in each of the samples 
were calculated from their peak AUC data using their respective standard curves (Table A-1). 
The Michaelis-Menten curve plotted from this data (Fig. A-3) was used to calculate an 
apparent KM of 7.52 ± 1.09 (S.E.) mM and Vmax of 0.024 ± 0.001 (S.E) mM min
-1
. 
 Table A-1. Average AUC data for kinetic calculations 
KYN peak AUC KYNA peak AUC [KYN]final (mM) [KYNA]final (mM) KYNstarting (mM) 
1492351 101436 19.95 0.33 20.28 
1344737 106213 17.98 0.35 18.33 
986326 85914 13.19 0.28 13.47 
653305 92582 8.74 0.30 9.04 
329155 52671 4.40 0.17 4.47 
167473 32619 2.24 0.11 2.35 
81549 15613 1.09 0.05 1.14 
45354 8017 0.61 0.03 0.64 
26057 4814 0.35 0.02 0.37 
15082 2175 0.20 0.01 0.21 
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Figure A-3. The activity assays were performed as described in section A-1, with the exception that KYN 
concentrations were varied from 0.2 – 20 mM in the reaction mixture. The apparent KM = 7.52 mM and 
Vmax = 0.024 mM min
-1
 (R
2
 = 0.9733). The experiments were performed in triplicate. 
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Appendix B Surface plasmon resonance measurement of NS-1502 binding 
This section is an extract of work featured in Journal Article 6: 
Article 6: Study of the Activity and Possible Mechanism of Action of a Reversible 
Inhibitor of Recombinant Human KAT-2: A Promising Lead in Neurodegenerative and 
Cognitive Disorders. 
PMID: 27367665, [Pubmed - indexed for MEDLINE], Molecules. 2016 Jun 29;21(7). pii: E856.  
DOI: 10.3390/molecules21070856. 
Alireza Nematollahi, Guanchen Sun, Gayan S. Jayawickrama, Jane R. Hanrahan and W. Bret 
Church. 
The affinity of the interaction between KAT-II and inhibitor, NS-1502, was measured using 
SPR. Immobilisation of KAT-II by amine coupling onto a CM5 chip, containing a 
carboxymethylated dextran layer, achieved total ligand binding of 20602 RU, which was 
suitable for measuring interactions with a small molecule such as NS-1502. Solvent 
corrections were performed due to the use of DMSO in the analyte solution, and the final data 
was referenced against a blank flow cell prior to generating a steady state affinity model 
which calculated the affinity of the interaction (KD: 7.2 x 10
-6
, chi
2
: 0.34). 
 
Figure B-1. Steady-state affinity model of the interaction between NS-1502 and KAT-II at 25 °C. 
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Appendix C Molecular docking of estrogens and fragment library 
C.1 Molecular docking protocol 
As the work presented here encompasses the docking of compounds into various kynurenine 
pathway enzymes, a more general docking protocol than those described in the journal 
articles is outlined below: 
- Crystal structures of human kynurenine pathway enzymes were downloaded from 
the Protein Data Bank (PDB)
*
. The proteins were prepared both with and without 
their respective cofactors present. Optimisation and minimisation of the protein 
was performed using the Impref utility in IMPACT (Schrödinger LLC) and the 
OPLS-2005 [2] force field, and hydrogen atoms were also added and water 
molecules not involved in the reaction were removed, using the protein preparation 
wizard in Maestro version 10.4.017 (Schrödinger LLC). The active site was 
determined by the location of ligand in the crystal structure. The ligands were 
prepared using LigPrep [3], using the OPLS-2005 force field, and were docked 
using Glide [4] with SP [5] or XP docking [6].  
*
The highest resolution structure which contained a ligand and its cofactor was prioritised 
for use. 
C.2 Validation of docking protocol 
In order to validate the docking protocol used, the selected protein structures were docked 
with their native ligand and the RMSD between the experimentally derived ligand and the 
docked ligand pose were calculated for SP docking (Table C-1A) and XP docking 
(Table C-1B). Up to ten poses were allowed to be generated for each docked ligand, and the 
docking score and RMSD is reported for the highest scoring pose with an RMSD below 2 Å.  
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 Table C-1A. SP docking of the original ligands contained in the protein structures 
Protein 
(PDB ID) 
SP docking 
score 
RMSD (Å) Rank # Poses 
within 2 Å 
# Poses 
between  
2-4 Å 
Total 
poses 
TDO (5TIA) -9.666 0.907 1 9 1 10 
IDO (2D0T) -6.039 1.197 2 3 2 10 
IDO (5WMU) -8.337 0.854 2 6 4 10 
KAT-I (3FVU) -9.153 0.54 1 3 4 10 
KAT-II 
(2R2N) 
- 
 
- - 0 0 10 
Kynureninase 
(3E9K) 
-4.216 1.675 5 2 1 10 
 
Table C-1B. XP docking of the original ligands contained in the protein structures 
Protein (PDB 
ID) 
XP docking 
score 
RMSD (Å) Rank # Poses 
within 2 Å 
# Poses 
between 
2-4 Å 
Total 
poses 
TDO (5TIA) -10.777 0.719 1 4 0 4 
IDO (2D0T) -5.892 1.479 
 
1 2 0 9 
IDO (5WMU) -8.271 0.592 1 7 0 7 
KAT-I (3FVU) -9.261 
 
0.431 
 
1 1 0 1 
KAT-II 
(2R2N) 
-8.164 1.272 3 1 2 10 
Kynureninase 
(3E9K) 
- - - 0 1 10 
The docking score is listed for the pose with the lowest RMSD to the ligand in the crystal structure. 
For TDO, IDO, and KAT-I, the protocol is validated for use with both SP and XP docking 
without a clear preference for one over the other. SP docking was not able to replicate the 
pose of the crystallised ligand in KAT-II, however XP docking was able. The opposite is true 
for kynureninase, with SP docking providing a better indicator of the experimental pose. For 
the docking of estrogens hereon, XP docking was used for TDO, IDO, KAT-I, and KAT-II, 
and SP docking was used for kynureninase. 
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C.3 Docking estrogens into the kynurenine pathway 
The inhibition of the kynurenine pathway enzymes by estrogen compounds has been 
evaluated, with experimental data suggesting that estrogen inhibition of both kynureninase 
and KAT occurs, while TDO inhibition is inconclusive (refer to section 1.2 and Chapter 4). 
One observation that is clear is that there are noticeable variations in the excretion of 
kynurenine pathway metabolites depending on the estrogen status of a person. Deriving a 
plausible understanding of estrogen inhibition in this pathway could therefore be of 
significance, particularly as changes to the levels of kynurenine pathway metabolites are 
associated with various disease states. In order to gain further understanding, docking was 
performed to observe the potential binding of estradiol and its sulfated ester forms with TDO, 
IDO, the KAT enzymes, and kynureninase in their holoenzyme and apoenzyme forms.  
For this section, “estrogens” will collectively refer to estradiol, estradiol 3-sulfate, estradiol 
17-sulfate and estradiol disulfate. Please also refer to Fig. C-1 below for the nomenclature 
that will be used when describing the estrogens.  
X
CH3
Y
A B
C D
 
Figure C-1. The scaffold of the estrogens, where X (at the 3-position) and Y (at the 17-position) are OH or 
SO4 depending on the compound. The aromatic ring is labelled A, and the other rings are B, C and D, 
respectively. 
Tryptophan 2,3-dioxygenase/indoleamine 2,3-dioxygenase  
TDO and IDO are haem-containing enzymes and are responsible for catalysing the 
oxidation of tryptophan into N-formylkynurenine in what is the first and rate-limiting step 
in the kynurenine pathway. 
Docking into TDO without the cofactor showed that all of the estrogens preferentially 
dock in the cavity vacated by the haem molecule. In this cavity, estradiol has many 
hydrophobic interactions with residues such as Phe-72, Phe-140, Leu-132, Val-332, 
Met-335, and Leu-336. The poses display an accommodation of the sulfate moieties, 
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allowing hydrogen bonds to be formed with Arg-159 and Tyr-350 for estradiol 3-sulfate, 
and with Gly-343 and Ser-345 for estradiol 17-sulfate, but otherwise they sit in the same 
pocket as estradiol. Estradiol disulfate however was not able to be docked into TDO.  
With or without the presence of a haem molecule, tryptophan docks in a space adjacent to 
the pocket favoured by the cofactor and the estrogens. Its main interactions are hydrogen 
bonds with His-76, Arg-144 and Thr-342. While this pocket appears to fit a molecule the 
size of tryptophan, the bulkier estrogens are unable to dock at all when the haem cofactor 
is present.  
Observations with IDO raise questions about other important aspects of substrate binding 
in enzymes and the veracity of docking. Tryptophan, co-crystallised in 5WMU, is located 
in close proximity to the haem molecule, with both its benzene and pyrrole rings forming 
pi-pi interactions with Phe-163, and the carboxyl group hydrogen bonding to Arg-231 and 
Thr-379. As with TDO, when haem is present, this substrate binding site appears to be 
insufficient in size to accommodate the estrogens. The removal of the nearby haem 
cofactor allows the docking of the estrogens where the cofactor was located, in similar 
poses, with hydrophobic interactions formed with many residues including Tyr-126, 
Phe-163, Phe-214, Ile-217, Phe-226, Ala-264, Ile-349, Val-350, Leu-384, and Leu-388. 
Upon examination of a second IDO structure, 2D0T, it is apparent that the co-crystallised 
ligands (in this case, a buffer component) can bind away from the area that the aromatic 
ring of tryptophan is anchored into, at the entrance to the binding cavity. This location also 
affords enough space for the estrogens to dock into 2D0T with haem present, however 
when the docked structure is aligned with 5WMU it can be seen that the estrogens clash 
with Thr-379 and Gly-380 in 5WMU. Although the electron density is well defined for 
these residues in 5WMU, it is disordered in 2D0T and has been removed from the 
structure as a result. Given it is at the entrance of the binding cavity and that the electron 
density is poor, it can be surmised that residues in this region (360-380) represent a 
flexible loop that may be associated with substrate binding. While it is apparent from 
docking into both crystal structures that the estrogens will not bind in a similar location to 
tryptophan when the haem cofactor is present, it is conceivable that the movement of the 
flexible residues in the binding site can open a cavity at the entrance into which the 
estrogens can bind. 
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Kynurenine aminotransferase-I 
The KAT isoforms catalyse the irreversible transamination of KYN into KYNA, using 
PLP as a cofactor. In KAT-I, PLP is covalently attached to Lys-247 and the enzyme 
notably has a hydrophobic crown consisting of aromatic residues such as Trp-18, Tyr-63, 
Tyr-101, Phe-125, Phe-278, and His-279.  
The key residues that interact with KYN in KAT-I are Asn-185 and Arg-398 which 
hydrogen bond with the carboxyl, and Gly-36 which interacts with the amine group. The 
aromatic ring sits in the hydrophobic pocket of KAT-I and forms pi-pi interactions with 
Tyr-63, Phe-125, and His-279.  
Estradiol docks into the hydrophobic crown in the same way regardless of the presence of 
PLP, with the aromatic ring forming pi-pi interactions with Tyr-63 and pi-cation 
interactions with Arg-398. When PLP is present, the other estrogens are docked with the 
orientation of the rings flipped. The aromatic ring occupies space in the pocket where the 
D-ring was situated for estradiol and has pi-pi interactions with Phe-278, while the D-ring 
is now next to Asn-185 and Arg-398, in the region where the aromatic ring in estradiol 
resided. Effectively this means that the 3-sulfate forms hydrogen bonds with Lys-65 and 
Thr-66 at the peripheries, while the 17-sulfate hydrogen bonds with Asn-185 and Arg-398. 
When PLP is not present, estradiol 17-sulfate maintains its conformation. Estradiol 
3-sulfate and estradiol disulfate are docked with the rings flipped back to the orientation of 
estradiol, such that the aromatic ring pi stacks with Phe-125. The primary result of this 
shift is that the 3-sulfate occupies the space that the phosphate moiety of PLP previously 
had taken up, where it can hydrogen bond with Tyr-63, Gly-100, Tyr-101, Ser-244, and 
Lys-255.  
The docking of the estrogens in KAT-I suggests that the estrogens are accommodated by 
the hydrophobic crown of KAT-I, and preferentially take up that pocket instead of the PLP 
binding pocket, however there is room for the sulfate groups to encroach into the location 
that is occupied by the phosphate of PLP when the latter is absent. 
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Kynurenine aminotransferase-II  
The KAT-II isoform is different in that it has more polar and neutral amino acids than 
KAT-I, and the N-terminal arm of KAT-II undergoes domain swapping to help form part 
of the active site of the opposite subunit from which it buds off from. In KAT-II, PLP is 
found covalently linked to Lys-263. 
When KYN enters the active site of KAT-II, Arg-20 forms a pi-cation interaction with the 
aromatic ring and this is the location at which there is a fold in the N-terminal residues, 
which controls entry into the active site. The carboxyl and amine group of KYN is 
anchored into the active site by a salt bridge formed with Arg-399, and hydrogen bonds 
with Gly-39 and Asn-202, respectively. 
Whether PLP is present in the active site or not, estradiol docks into KAT-II in a manner 
which mirrors kynurenine. The aromatic ring is situated adjacent to Arg-20 and the rest of 
the molecule projects towards Arg-399 and can form hydrogen bonds there with its 
17-hydroxyl moiety. Estradiol 3-sulfate also docks similarly in both cases and the 3-sulfate 
forms hydrogen bonds with the nearby Arg-20. As with the others, when PLP is present, 
estradiol 17-sulfate is situated near Arg-20 and the 17-sulfate this time forms hydrogen 
bonds with Arg-399. Different poses are preferred however for estradiol 17-sulfate when 
PLP is not present. Instead of being projected towards Arg-399, it docks so that the C- and 
D-rings are near Lys-263, and the 17-sulfate forms bonds with it.  
Estradiol disulfate is a mixture of these estrogens. When PLP is not present, it is orientated 
with the aromatic ring adjacent to Arg-20 where the 3-sulfate forms hydrogen bonds with 
it. The rest of the molecule stems towards Lys-263, and the 17-sulfate moiety forms 
hydrogen bonds with Asn-202 and Lys-263. When PLP is present, estradiol disulfate 
cannot dock in the active site. 
Experiments have shown clearly that the estrogens can inhibit the KAT enzymes, with the 
sulfated forms being the most potent. It is hypothesised that the 17-sulfate is primarily 
responsible for this increased potency, as opposed to the 3-sulfate position. It has also 
been seen that the inhibition of estrogen disulfate can be reversed by increasing PLP 
concentrations. The docking suggests a mechanism by which this can arise in KAT-II 
inhibition. While the docking conformation of estradiol and estradiol 3-sulfate is relatively 
unchanged by the presence or absence of PLP, estradiol 17-sulfate and estradiol disulfate 
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both preferentially dock near Lys-263 when PLP is absent, which is the amino acid 
responsible for covalently binding to the PLP cofactor. Further, the modelling suggests 
that estradiol disulfate cannot dock in the active site when PLP is present.  Hence if it were 
to occupy its preferred position, where PLP usually is located, it may not only act as a 
competitive inhibitor of the substrate, but it may also compete with the cofactor for the 
apoenzyme. 
Kynureninase 
Kynureninase is a homodimeric enzyme that catalyses the conversions of KYN and 3-HK 
into AA and 3-HAA acid, respectively. It is a PLP-dependent enzyme, with the cofactor 
covalently attached to Lys-276. The PLP binding site contains residues such as Thr-138, 
Tyr-275, Trp-305, Ser-332, and Asn-333, which hydrogen bonds with the phosphate in 
PLP, and Asp-250 which interacts with the PLP amine, and also allows the formation of 
pi-pi interactions between PLP and Phe-165. 
Both KYN and 3-HK bind near PLP, in the same location, with hydrogen bonds formed 
between the amine group and Ser-75 and Asp-426 and between the carboxyl group and 
Arg-434. The carboxyl can also form a salt bridge with Lys-276, and the aromatic ring of 
the substrates can form pi-pi interactions with His-102 and Trp-305. 
The estrogens dock in a similar manner to each other, whether PLP is present in the active 
site or not. The aromatic ring of estradiol is in a comparable position to the aromatic ring 
of KYN and 3-HK, and forms pi-pi interactions with Trp-305. The 3-hydroxyl and 
17-hydroxyl groups are in proximity to polar groups such as the oxygen atoms in the 
hydroxyl of Tyr-275 and carbonyl of Glu-103, respectively, and may form additional 
hydrogen bonds. While KYN and 3-HK extends from the location of their aromatic ring 
towards other residues near the active site such as Ser-75, Arg-426, and Arg-434, estradiol 
is instead positioned away from the active site such that it leads out of the binding cavity.  
The addition of sulfates on the other estrogens increases the bulk, and is accommodated by 
the main core of estradiol 3-sulfate and estradiol 17-sulfate being docked further away 
from the active site, and allowed to be flexible in the case of estradiol 17-sulfate. Estradiol 
disulfate is docked similarly however the 17-sulfate is positioned to form hydrogen bonds 
with Lys-276 and Arg-324. Despite these few interactions, estradiol disulfate and the other 
sulfated forms of estradiol in particular cannot interact with the active site to the same 
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degree as the natural substrates due to their size, and this is reflected in their relatively 
poor docking scores.  
In kynureninase, the PLP binding site is quite narrow such that it does not seem as though 
the estrogens can bind in this location even when PLP is removed, however the substrate 
active site extends out of the binding cavity and can house the estrogens. It is therefore 
plausible that any potential inhibition of kynureninase by estrogen compounds is 
independent of PLP binding and is purely a result of the estrogens denying the natural 
substrates entry into the active site. This is consistent with experimental results indicating 
that estrogen inhibition of kynureninase is not competitive with respect to the PLP, and 
competitive with respect to the substrate. 
Summary of estrogen docking in the kynurenine pathway 
The scores of the estrogens docked into the proteins are listed in Table C-2. With the 
exception of kynureninase, the removal of the cofactors from the proteins not only 
introduces but is often necessary to form a sufficiently large cavity capable of binding to 
the estrogens. The absence of the haem cofactors in TDO and IDO in particular is very 
conducive to estrogen docking as it presents a hydrophobic pocket that can form many 
interactions with the estrogens, and with the cofactor in place the estrogens actually do not 
dock well in these proteins. KAT-I naturally contains a hydrophobic pocket in its active 
site and, as a result, is relatively capable of docking the estrogens with or without PLP 
present. On the other hand, while KAT-II appears large enough to dock estradiol with PLP 
present, the removal of the cofactor certainly allows better interactions to form for the 
sulfate esters. Estrogen docking in kynureninase is more consistent, regardless of the 
cofactors presence, and is restrained to the peripheries of the active site. 
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Table C-2. Docking scores of estrogens and natural substrates into enzyme structures 
 TDO 
(5TIA) 
IDO 
(5WMU) 
IDO 
(2D0T) 
KAT-I 
(3FVU) 
KAT-II 
(2R2N) 
Kynureninase 
(3E9K) 
Estradiol - -5.9 - -6.0 -3.6 -4.1 -7.2 -6.9 -6.3 -6.3 -5.4 -5.5 
Estradiol 
3-sulfate 
- -6.1 - -1.4 -3.1 -4.3 -7.6 -8.8 -3.2 -6.2 -5.2 -5.1 
Estradiol 
17-sulfate 
- -5.9 - -6.1 -4.9 -4.7 -8.4 -9.3 -6.4 -4.1 -4.2 -3.9 
 
Estradiol 
disulfate 
- - - 1.0 -2.3 -4.7 -8.6 -9.2 - -8.0 0.9 -2.6 
KYN       -10.5 -9.1 -8.1 10.0 -6.6 -6.3 
Tryptophan -9.4 -9.5 -7.8 -7.2 -5.1 -4.6       
3-HK           -6.4 -5.8 
The columns for the separate proteins are subdivided to display the scores when docked into the holo (left, 
no highlights) and apo (right, highlighted grey) forms of the proteins. The red highlighted cells indicate that 
the molecule was not docked in the protein, while the dash indicates that it failed to dock in the protein.  
The docking raises some important considerations: 
- Can different mechanisms exist for inhibition of different enzymes in the 
kynurenine pathway? 
If the docking is considered to be representative of the binding ability of the estrogens, 
there are two separate interpretations to consider: 
1) Estrogens can compete with the substrate for the active site or block entry into the 
active site. This is evidenced in the docking by the results for KAT-I, KAT-II, 
kynureninase and IDO (2D0T). 
2) Estrogens can compete with the cofactor for binding into the apoprotein. Evidence 
for this arises from the estrogens not docking in TDO, IDO (5WMU) and KAT-II 
(specifically only estradiol disulfate for the latter) when their cofactors are present, 
while docking in a favourable manner in TDO, IDO, KAT-I, and KAT-II at the 
location of the cofactors, when the cofactors are removed. 
Experimental evidence of both scenarios has been seen in literature, with estrogens 
observed able to compete with PLP for the apoenzyme form of KAT, but competing only 
with the substrate, and not PLP, in kynureninase. There also remains the possibility that 
both forms of inhibition may occur in a single enzyme. For example, Chapter 3 details the 
discovery of two fragment molecules, F0037-7280 and F6037-0164, which inhibit KAT-II. 
F0037-7280 inhibition was found to be independent to PLP concentrations (an effect that 
is not suspected to be a result of irreversible binding to PLP), whereas F6037-0164 
displayed lower inhibition when PLP was increased in the reaction mixture and therefore 
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may have competed with it. The docking for these fragments were consistent with this as 
the best calculated pose for F0037-7280 did not differ whether PLP was present in the 
active site or not, whereas the poses for F6037-0164 changes dramatically to occupy the 
PLP binding site when the latter is removed (a diagram of this is shown in Fig. 4 and 
Fig. 5 of the journal article contained within Chapter 3). 
- How reflective are the crystal structures of substrate and estrogen binding? 
One of the pitfalls of a crystal structure is that it is a snapshot of a protein-ligand complex, 
and this is carried over when using it for the purposes of docking. Relevant to this study 
was the finding that the IDO structure, 2D0T, incorporated co-crystallised ligands and 
estrogen docking in regions near where one would expect flexible residues (that had been 
removed in this structure). To determine how these removed residues could impact 
docking, a comparison was made with a second IDO structure (5WMU) which showed that 
these residues could restrict estrogen binding by closing the active site. Therefore, while 
the best insight is certainly provided by complete structures with bound ligands, docking 
results must be interpreted with the caveat that it cannot fully account for processes that 
occur in ligand binding, such as flexible loops broadening an active site cavity. 
C.4 Docking fragment compounds into kynurenine aminotransferase-II 
A fragment library containing 1000 compound was used to search for potential new leads for 
KAT-II inhibition. The discovery and docking of the two fragment hits, F0037-7280 and 
F6037-0164, has been discussed in Chapter 3, however further explorations of the docking 
will be very briefly discussed here. The 18 best fragment hits determined from SPR were 
docked into the active site of KAT-II and their scores can be seen in Table C-3 alongside 
their inhibitory ability (as determined by KAT-II inhibition assays). The top three scoring 
poses from the docking also corresponded to the fragments that inhibited KAT-II the most in 
the inhibition assays. Note: F3412-0030 was only not evaluated further in Chapter 3 due to its 
structural similarity to F0037-7280. 
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 Table C-3. KAT-II docking and inhibition with fragment hits 
Fragment XP docking score KAT-II inhibition 
F0037-7280 -6.955 67% 
F6037-0164 -6.756 15% 
F3412-0030 -6.329 32% 
F2483-0047 -6.167 - 
F3394-1274 -6.098 - 
F6230-0300 -5.956 - 
F2106-0130 -5.604 3% 
F6445-6917 -5.595 - 
F2336-1079 -5.477 - 
F2493-3416 -5.339 - 
F5871-3538 -5.2 4% 
F9995-0188 -5.153 - 
F3371-0639 -5.012 - 
F3358-0288 -4.858 4% 
F6229-0348 -4.518 - 
F2190-0687 -4.323 4% 
F3308-0230 -4.16 - 
F5847-0169 -3.488 - 
The fragments are arranged in the order of their docking scores.  The fragments were docked into the active 
site of KAT-II. 
In order to try and evaluate the fidelity of the 18 fragments listed in Table C-3 towards the 
active site of KAT-II, the SiteMap [7] software from the Schrödinger Maestro suite was used 
to calculate potential binding sites away from the active site (Fig C-2). Receptor grids were 
generated at each of the locations determined, and the prepared fragment molecules were 
docked into the sites. Table C-4 displays the docking score at each of the potential binding 
sites, along with the scores of the fragments in the active site re-listed for comparison. These 
results indicated that the best poses of the fragments would be located in the active sites (with 
the exception of two fragments), and did not offer any obvious insights as to why only three 
of the fragments displayed relatively high inhibition while the rest seemingly did not inhibit 
KAT-II in the assays. 
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 Figure C-2. Receptor grids were generated from the eight sites calculated to be potential ligand binding 
sites, as determined from SiteMap. 
 Table C-4. Fragment hits in calculated, potential binding sites of KAT-II 
 
Active 
site Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 Site 7 Site 8 
F0037-7280 -6.96 -3.61 -4.83 -2.86 -4.56 -2.55 -3.98 -3.75 -3.91 
F2106-0130 -5.60 -3.36 -2.55 -1.67 -3.06 -1.59 -2.76 -3.11 -3.30 
F2190-0687 -4.32 -3.17 -2.21 -3.14 -3.08 -2.54 - -2.34 -3.43 
F2336-1079 -5.48 -3.97 -4.54 -3.73 -4.83 -1.98 -3.70 -2.89 -3.95 
F2483-0047 -6.17 -3.33 -2.27 -1.34 -3.08 -1.06 -2.23 -2.21 -2.21 
F2493-3416 -5.34 -4.55 -1.43 -1.35 -3.28 -2.67 -2.18 -1.84 -3.62 
F3308-0230 -4.16 -3.09 -5.01 -2.91 -2.57 -3.18 -3.62 -4.85 -3.49 
F3358-0288 -4.86 -4.75 -3.09 -2.19 -4.49 -1.94 -3.46 -4.25 -2.89 
F3371-0639 -5.01 -3.67 -1.91 -2.59 -3.29 -1.22 -3.10 -1.87 -3.22 
F3394-1274 -6.10 -4.75 -4.52 -4.71 -6.07 -3.38 -3.68 -4.66 -4.65 
F3394-1274 -5.85 -4.41 -4.56 -3.56 -4.87 -3.78 -4.43 -5.13 -3.96 
F5847-0169 -3.49 -3.92 -2.59 -1.91 -3.46 -1.92 -2.96 -2.54 -3.74 
F5871-3538 -5.20 -3.83 -3.93 -3.19 -3.85 -2.32 -2.61 -3.64 -4.27 
F6037-0164 -6.76 -4.66 -3.13 -2.54 -3.47 -1.18 -2.91 -3.38 -4.45 
F6229-0348 -4.52 -3.30 -3.14 -2.27 -3.49 -1.31 -2.97 -2.30 -3.52 
F6230-0300 -5.96 -4.07 -3.43 -3.94 -4.37 -1.90 -3.49 -4.38 -4.39 
F6445-6917 -5.60 -2.49 -3.25 -3.14 -3.79 -2.67 -2.67 -3.20 -3.85 
F9995-0188 -5.15 -3.78 -2.41 -3.34 -4.70 -2.89 -3.37 -3.23 -3.90 
Highlighted in grey are the highest scoring poses for the respective fragments. Of the fragments docked, 
only two were calculated to have a better docking score at a site away from the active site.  
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Appendix D Crystallisation of kynurenine aminotransferase-II 
D.1 Outline of crystallisation protocol 
Recombinant human KAT-II crystals were grown using the hanging drop vapour diffusion 
technique. 3 μL of 10 mM dithiothreitol was added into a 20 μL aliquot of 10 mg/mL 
recombinant KAT-II. The protein solution was separated into 10 μL aliquots, and 1 μL of 
25 mM substrate or inhibitor was mixed into each of these aliquots for the purpose of 
co-crystallisation. 1 μL of the protein-substrate or protein-inhibitor solution was mixed with 
1 μL of reservoir solution (24% polyethylene glycol 4000, 0.1 M Na citrate pH 5.6, 200 mM 
NaCl) on a siliconised cover slip, and was equilibrated against 1 mL of reservoir solution. 
The crystals were grown for a week at 20 °C. 
D.2 Data collection and processing 
KAT-II crystals were grown co-crystallised with KYN and the inhibitors, estrogen disulfate, 
JN-01 and JN-02 (Fig. D-1). Data collection took place at the Australian Synchrotron 
(Clayton, Victoria) using the MX2 beamline. Prior to detection, the KAT-II crystals were 
placed onto a LithoLoop (0.1 mm) and flash-frozen in liquid nitrogen. The mounted crystal 
was kept at 100 K with a cold nitrogen stream. A more comprehensive description of data 
collection parameters for the dataset used for structure determination and refinement can be 
seen in Table D-1. Data reduction was completed using XDS [8], and data scaling and 
merging was completed with AIMLESS [9]. The resolution of the collected data that was 
used was calculated to be 1.47 Å, which is the highest resolution for human KAT-II to date. 
 
Figure D-1. Images of human KAT-II crystals grown by the hanging drop vapour diffusion technique, 
captured using the Dino-Lite microscope camera. 
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 Table D-1. Collection statistics for human KAT-II crystal structure 
X-ray source Australian Synchrotron MX2 
Wavelength (Å) 0.9537 
Temperature (K) 100 
Detector Eiger 16M 
Detector distance to crystal (mm) 200 
Rotation range per image (°) 0.1 
Total rotation range (°) 360 
Exposure time per image (s) 0.1 
Space group P 43212 
Unit cell (Å, °) a = b = 102.765 c = 86.498  
α = β =   = 90° 
Resolution range Å 45.96 – 1.47 (1.52 – 1.47) 
Total reflections 2115859 (204962) 
Unique reflections 79172 (7700) 
Multiplicity 2.0 
Completeness (%) 99.89 (98.97) 
Mean I/σ(I) 41.07 (11.61) 
Wilson B-factor 14.49 
Rmerge 0.05847 (0.2693) 
Rmeas 0.05963 (0.2746) 
CC1/2 0.999 (0.991) 
The statistics for the highest-resolution shell are shown in parentheses. 
D.3 Solving and refining the crystal structure 
The collected datasets were processed using the PHENIX (v1.12_2829:2017) software suite 
[10]. The quality of the datasets were assessed by Phenix.xtriage [11], which performs 
„sanity‟ checks and identifies outliers, twinning, anisotropy, and other idiosyncrasies, as well 
as providing information on the unit cell volume, and the completeness and strength of the 
data.  From the datasets collected, the most suitable for solving and refining was from a 
dataset of KAT-II co-crystallised with JN-02. 
The structure of the human KAT-II was solved by MR, using PHASER [12]. The KAT-II 
structure, 5EUN, was used as the search model for MR, and a solution was found with a 
calculated log-likelihood gain of 29068.4 and a translation function z-score of 136.4. For a 
successful solution the log-likelihood gain typically needs to be high and positive, and the 
translation function z-score should be > 8. The space group determined by MR was P43212, 
with unit cell parameters of a = b = 102.77 Å, c = 86.50 Å, α = β =  = 90°. 
The solved structure was refined using Phenix.refine [13], with the final refinement statistics 
shown in Table D-2. Somewhat unexpectedly, the KAT-II cofactor, PLP, was not observed in 
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the solved crystal structure, and nor were there any signs of the presence of JN-02. Regions 
of lower order, including residues 20-33 and 367-377, displayed poor electron density, 
therefore the occupancy of these atoms were set to 0.00. Out of these residues, Arg-20 in 
particular is noteworthy for being located at the site of conformational changes which is 
thought to regulate the entry of molecules into the active site. Interestingly, electron density 
seemed apparent for the guanidine group in the Arg-20 side-chain, suggesting that this group 
was relatively anchored despite the movement of the remainder of the residue. If it were to 
take up this position, near the symmetry placed residues Arg-399 and Asn-202 (Fig. D-2), 
Arg-20 would effectively block off the active site, which could conceivably be either the 
cause or the result of the lack of inhibitor or cofactor in the active site. This is conjecture 
however, as the lack of electron density for the other aspects of the residue makes it difficult 
to unambiguously determine if the density that is observed truly signifies the location of the 
guanidine group. Electron density was also visible for the backbone of the hexahistidine tag, 
but was generally not seen for the imidazole side-chains with the exception of the first 
histidine attached to the N-terminus (Fig. D-3). The real-space R-value z-scores also 
suggested additional residues which had a relatively low correlation with the electron density 
map. These residues were typically confined to regions near the aforementioned sites of low 
order, such as residues 18-19, 34, 363, 378-380. There was some arbitrariness to determine a 
cut-off by which the atoms in these residues would be included while the others were deemed 
to have 0.00 occupancy, but ultimately the main determining factors were that these residues 
fit the electron density relatively well and that the temperature factors of these atoms were 
not nearly as high as the low ordered regions. The mean temperature factors for the protein 
chain (excluding residues 20-33 and 367-377) can be seen in Fig. D-4, and, as would be 
expected, the main chain of the amino acids in the protein generally have lower temperature 
factors than the side chains. The active site residues in particular have a lower mean 
temperature factor than the protein at large and the disordered, flexible residues. Out of all 
the water molecules in the structure, five were on special positions on a two-fold axis, and 
therefore the occupancy of the atoms was set to 0.50. Of these five, only one water molecule 
was particularly noteworthy, with a very low temperature factor of 4.83 Å
2
. However, there is 
insufficient evidence from the electron density to indicate that this reflected anything but a 
water molecule. 
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 Table D-2. Refinement statistics for human KAT-II crystal 
Resolution range Å 45.96 – 1.47 (1.52 – 1.47) 
Reflections used in refinement 79169 (7700) 
Reflections used for Rfree 2000 (195) 
Rwork 0.1735 (0.1825) 
Rfree 0.1879 (0.2018) 
CCwork 0.958 (0.919) 
CCfree 0.973 (0.895) 
Protein residues 425 
RMSbonds 0.009 
RMSangles 1.00 
Ramachandran favoured (%) 96.50 
Ramachandran allowed (%) 3.26 
Ramachandran outliers (%) 0.23 
Rotamer outliers (%) 0.27 
Clashscore 1.11 
Average B-factor 20.70 
PDB ID 6D0A 
The statistics for the highest-resolution shell are shown in parentheses. 
 
Figure D-2. Evidence of electron density is present for the guanidine group of the Arg-20 side-chain, close 
to the active site residues Asn-202 and Arg-399. The blue mesh in the diagram displays positive density for 
atoms, and the green mesh displays where it is expected that atoms are missing in the current model in 
comparison to the crystal structure. As the Arg-20 occupancy was set to 0.00, the guanidine group is 
enveloped in the green mesh. 
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Figure D-3. The first histidine residue that is part of the hexahistidine tag has visible electron density (blue 
mesh) for both the main chain and the imidazole side chain. The subsequent histidine residues (of which 
only two are depicted above) have visible density for the main chain, but not the imidazole rings.  
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Figure D-4. The mean temperature factors for amino acid residues in the refined KAT-II structure. The 
gaps in the figures are for residues 20-33 and 367-377, which have atoms of 0.00 occupancy in the final 
structure. Average temperature factors are displayed for (A) the main chain of the residues and (B) the side 
chain of the residues, and (C) shows an overlay of the two graphs. 
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The refined model, referred to by the PDB ID 6D0A hereon, and the previously deposited 
structures of human KAT-II were assessed using the MolProbity [14] web-based server, 
which generated geometry statistics of the proteins (Table D-3), and the DPI of each structure 
was calculated [15]. Despite rotamer outliers present in all but one KAT-II structure, the 
single outlier in 6D0A (Asn-239) was observed as such in only 2R2N, 4GE9 and 5TF5. At 
least in the case of 6D0A, the outlier is acceptable because the electron density for Asn-239 is 
clearly defined. The single Ramachandran plot outlier in 6D0A is observed in one of the 
histidine-tag residues and not in the KAT-II protein chain itself. 6D0A also features no Cβ-
deviations, bad bonds or bad angles, comparable only to 5EUN in this regard. From the 
calculated DPI, 6D0A also demonstrates superior precision of the determined atomic 
coordinates compared to the other structures.  
 Table D-3. MolProbity protein geometry statistics and DPI of human KAT-II structures 
 Goal / 
expected 
6DOA 2QLR 2R2N 2VGZ 2XH1 3DC1 3UE8 4GDY 
Resolution (Å) - 1.47 2.3 1.95 2.3 2.1 2.5 3.22 2.89 
*DPI (Å) - 0.07 0.26 0.16 0.23 0.18 0.32 0.57 0.40 
Poor rotamers 
(%) 
< 0.3 0.27 17.28 10.61 4.86 8.24 9.24 15.13 7.37 
Favoured 
rotamers (%) 
> 98 98.14 71.95 82.77 88.75 84.64 79.60 71.85 84.31 
Ramachandran 
outliers (%) 
< 0.05 0.23 1.55 0.95 0.37 0.25 0.42 1.72 0.60 
Ramachandran 
favoured (%) 
> 98 96.50 91.61 95.98 97.68 96.20 92.30 89.22 94.85 
Cβ deviations 
> 0.25 Å 
0 0 109 35 3 14 23 53 34 
Bad bonds (%) 0 0 0.54 0.03 0.09 0.02 0.13 0.02 0 
Bad angles (%) < 0.1 0 0.67 0.12 0.11 0.15 0.08 0.51 0.24 
Cis prolines 
(%) 
≤ 5% 6.45 4.84 9.68 6.67 6.67 4.84 6.78 6.35 
Cis non-
prolines (%)  
< 0.05 0 0 0 0 0 0 0 0.39 
Twisted 
peptides (%)  
0 0 1.06 0.71 0 0 0.78 0 0 
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 Table D-3 continued  
 Goal / 
expected 
6DOA 4GE4 4GE7 4GE9 4GEB 5EFS 5EUN 5TF5 
Resolution (Å) - 1.47 2.41 2.1 2.43 2.15 1.83 1.83 1.81 
*DPI (Å) - 0.07 0.22 0.15 0.27 0.14 0.11 0.11 0.16 
Poor rotamers 
(%) 
< 0.3 0.27 4.74 5.12 6.79 5.38 0.27 0 0.54 
Favoured 
rotamers (%) 
> 98 98.14 89.72 89.62 83.47 89.11 94.05 95.12 93.77 
Ramachandran 
outliers (%) 
< 0.05 0.23 0..36 0.24 0.23 0.12 0 0 0 
Ramachandran 
favoured (%) 
> 98 96.50 97.51 98.23 96.65 97.07 95.27 95.24 95.24 
Cβ deviations 
> 0.25 Å 
0 0 26 30 68 3.24 0 0 0 
Bad bonds (%) 0 0 0.01 0.06 0.03 0.01 0.03 0 0.20 
Bad angles (%) < 0.1 0 0.13 0.15 0.42 0.16 0 0 0.05 
Cis prolines 
(%) 
≤ 5% 6.45 6.35 6.25 6.25 6.25 6.25 6.45 6.45 
Cis non-
prolines (%)  
< 0.05 0 0 0 0.13 0.25 0 0 0 
Twisted 
peptides (%)  
0 0 0 0 0 0 0.24 0.47 0.47 
The structure determined in this work, 6D0A, is highlighted in grey and placed as a reference for both halves of 
the table. *The DPI (Å) was calculated using R-free.  
Like almost all of the other KAT-II structures, 6D0A features 2 cis prolines (cis peptides are 
those with an ω angle between - 30° and + 30) located at Pro-140 and Pro-203, in a single 
monomer chain. 2R2N is the only structure which contains an additional cis proline at 
Pro-18, while 2QLR and 3DC1 contained twisted prolines (twisted peptides are those with 
an ω angle greater than 30° from planar) in some chains at Pro-203. While approximately 5% 
of proline residues are cis, only 0.03% of all non-prolines residues are expected to be cis [16]. 
Twisted peptides are rarer again and are largely considered modelling errors. Due to their 
unfavourable conformations, cis non-prolines and other rare conformations are generally only 
conserved at functionally important sites [16]. A breakdown of the residues deemed to have 
cis (non-proline) or twisted configurations is displayed in Table D-4. Of these residues, only 
Ile-19, Arg-20 and Asn-202 are within 5 Å of PLP and the substrate, KYN, in 2R2N. Many 
of the remaining residues listed have little relevance to catalytic activity and tend to be 
located in the peripheries of the protein. The exceptions to this may be residues 21-33 as they 
tend to be more flexible and may be involved in substrate entry into the active site, however 
they have no direct role in the active site. 
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 Table D-4A. cis non-proline peptides in KAT-II structures 
Structures containing cis non-prolines Residues 
4GDY Thr-21 
4GE9 Gly-29 
4GEB Asn-57 
 Table D-4B. Twisted peptides in KAT-II structures 
Structures containing twisted peptides Residues 
2QLR Pro-18, Arg-20, Met-22, Asp-24, Thr-99, 
Gly-107, Lys-188, Asn-189, Pro-203, 
Thr-204, Phe-241, Thr-342, Gly-343 
2R2N Ser-17, Glu-181, Asp-182, Lys-188, 
Phe-241, Thr-342, Gly-343 
3DC1 Ile-19, Arg-20, Gly-29, Pro-30, Lys-31, 
Ser-32, Met-33, Asn-185, Asn-202, Pro-203, 
Ser-404 
5EFS Pro-18, Asn-189 
5EUN Pro-18, Asn-189 
5TF5 Phe-241 
The chains are not specifically mentioned to avoid duplicates, but the residues are taken from all the chains of 
the respective protein structure. In red are the residues within 5 Å of PLP and KYN in 2R2N which contribute to 
the active site. 
The final refined structure from this work, 6D0A, is the highest resolution structure for 
human KAT-II, with the most accurately determined atomic coordinates, and is relatively free 
of the protein geometry concerns that are a feature of most of the other deposited human 
KAT-II structures. 6D0A also displays the protein in its apo form, in a configuration which 
may show the active site relatively closed off compared to other structures. 
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Appendix E Supplementary information for published articles
E.1 Supplementary information for Article 2: Fragment screening of human 
kynurenine aminotransferase-II 
Supplementary Figure S1. The amino acids with an atom within 5.0 Å of kynurenine 
(yellow) in KAT-II were chosen for display, with PLP also depicted (magenta). Residue Tyr-
142 was removed for clarity. The carboxyl moiety forms a salt bridge (yellow dashes) with 
Arg-399, and the amine group forms hydrogen bonds (yellow dashes) with Asn-202. The 
aromatic ring forms pi-pi interactions (green dashes) with Tyr-74, and pi-cation interactions 
(blue dashes) with Arg-20. 
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Supplementary Figure S2A. Evaluation of the best hits from the initial SPR screen. Positive 
control (NS-1502) is in red. Fragments are in alternating dark and light blue colours. 
Displayed is the response (RU) of each fragment for increasing concentrations (ranging 6.25 
– 100 μM). 
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Supplementary Figure S2B. Evaluation of the best hits from the initial SPR screen. Positive 
control (NS-1502) is in red. Fragments are in alternating dark and light blue colours. 
Displayed is the response (RU) of each fragment for increasing concentrations (ranging 6.25 
– 100 μM). 
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Supplementary Figure S2C. Evaluation of the best hits from the initial SPR screen. Positive 
control (NS-1502) is in red. Fragments are in alternating dark and light blue colours. 
Displayed is the response (RU) of each fragment for increasing concentrations (ranging 6.25 
– 100 μM). 
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Supplementary Figure S3 
The top 18 fragments selected from the SPR screening, and NS-1502. The structural 
similarity of an aromatic ring fused to a five membered ring can be seen in F2106-0130, 
F3308-0230, F3358-0288, F3394-1274, F5871-3538, F6037-0164, F6229-0348, and F6230-
0300. 
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Supplementary Figure S4. The amino acids with an atom within 5.0 Å of F3412-0030 
(yellow) were chosen for display. F0037-7280 is docked into 2R2N with PLP (magenta) 
present. Residues Gly-39, Leu-40, Ser-143, Gly-144 removed for clarity. The carbonyl on the 
succinimide-like ring forms a hydrogen bond (yellow dashes) with Arg-399. The aromatic 
ring forms pi-pi interactions (green dashes) with Tyr-74. 
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 Supplementary Figure S5. (A) F6037-0164 is docked into 3FVU (yellow). (B) F6037-0164 
is docked into 2R2N (yellow). The surface view of the protein shows that the fragment is 
close to accessing the exterior of KAT-I (A), but sits in the active site cavity in KAT-II (B). 
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Supplementary Table S1. The Inhibition Result for the Top 18 Fragments Selected from the 
SPR Screening.  
Fragment KAT-II Inhibition  
F0037-7280 67% 
F2106-0130 3% 
F2190-0687 4% 
F2336-1079 - 
F2483-0047 - 
F2493-3416 - 
F3308-0230 - 
F3358-0288 4% 
F3371-0639 - 
F3394-1274 - 
F3412-0030 32% 
F5847-0169 - 
F5871-3538 4% 
F6037-0164 15% 
F6229-0348 - 
F6230-0300 - 
F6445-6917 - 
F9995-0188 - 
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E.2 Supplementary information for Article 3: Inhibition of human kynurenine 
aminotransferase isozymes by estrogen and its derivatives
Figure S1. Estradiol disulfate interactions with KAT-II using SPR. 
Steady state affinity model of estradiol disulfate interacting with KAT-II bound on a CM5 sensor chip 
at 25 °C (KD: 5.05x10
-6
, chi
2
: 0.481). 
Figure S2. Estradiol docked into the active site of KAT-II. 
The amino acids with an atom within 5.0 Å of estradiol (yellow) were chosen for display. Residues 
Tyr-142, Gly-144, Gln-289, and Val-290 were removed for clarity. The aromatic A ring of estradiol 
forms pi-pi interactions (green dashes) with Tyr-74, and pi-cation (blue dashes) interactions with Arg-
20. The 3-hydroxyl group forms hydrogen bonds (yellow dashes) with Ser-75, and the 17-hydroxyl
group forms hydrogen bonds with Arg-399. Image generated with PyMOL
63
. 
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Figure S3. Estrone docked into the active site of KAT-II. 
The amino acids with an atom within 5.0 Å of estradiol (yellow) were chosen for display. Residues 
Tyr-142, Gly-144, Gln-289, and Val-290 were removed for clarity. The aromatic A ring of estrone 
forms pi-pi interactions (green dashes) with Tyr-74, and pi-cation (blue dashes) interactions with Arg-
20. The 3-hydroxyl forms hydrogen bonds (yellow dashes) with Ser-75, and the 17-carbonyl group
forms hydrogen bonds with Arg-399 and Asn-202. Image generated with PyMOL
63
. 
Figure S4. Estradiol 3-sulfate docked into the active site of KAT-II. 
The amino acids with an atom within 5.0 Å of estradiol (yellow) were chosen for display. Residues 
Tyr-142 and Gly-144 were removed for clarity. The 3-sulfate group of estradiol 3-sulfate forms 
hydrogen bonds (yellow dashes) with Arg-20. Image generated with PyMOL
63
. 
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Figure S5. Estrone sulfate docked into the active site of KAT-II. 
The amino acids with an atom within 5.0 Å of estradiol (yellow) were chosen for display. Residues 
Tyr-142 and Gly-144 were removed for clarity. The 3-sulfate group of estrone sulfate forms hydrogen 
bonds with Arg-20, and Thr-23. Image generated with PyMOL
63
. 
Figure S6. Estradiol 17-sulfate docked into the active site of KAT-II. 
The amino acids with an atom within 5.0 Å of estradiol (yellow) were chosen for display. Residues 
Tyr-142, Gly-144, Gln-289, and Val-290 were removed for clarity. The 17-sulfate group of estradiol 
17-sulfate forms hydrogen bonds (yellow dashes) with Lys-263. Image generated from PyMOL
63
. 
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Table S1. Inhibition of estrogen disulfate and PF-04859989 on KAT-II. 
PLP Concentration (μM) Estrogen Disulfate Inhibition % ± S.E. PF-04859989 Inhibition % ± S.E. 
10 90.78 ± 0.26 52.32 ± 1.12 
50 85.16  ± 1.82 51.64 ± 2.04 
100 78.83  ± 0.77 48.75 ± 0.81 
200 76.28 ± 1.88 50.71 ± 0.68 
The inhibition caused by estrogen disulfate lowers with increasing PLP concentrations in the assay, 
but remains relatively unchanged in the case of the irreversible inhibitor, PF-04859989. 
Table S2. XP docking of estrogen compounds into KAT-II active site. 
Ligand Glide XP 
Score 
(Kcal/mol) 
Glide Energy 
(Kcal/mol) 
Hydrogen 
Bonds 
Ligand 
Interacting 
Atoms 
Protein Interacting 
Atoms 
Bond 
Length 
(Å) 
Estradiol -6.3 -37.0 3 H (3-OH) 
O (17-OH) 
O (17-OH) 
O (Ser-75) 
H
η12
 (Arg-399) 
H
η22
 (Arg-399) 
1.7 
1.9 
2.3 
Estradiol 3-sulfate -6.2 -30.3 2 O (3-SO4)
O (3-SO4) 
H
η21
 (Arg-20) 
H
ε
 (Arg-20) 
1.6 
1.6 
Estradiol disulfate -8.0 -40.3 4 O (3-SO4)
O (3-SO4)
O (17-SO4)
O (17-SO4) 
H
η21
 (Arg-20) 
H
ε
 (Arg-20) 
H
δ21
 (Asn-202) 
H
ζ3
 (Lys-263) 
1.6 
1.6 
1.9 
2.3 
Estradiol 17-sulfate -4.1 -36.6 1 O (17-SO4) H
ζ3
 (Lys-263) 2.5 
Estrone -7.4 -40.2 3 H (3-OH) 
O (17=O) 
O (17=O) 
O (Ser-75) 
H
δ22
 (Asn-202) 
H
η12
 (Arg-399) 
2.3 
2.2 
2.1 
Estrone sulfate -5.2 -26.2 3 O (3-SO4)
O (3-SO4)
O (3-SO4) 
H
ε
 (Arg-20) 
H
η21
 (Arg-20) 
H
γ1
 Thr-23 
1.9 
2.3 
1.9 
Displayed are the Glide XP score, Glide energy, and number of hydrogen bonds formed between the 
ligand and the KAT-II protein with details on which atoms and residues take part in these hydrogen 
bonds.  
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E.3 Supplementary information for Article 4: Improvement of kynurenine 
aminotransferase-II inhibitors guided by mimicking sulfate esters 
S1 Fig. Structures of existing KAT-II inhibitors. 
S2 Fig. Structure of estradiol disulfate. 
168
S3 Fig. Estradiol disulfate docked into the KAT-II active site. The amino acids within 5.0 
Å of estradiol disulfate (green) were chosen for display. Residues Tyr-142 and Gly-144 were 
removed for clarity. The 3-sulfate forms hydrogen bonds (yellow dashes) with Arg-20 and 
the 17-sulfate forms hydrogen bonds with Asn-202 and Lys-263. Image generated with 
PyMOL [29]. 
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S1 Appendix. 
1
H-NMR and 
13
C-NMR results for JN-01.
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S2 Appendix. HRESIMS results for JN-01. 
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S3 Appendix. HRESIMS results for JN-01. 
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S4 Appendix. 
1
H-NMR and 
13
C-NMR results for JN-02. 
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